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Summary
Hepatitis C Virus (HCV) is the major cause of post-transfusion non-A. 
non-B hepatitis. HCV is a member of the Flaviviridae, a family of viruses 
characterised by a single-stranded, positive sense RNA genome. The genome 
of HCV is approximately 9.6kb and contains a large open reading frame 
(ORF) that encodes the viral polyprotein.
The viral polyprotein contains the structural proteins (Core, El and E2) 
at the N-terminus and the non-structural proteins (NS2-NS5B) within the 
rem ainder of the polyprotein. The HCV polyprotein is processed by cellular 
and viral-encoded proteases. A serine protease, contained within the NS3 
protein, is responsible for the majority of cleavage events within the non- 
structural region of the polyprotein.
A cell-based assay to study the cleavage of an HCV substrate in trans 
by the NS3 serine protease was developed, and using this assay 
characterisation of the substrate specificity of the NS3 serine protease was 
carried out. HCV proteins were expressed from plasmid DNAs in vTF7.3 
infected mammalian cells and the cells lysed and immuneprecipitated before 
analysis by SDS-PAGE. A truncated NS5 substrate was constructed with an 
epitope tag at both termini to enable immuneprecipitation of the substrate 
and cleavage products.
The consensus amino acid motif for cleavage by NS3 had been 
previously determined (D/E X X X X C /T  S/A) and mutagenesis within an 
HCV NS5 substrate confirmed the importance of these residues (P6, PI, P I7). 
The importance of the P6 residue appeared to be more important for cleavage 
at the NS5A/NS5B cleavage site than at other cleavage sites within the HCV 
polyprotein.
The amino acid sequence of the HCV Gla polyprotein was searched for 
the consensus NS3 cleavage site motif. In addition to the sites cleaved by NS3 
an additional three potential sites were found. Analysis of one of these sites 
demonstrated that an acidic residue at P5 was important for efficient cleavage 
in trans by the NS3 serine protease. In addition to this the presence of an 
additional serine residue in close proximity to the PI and P I7 residues was 
observed to have a negative effect on the efficiency of processing.
The protease requirement for processing of an HCV NS5 substrate was 
investigated. The NS5A/NS5B cleavage site was processed when the NS5 
substrates were coexpressed with NS34A. Coexpression with NS3 and NS3P 
did not result in the generation of cleavage products. When specific amino 
acids were substituted with residues found within other HCV isolates the NS3 
alone was able to process in trans. These investigations illustrated that 
additional residues to the catalytic triad within the NS3 protease are 
important for cleavage in trans, at least for the NS3 protein alone.
An NS3 serine protease from a different HCV subtype was shown to be 
able to process the HCV Gla NS5 substrate.
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Chapter 1 - Introduction
1. Viral Hepatitis.
Viral hepatitis is a major cause of liver disease worldwide. In 
addition to hepatitis C virus (HCV) there are a number of different and 
varied viruses that cause hepatitis.
Hepatitis A virus (HAV) is transmitted primarily by the faecal-oral 
route and is acid and heat stable. It was originally classified as Enterovirus 
72 but has been classified as an Hepativirus. Unlike other picornaviruses it 
has a significantly different nucleic acid and amino acid sequence, it adapts 
w ith difficulty to growth in cell culture and has only one serotype. It is a 
non-enveloped particle of approximately 27~32nm in diameter. The HAV 
capsid contains a linear, single-stranded, positive sense RNA genom e 
(~7.5kb) and m ultiple copies of 3 or 4 viral proteins. The RNA genome is 
uncapped and contains a 5' non-coding region (NCR) constituting 10% of the 
genome that is covalently linked to the viral protein VPg. There is a single 
open reading frame encoding all the viral proteins followed by a short 3' 
NCR. Both the 5' and 3'NCRs are believed to play roles in viral replication 
(Hollinger and Ticehurst, 1996).
Hepatitis B virus (HBV) is transmitted by sexual contact, blood to 
blood contact and from mother to child (parenteral transmission). The 
prim ary infection may be asymptomatic or can exhibit varying degrees of 
acute hepatitis. Five percent of these cases lead to chronic infection w ith 
varying symptoms. The HBV virion is a complex, double shelled particle 
known as the Dane particle. The outer shell is a lipid containing envelope of 
approximately 7nm containing the viral surface antigen (HBsAg). The 
electron-dense inner core (capsid) is 27nm in diameter and contains the viral 
DNA and polymerase. The HBV genome is a relaxed, circular, partially 
duplex DNA of 3.2kb. The circularity of the genome is m aintained by 5' 
cohesive ends. The two DNA strands are not perfectly symmetrical. The 
negative strand is of unit length and has a protein covalently attached to the 
5' end. The positive strand is less than unit length and is capped by an 
oligoribonucleotide at the 5' terminus. There are 4 ORFs contained w ithin 
the DNA, encoding the viral proteins (Ganem, 1996; Hollinger, 1996).
Hepatitis D virus (HDV) is a subviral agent and requires HBV to 
provide envelope proteins. The HDV particle is approximately 28-39nm in 
diameter and contains a spherical nucleocapsid of approximately 19nm in 
diameter. The outer surface of the capsid is composed of lipids and the three 
HBV surface antigens. The HDV nucleocapsid contains a 1.7kb single­
stranded RNA genome and multiple copies of the only HDV encoded 
protein, the D antigen. The linear genome has the potential to fold on itself
l
(-70% can base pair) to form an unbranched rod-like structure and can also 
act as a ribozyme to carry out self-cleavage. Superinfection with HDV 
produces a varied but more severe hepatitis than the other hepatitis viruses 
and fulminant hepatitis is a frequent occurrence. Sixty to seventy percent of 
cases result in liver cirrhosis and a chronic infection is usually preceded by 
acute infection. Co-infection with HBV usually results in an acute, self- 
limiting disease (Taylor, 1996).
Hepatitis E virus (HEV) is defined as epidemic or enteric non-A, non- 
B hepatitis. Similar to HAV it is a water-borne virus that has been likened 
to caliciviruses. The virion is a non-enveloped 27-30nm particle of 
indefinite surface substructure containing a 7.5kb single-stranded, positive- 
sense RNA genome. A short 5'NCR (-27 nucleotides) is followed by three 
overlapping ORFs encoding the structural and non-structural proteins. 
Little is known about HEV replication. Not all HEV infections are apparent. 
Approximately a third of HEV infections result in jaundice, anorexia and 
hepatomegaly with a half also exhibiting abdominal pains, nausea and 
vomiting (Purcell, 1996).
Hepatitis G Virus (HGV or GBV-C) is a member of the Flaviviridae 
family (as is HCV). HGV contains a positive-sense RNA genome containing 
a single ORF and its organisation is similar to HCV although it only has a 
25% homology to HCV at the nucleotide level. HGV is transmissable 
through blood transfusion and by exposure to blood products or 
intravenous drug abuse. Infection may result in acute or chronic hepatitis 
and co-infection with HBV and HCV is common (Thomas et al., 1997).
1.1. History of HCV
The major cause of viral hepatitis associated with blood transfusions 
was designated non-A, non-B hepatitis (NANBH) until 1989 when Choo et al. 
isolated a cDNA clone and designated it hepatitis C virus (HCV). A cDNA 
library derived from infectious material was constructed in the 
bacteriophage A,gtll. This vector, which allows efficient expression of 
cDNA-encoded polypeptides, was used to produce a library that was 
screened for the presence of viral antigens with serum from a chronic 
NANBH patient. The library was derived from chimpanzee plasma 
containing a relatively high infectious titre to increase the likelihood of 
interaction with viral antibodies from the NANBH-infected serum.
After ultracentrifugation nucleic acid obtained from the pellet 
believed to contain the virus was denatured and cDNAs produced from both 
the RNA and DNA present using random primers. Two clones were shown 
not to be derived from the host genome and could hybridize to total RNA 
extracted from infectious chimpanzee liver. The initial clone (5-1-1) was 
significantly smaller than the second (clone 81), which was isolated from the 
same library and was determined to be larger and overlapped clone 5-1-1. 
These clones were demonstrated to be derived from an exogenous RNA 
molecule associated with NANBH infection. As only one strand of the
cDNA clone was able to hybridize to the HCV RNA extracted the genome 
was believed to be single-stranded. The RNA extracted from the infected 
chimpanzee was between 5,000 and 10,000 nucleotides in length. This RNA 
bound to oligo (dT)-cellulose indicating that there may be an A-rich stretch 
somewhere within the molecule.
The nucleotide sequence of one clone (5-1-1) demonstrated that the 
cDNA strand that produced the immunoreactive polypeptide contained a 
single, continuous open reading frame (ORF) and the polyprotein encoded 
was shown to be closely associated with NANBH infection. The serum used 
to initially identify the clone also reacted specifically to the polypeptide 
encoded by this clone. The genome itself was shown to have a positive 
polarity with respect to the translation of the viral polyprotein. This 
analysis led to the assumption that HCV was a member of the Flaviviridae as 
the virus contained a positive-stranded RNA molecule of approximately 
10,000 nucleotides (Choo et al., 1989).
The first full-length HCV sequence was derived from a chimpanzee 
infected with a contaminated Factor VIII concentrate (Choo et al, 1991) and 
this was determined as the HCV prototype HCV-1. The similarity of HCV 
to both flaviviruses and pestiviruses was seen in the size of the polyproteins 
encoded by the genome (3010, 3400 and ~4000 respectively). There were 
also small regions of amino acid homology with the NS3 and NS5 proteins 
of flaviviruses (Miller and Purcell, 1990; Choo et al, 1991). The virus particle 
has not been characterised because of poor in vitro replication systems. It 
has been shown that it has a chloroform sensitive outer envelope (Bradley et 
al, 1985) which is believed to be lipid based (Tremolada et al, 1992). 
Icosahedral particles have been isolated using anti-core monoclonal 
antibody-coated grids showing that native core is present as part of the 
virus particle (Takahashi et al, 1992a). Yuasa et al. (1991) determined that 
HCV particles were between 30-38nm in diameter.
HCV infection can be detected by anti-HCV antibodies, antigens to 
immune response elements and the detection of HCV RNA by reverse 
transcriptase (RT) PCR (Nakatsuji et al, 1992). HCV infection is often 
asymptomatic but leads to a chronic infection in greater than 50% of cases 
(Kuo et al, 1989). The development of chronicity varies but is seen to occur 
at a higher level than for HBV. Chronic infection has been linked with liver 
cirrhosis and hepatocellular carcinoma (Alter et ah, 1989; Saito et al, 1990). It 
is estimated that approximately 500 million people are chronic carriers of 
HCV (Dhillon and Dusheiko, 1995) illustrating that it is a serious hum an 
pathogen requiring study.
1.2. Exposure to HCV.
HCV is a blood-borne virus and is detected in low titres only. A 
significant degree of HCV infection due to transfusions with contaminated 
blood was observed, especially before an adequate detection system was 
established. Patients suffering from renal failure, who rely on dialysis and
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eventually a kidney transplant, were also under a high risk of HCV 
infection. Effective screening for HCV contamination of blood has been 
invaluable in the reduction of the number of infected individuals. Patients 
with coagulation disorders, treated with contaminated plasma products, 
were also at high risk before HCV screening. Intravenous drug users are 
currently the highest risk group for HCV infection (Watson et al., 1992; 
Degos, 1994). The use of sterile needles would reduce the spread of disease 
w ithin this particular group. Healthcare workers are also at risk from  
needlestick injuries.
The majority (60-70%) of HCV cases are believed to result from  
parenteral transmission (Bastie et al., 1995), i.e. through blood transfusions 
w ith contaminated blood or intravenous drug abuse, although other routes 
exist. Improved analysis should help to clarify non-parenteral routes of 
infection. Infection w ith HCV occurs through interaction between adults 
(i.e. through exchange of infected blood, needles, etc.). Transmission from  
mother to unborn child has been documented in a number of cases (Uehara 
et al., 1993; Resti et al., 1995). The titre of the HCV RNA found in the m other 
was directly proportional to the risk of transmission (Ohto et al., 1994), and a 
titre of approximately 106/rrd  or higher was shown to be required for 
transmission of HCV to the unborn child (Moriya et al., 1995; Ohto et al., 
1994). It has been shown that mothers testing seropositive for HCV 
antibodies, but negative for HCV RNA do not infect the unborn child 
(Zuccotti et al., 1995). There is some evidence that coinfection with HIV 
increases the risk of vertical transmission (Zanetti et al., 1995). Infection of 
children from breast milk is not considered a risk (Moriya et al., 1995; Kage 
et al., 1997). Although sexual transmission of HCV is possible the risk of 
infection is extremely low (Healey et al., 1995; Tong et al., 1995; Scotto et al.,
1996). Prevention of exposure to HCV can be accomplished through the use 
of clean blood supplies, improvement of general hygiene (i.e. through the 
use of sterile needles, extensive hand washing and proper disinfection and 
sterilisation) and reduction of high HCV-RNA titres in infected mothers.
1.3. HCV infection.
There are three distinct phases throughout the clinical course of HCV 
infection:-
(i) The acute phase - This phase can last 2-3 years after disease onset 
and is usually asymptomatic.
(ii) The silent phase - Throughout this period there is a low level of 
serum  transaminases observed.
(iii) The reactivated phase - The serum transam inase/ transferase level 
increases and thereafter fluctuates in a moderately high range until 
hepatocellular carcinoma (HCC) develops. Consequently all 
sufferers of HCC have abnormal serum transferase levels.
The acute phase of HCV is asymptomatic. There is an observable difference 
between HCV cases leading to chronicity. Chronicity is defined by the
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persisitence of an abnormal serum amino acid transferase level for m ore 
than one year (Kiyosawa et al, 1994). In cases where infection originated 
from a blood transfusion, 74% of patients developed a chronic infection. In 
cases of sporadic infection (i.e. cases of infection not resulting from infected 
blood) 55% of patients degenerated to chronicity. The likelihood of chronic 
infection may depend on the size of the infectious inoculum at the initial 
infection.
In chronic carriers there is always a detectable amount of HCV RNA. 
A "first generation antibody test" for HCV, anti-ClOO, can be used as a 
diagnostic tool but the protein it identifies has been observed to decline 
despite persistence of HCV RNA. This antibody reacts with an epitope 
located in the NS4 region (Watson et al., 1992). A second generation 
antibody test, anti-HCV2, detects a protein that is always present (Kiyosawa 
et al., 1994) and reaction with this indicates an HCV infection. The relatively 
low titre of HCV in the large percentage of patients does not perm it 
efficient detection of HCV antigens (Takahashi et al., 1992b) and a m ore 
conclusive detection method is required. The detection of HCV infection by 
identifying the HCV RNA genome is a more efficient system. Targetting 
the highly conserved untranslated region at the 5' end of the RNA genome 
(5'UTR), primers conserved between different HCV genotypes against this 
region are used in a combined reverse transcription and polymerase chain 
reaction (RT-PCR) to get a highly sensitive HCV detection assay (Weiner et 
al., 1990).
The progression to chronicity is unclear, probably due to the 
complexity of the factors involved. The likelihood of developing chronic 
HCV infection may depend on the size of the infectious inoculum at the 
initial infection, the route of infection or the HCV genotype (Yoshioka et al, 
1992). There are at least six genotypes of HCV and theoretically each could 
evolve within an individual, different genes evolving at different rates 
(Kiyosawa et al, 1994). Cases have been documented where a patient has 
been infected with two genotypes and infection with a higher num ber of 
genotypes is therefore theoretically possible.
1.4. Treatment.
Treatment of HCV infection is with interferon-a, which acts as an 
antiviral and immunomodulating agent. In the case of HCV it is observed 
to reduce levels of alanine transaminase (ALT) in some chronic HCV 
sufferers. After 6 months of thrice-weekly treatment of 3-6 mega-units (MU) 
of interferon-a there is a normalisation of ALT levels in approximately 50% 
of those treated. Unfortunately only 25% of these cases retain normal ALT 
levels once therapy has been stopped. The use of HCV RT-PCR corroborates 
these results. It should be noted that the absence of HCV RNA does not 
necessarily mean that there is no HCV infection. Virus may persist in the 
liver, extrahepatic sites or in plasma in levels undetectable by RT-PCR 
(reviewed by van der Poel et al, 1994).
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Although the use of interferon-a does have side effects these are 
resolved after therapy cessation and are partly due to the dose level. 
Interferon treatm ent in the early/acute phase has been postulated to reduce 
the likelihood of chronic infection.
Ribavirin, a guanosine analogue administered orally, is observed to 
normalise ALT levels while not eliminating HCV RNA. Treatment 
term ination results in a return to abnormal levels of ALT (Di Bisceglie et ah, 
1992). Com bination therapy of ribavirin and interferon-a induced a 
sustained response in patients who initially responded to interferon 
treatm ent but relapsed after cessation of treatment. Normal levels of ALT 
were observed in 75% of these patients after combination therapy, w ith no 
HCV RNA detection after 6 months (Brillanti et ah, 1994, 1995). 
Com bination therapy of interferon-a and ribavirin increases the sustained 
response two-fold in comparison with interferon-a treatm ent alone 
(Brillanti et ah, 1995; Bellobuono et ah, 1997).
Because of the problems with vaccine development for HCV (1.5.) the 
most effective and realistic treatment for HCV is antivirals. In addition to 
interferon-a and ribavirin treatment other therapies have been investigated. 
A combination therapy of inteferon with ofloxacin (Takada et ah, 1996) or 
thymosin alpha (Rasi et ah, 1996), as well as amantidine treatment (Smith, 
1997), have been tested although these investigations have shown only 
limited success.
Specific antivirals against proteins believed to be essential for virus 
replication (such as the protease or the polymerase) are most likely to be of 
use in treatm ent of HCV and prevention of disease. A detailed knowledge 
of these proteins is vital for development of an efficient antiviral against 
HCV.
1.5. Prevention.
W ithout any effective therapy against HCV infection a vaccine 
against HCV would be invaluable. Development of a vaccine is 
complicated by the fact that re-infection with the same or different isolates 
of HCV results in a second incidence of disease (Farci et ah, 1991). The 
presence of different genotypes of HCV and the evolution of quasispecies 
within an infected individual has made the development of a "universal" 
vaccine problematic. Original vaccines took the form of recom binant 
envelope vaccines that were only able to combat low titre challenge w ith 
HCV in chimpanzees. It has been speculated that use of the highly 
conserved core protein in a vaccine may be useful in increasing efficacy 
(Hitomi et ah, 1995). Tokushige et ah (1996) immunised BALB/c mice w ith 
vectors expressing the highly conserved core gene that resulted in a low- 
level anti-HCV core humoral immune response. As well as this experiment 
a myeloma cell line constitutively expressing HCV core protein was 
inoculated into BALB/c mice, resulting in plasmacytomas. A strong CTL
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response was generated in comparison to mice injected with vector DNA. 
These experiments show that the HCV core protein, can be used to generate 
strong CTL activity and is a promising candidate as an antiviral agent. The 
use of conserved viral epitopes in a vaccine may result in a less aggressive 
disease w ith milder symptoms that is more susceptible to interferon 
treatm ent (Koshy and Inchauspe, 1996).
1.6. Genome structure of the Flaviviridae.
All members of the Flaviviridae i.e. flaviviruses, pestiviruses and 
HCV, have a positive sense, single-stranded RNA genome. The genomes 
encode a single open reading frame (ORF) flanked by non-coding regions at 
the 5' and 3' termini. The open reading frame encodes a single polyprotein 
containing the structural proteins at the N-terminus followed by the non- 
structural proteins. The basic genomic organisation of the Flaviviridae is 
illustrated in Fig. 1.1. The polyprotein is processed by host and virally 
encoded proteases both co- and post-translationally to produce the m ature 
viral proteins. Genomes of flaviviruses are approximately l lk b  in size, 
encoding an open reading frame (ORF) of approximately lOkb preceded by 
a short, capped 5' untranslated region (UTR) of approximately 95-132 bases 
in length. The 5' UTR has a type I cap (m7GpppAmp) followed by the 
conserved dinucleotide sequence AG and lacks cap-associated and internal 
base methylated adenine residues (Chambers et al., 1990). The 3' UTR is 
significantly longer than the 5' end and is extensively heterogeneous in size 
and sequence between different flaviviruses. The bulk of this heterogeneity 
is found at the proximal 5' end (Proutski et al, 1997; Wallner et al, 1995) and 
it is sometimes followed by a polyA stretch. The 3' end contains 
approximately 350 nucleotides and exhibits a higher degree of conservation. 
This section can be divided into 3 regions of distinct secondary structure, the 
last of which consists of a long, stable hairpin (LSH) structure (Proutski et al., 
1997). The 3' LSH is believed to be important for regulation of replication 
and is known to bind host cellular proteins thought to be part of the 
replication complex (Blackwell and Brinton, 1995).
The pestivirus genome is significantly longer than that of the 
flaviviruses (approximately 12.5kb), with an ORF producing a polyprotein 
of approximately 4000 amino acids and a 5' UTR of approximately 385 
nucleotides. The 5" UTR contains an internal ribosome entry site (IRES) 
directing cap-independent translation (Poole et al., 1995; Rijnbrand et al.,
1997). The 3' UTRs of pestiviruses are between 188 and 228 nucleotides in 
length and can be divided into two distinct regions - the variable (3'V) and 
the conserved (3'C) regions (Deng and Brock, 1993). The variable region can 
be as long as 127 nucleotides and is preceded by the stop codon of the ORF. 
This region exhibits a high degree of sequence heterogeneity as well as 
different pestiviruses containing deletions. The 3'V region is not believed 
to be im portant in replication. The 3'C region is 102 nucleotides in length, 
is highly conserved and contains an AU rich stretch and imperfect repeat
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Fig. 1.1. Genomic organisation of the Flaviviridae
sequences with considerable conservation. This region may contain some 
im portant signals for viral RNA replication. Between different viruses the 
position of the repeat stretches and the nucleotide sequence is not as highly 
conserved. Between different isolates, however, the conservation is very 
high (Deng and Brock, 1993). The 3'UTR as a whole has considerable 
secondary structure consisting of four predicted stem loops. Stem loop I is 
contained within the conserved region and the sequence is conserved 
between all 5 pestiviruses analysed. Stem loop II uses sequence from both 
3'C and 3'V and is relatively well conserved structurally. The two 
rem aining stem loops (III and IV) are both in 3'V and are less conserved in 
terms of length and structural detail (Deng and Brock., 1993).
The HCV genome is approximately 9.6kb and contains a highly 
conserved 5' UTR (between different genotypes) of approximately 341 
nucleotides in length. Due to the highly conserved nature of the 5' UTR 
there is very little difference in the nucleotide length within this region. 
Translation of the HCV polyprotein is directed by an IRES element. 
Direction of protein translation by an IRES element is also seen in 
pestiviruses with one significant difference, in that twenty-one nucleotides 
of the HCV ORF are required for IRES activity (Lu and Wimmer, 1996; 
Reynolds et a l, 1995). Almost the entire 5' UTR constitutes the IRES elem ent 
w ith the first 29 nucleotides at the extreme 5' terminus not required (Wang 
et al., 1995). The remaining region forms a highly conserved secondary 
structure of stem-loops and a pseudoknot that are essential (Rijnbrand et al., 
1995, 1996; Wang et al, 1995). The single exception is the first hairpin 
structure (Rijnbrand et al, 1996) which is not required. The AUG codon used 
in translation is located in a stem loop whose sequence is conserved 
throughout HCV genotypes (Honda et al, 1996). This stem loop, although 
believed to be unstable, is probably responsible for the direct ribosom e 
entry observed close to the authentic AUG (Reynolds et a l, 1996). The 5'UTR 
is believed to bind polypyrimidine tract binding protein (PTB) utilising 3 
distinct regions (Ali and Siddiqui, 1995). A 25 kDa protein has also been 
demonstrated to bind to the 5' UTR (Fukushi et al, 1997). This protein binds 
to the a-branch of stem loop II. The primary sequence of the a-branch m ay 
act as a ris-element for translation initiation. There is no direct evidence of 
stem-protein interaction and this a-branch alone may not be able to bind 
cellular factors.
The role of PTB in the HCV IRES is unclear. It may be that other 
proteins associate w ith PTB and that this interaction is important. It has 
been reported that recombinant PTB does not bind to the HCV 5' UTR and 
that this protein did not stimulate HCV IRES function (Reynolds et al, 1995). 
Although highly conserved, the 5'UTR does contain some small differences 
between different genotypes. These differences are thought to explain the 
observation that IRES elements from different genotypes have varying 
efficiencies at promoting translation initiation (Buratti et al, 1997; Collier et 
al, unpublished data). The secondary structure of the 5'UTR of HCV is 
illustrated in Fig. 1.2.
The ORFs of HCV genomes are between 9027 and 9111 nucleotides in 
length and hence encode 3009 to 3037 codons (Adams et al, 1997). The open
u u
U A 
G C  
G C  
G C
JcgU
lllb
5'
lib G °C 
A
U U 85 IcTSl 
UG 
G C  
C G  
G U  
a A U A
A G« U
gca
C A
A „G U
iG C 
!A U [CG 
C Giew 
iU.fii UA 
AU 
'  AU ,
U CACCGG U
G GUGGCC G
A A CCC U
c c ' A y G 55 G C  '
Ilia
171. .228
C
GGG G lllc
1£
238
70'
>AU[
lla
,UG
97
c - o  c G U 
A UCUU U . AGGAl
CG
cu G
UA
C G
CG
UC'
U
G
C
A
cG
G C  
C G
G C AUA
C G
UA
G C
GU
1 4 4 - U G ~ 249
UA' a
GCdSi
c g g a ;  
c
llld
131
\
GCCA _GACACUCCACCAUGAAUCACUCi =AcCCCOdCUCCpGGGr l “ GCCU*3 A^ 296 I I I a
'U  
A UG U 
C G  
C G
^ A  G C
,A U ,
A
\
275
UAGUG
AGCGC,
UU
UG
5 C G 20 
CG  
CG  
C G  
CG  
U U 
G A
UGGG U
G (XUAAACCUCAAAGAAAAACCAAACGUAAC..
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Translation initiates at the shaded AUG triplet.
reading frames are all followed by a 3' UTR consisting of a short variable 
region, a variable polypyrimidine tract of between 73 and 98 nucleotides in  
length (Yamada et al., 1996) and a 98 nucleotide sequence denoted the X-tail 
(Tanaka et a l, 1995). The X-tail is highly conserved between different HCV 
genotypes (Tanaka et al, 1996; Kolykhalov et al, 1996) and is believed to 
have a high degree of secondary structure (Kolykhalov et al, 1996). The 3' 
terminal 46 bases form a stable stem loop structure (stem loop I) w ith a 6 
nucleotide single stranded loop. The remaining 52 nucleotides are believed 
to fold into more than one secondary structure. The X-tail is probably 
involved in m ultiple RNA-protein interactions with stem loop I acting as a 
recognition site for viral a n d /o r  cellular proteins (Blight and Rice, 1997). It 
has been shown that the X-tail binds the 58-kDa protein PTB. The sequence 
requirem ent for this binding is very specific and sensitive to m utation (Ito 
and Lai, 1997) despite differing from the consensus PTB-binding consensus 
sequence. The predicted optimal secondary structure of the 3' UTR is 
required for PTB binding and involves primary loop sequences and stem  
structures of SL2 and SL3 (Ito and Lai, 1997). It is speculated that the X-tail 
may be im portant in replication of the HCV genome, modulation of 
translation or RNA stability. The predicted secondary structure of the 3'UTR 
is shown in Fig. 1.3.
1.7. Heterogeneity of the HCV genome.
All members of the Flaviviridae replicate using a virus-encoded RNA 
polymerase and so exhibit a high degree of sequence variation. Different 
isolates of HCV show significant differences in sequence in specific regions 
of the virus genome. Within a single HCV isolate there is a high degree of 
sequence variation and these variants are called quasispecies. The existence 
of quasispecies is not unique to HCV. RNA polymerases encoded by RNA 
viruses lack a proof-reading function. The absence of a proof-reading 
function leads to a high frequency of mutation after replication. It has been 
observed in HIV-1 that biological properties vary from clone to clone 
during the course of infection (Duarte et al, 1994a). The existence of 
quasispecies has also been observed in influenza A and the hum an 
hantaviruses as reviewed by Duarte et a l (1994b).
Some regions within HCV, for example the envelope region, are 
particularly variable leading to different HCV groups having different 
antigenic and biological properties. The NS5 region also contains a highly 
variable, type-specific region that reduces the effectiveness of antibody 
assays against this particular protein, in HCV genotype determination. In 
contrast other regions are very highly conserved (e.g. the 5'UTR and the X- 
tail).
Genotype determination has been carried out using regions encoding 
the core, NS3 and NS5 proteins. Despite some variation in sequence the 
genotype determined corroborated with that obtained by sequencing the 
entire genome. These sequencing studies, particularly those in the NS5
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region, have led to the classification of different HCV isolates into a 
distinctive hierarchy.
The broadest classification for HCV is that of genotypes. There are six 
major genotypes numbered 1-6 (Simmonds et al., 1993) which are between 66 
and 72% similar at the nucleotide level. If an HCV sequence has less than 
72% similarity to any of the existing sequences it will be classified as a new 
HCV genotype. The sequence similarity between different HCV genotypes 
is illustrated in Table 1.1. (taken from Adams et al., 1997).
In each genotype there are usually two to three clusters of m ore 
closely related variants. These groups are called subtypes and are between 
75 and 86% similar. For genotype 1 there are three subtypes (la, lb , lc).
A phylogenetic tree can be constructed for different HCV genotypes 
and is illustrated in Fig. 1.4. The phylogenetic tree can be produced by 
comparison between the 5'UTR, core, NS3 and NS5 regions of different HCV 
isolates and classifies them in to types and subtypes.
Individual HCV sequences are classified as isolates. Analysis of HCV 
genotypes has been carried out using the NS5, core and 5'UTR regions 
(although the 5'UTR shows very little sequence disimilarity).
A further feature of the heterogeneity of the HCV genome regards 
the existence of quasispecies within an individual isolate. This feature was 
observed in individuals infected with one isolate of HCV, yet still showing 
heterogeneity between the genomes present. The rate of mutation in HCV 
genomic sequence has been estimated at being between Kb3 and lO-4 base 
substitutions per genome per year (Martell et al., 1992). The presence of 
quasispecies may give HCV an adaptive advantage during infection and 
may play a role in vaccination failure, establishment of persistent infection, 
resistance to antiviral agents and changes in virulence.
Fifty-five percent of the infecting HCV genomic sequences have been 
shown to differ from the consensus sequence of the infecting isolate. 
Although many of these base changes will have no effect on the encoded 
amino acid sequence, some will introduce stop codons resulting in defective 
genomes while others result in amino acid changes that may have an effect 
(Martell et al., 1992).
1.8. HCV encoded proteins.
HCV, like all members of the Flaviviridae, produces a single 
polyprotein that is subsequently processed into individual proteins. These 
proteins can be classified into two distinct groups, the structural proteins 
and the non-structural proteins. HCV produces at least three structural 
proteins (Core, El and E2) and six non-structural proteins (NS2, NS3, NS4A, 
NS4B, NS5A, NS5B).
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1.8.1. Core protein.
The HCV core protein is believed to be composed of the first 191 
amino acids of the viral polyprotein (Hijikata et al., 1991b; Ralston et al.,
1993). Core is particularly rich in arginine and lysine residues at its N- 
term inus and is an unglycosylated protein of approximately 21kDa (Hijikata 
et al., 1991b; Lo et al., 1994; Harada et al, 1991). A second major species of 
19kDa (PI9) has also been identified (Santolini et al., 1994). Processing to 
produce P I9 occurs at either amino acid 179 or 182 by a eucaryotic signal 
peptidase. This cleavage event does not require previous processing at the 
N-terminus of full-length core (Hussy et al, 1996). Besides these two major 
products a third, minor protein of 151 amino acids is also observed w ith a 
molecular mass of 16kDa (P16) (Lo et al, 1995).
The full length core protein is released from the polyprotein through 
the action of a signal peptidase of the endoplasmic reticulum. Cleavage is 
m ediated by the removal of the putative signal sequence 18 amino acids 
located at the C-terminus of core. Core protein is normally observed in the 
cytoplasm of cells, but there is a sequence at the N-terminus of the core 
protein that targets the protein to the nucleus. The target sequence is only 
used when the hydrophobic stretch at the carboxy-terminus is rem oved 
(Ravaggi et al., 1994; Chang et al., 1994). The amino acid sequence believed 
to play an im portant role in nuclear localisation is PRRGPR (Suzuki et al,
1995). The two major species of core (P21 and P19) are associated with the 
endoplasmic reticulum whereas P I6, which lacks the C-terminus of core, is 
localised in the nucleus (Lo et al., 1995). The different subcellular 
localisation of these core species suggests that they may have different 
biological functions.
M ultimerisation of core takes place using the amino-term inal 
hydrophilic region (115 amino acids) with interaction occuring between 
amino acids 36 and 91 (Matsumoto et al., 1996). This feature of core protein 
is observed for both membrane-bound and free protein and so must take 
place at an early stage in viral assembly. Core has been observed to bind 
membranes and has also been shown to co-localise with the E2 glycoprotein 
and a cellular ER membrane marker. Besides the ability of core to bind 
RNA it has also been shown to bind the large ribosomal subunit, utilising 
the same N-terminal region used for RNA binding. Binding to the 
ribosome may be mediated by RNA binding (Santolini et al., 1994). The core 
protein is also phosphorylated by protein kinase A and protein kinase C 
although phosphorylation is not required for entry into the nucleus (Shih et 
al, 1995).
Core protein has been shown to activate the Rous sarcoma virus long 
terminal repeat (LTR), human c-myc and simian virus 40 (SV40) early 
promoters. Core has also been shown to suppress the c-fos promoter and the 
hum an immunodeficiency virus type 1 (HIV-1) LTR (Srinvas et al, 1996). 
The effect of transcriptional regulation of cellular proto-oncogenes suggests 
a possible role in deregulation of normal hepatocyte growth and
hepatocarcinogenesis (Ray et al, 1995). The effect of core on the 
developm ent of carcinogenesis has been further developed. It has been 
shown that the core gene cotransfected with H-ras can induce rapid 
proliferation, anchor-independent growth and tum our formation in athymic 
nude mice (Ray et a l, 1996). Core has also been shown to have the ability to 
inhibit apoptotic cell death (Ray et al, 1996) and suppress the transcriptional 
activity of the p53 promoter (Ray et al, 1997). Core has been shown to bind 
the cytoplasmic tail of membrane-bound lymphotoxin-beta receptor (LT 
beta R) using the same amino acids required for core m ultim erisation 
(Matsumoto et al, 1997). LT beta R is a member of the tum our necrosis 
factor receptor family and is involved in germinal centre formation, 
developmental regulation of peripheral lymphoid organs, lymph node 
development and apoptotic signalling. The ability of core to bind LT beta R 
may have an imm unom odulating function possibly important in viral 
persistence.
1.8.2. The envelope glycoproteins.
El (gp35) is a glycosylated protein of approximately 35 kDa. It is has 
5 or 6 potential N-linked glycosylation sites (Matsuura and Miyamura, 1993) 
and after deglycosylation this 192 amino acid protein has a molecular mass 
of 22kDa. El is known to interact through its carboxy-terminus with the 
HCV core protein (Lo et al, 1996).
After glycosylation at a possible 11 sites the 363 amino acid E2 
protein has a molecular mass of 70kDa (Miyamura and Matsuura, 1993) and 
is known as gp70. E2 is equivalent to the major envelope protein of 
pestivruses (E2) and NS1 of flaviviruses. Both these proteins confer 
protective imm unity in immunised animals against the respective viral 
infections. E2 is the most highly variable HCV protein (Kato et al, 1992; 
Weiner et al, 1991) with hypervariable regions in the N-terminus. 
Hypervariable region 1 (HVR1), representing the N-terminal 34 amino acids 
contains B cell epitopes specific to each isolate (Kato et al, 1994). Mutation in 
this region is believed to be important in the evolution of escape mutants of 
HCV. Both El and E2 are released from the viral polyprotein by host-cell 
signal peptidases. E2 contains an additional cleavage site 60 amino acids 
from its C-terminus. Cleavage at this site releases a 7kDa protein called p7 
(Lin et a l, 1994a; Mizushima et al, 1994; Selby et al, 1994; Lanford et al, 1993; 
Grakoui et al, 1993c). Processing to give p7 appears to occur post- 
translationally at a novel, microsomal membrane dependent cleavage site. 
This cleavage event means that there are two different sized E2 proteins 
produced by HCV, the different functions of which, if any, are not known. 
E2 has been observed to interact with NS2 (Matsuura et al, 1994; Selby et al,
1994).
El and E2 interact with each other (Dubuisson et al, 1994; Grakoui et 
al, 1993c; Lanford et al, 1993) usually through non-covalent bonding 
(Ralston et al, 1993). Disulphide bonding has also been demonstrated
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(Grakoui et ah, 1993c). It has been shown that the non-covalent complexes 
form slowly to give a stable heterodimer in stark contrast to the complex 
formed containing disulphide bonds that are the result of misfolding 
(Dubuisson et ah, 1994). Folding of the individual proteins through the 
formation of disulphide bonds is required before heterodimer form ation 
can take place. The rate-limiting step for heterodimer formation is thought 
to be the folding of El (Dubuisson et ah, 1996). The N-terminus of El is 
im portant for interaction with E2. Amino acids 415-500 of the polyprotein 
fall w ithin the N-terminus of E2 and are important for interaction with El. 
W ithin this region several discontinuous sites seem to contribute to strong 
binding, particularly the amino acid sequence WHY located at residues 489- 
491. Glycosylation is not required for heterodimer formation (Yuki et ah, 
1997).
The high degree of variation within the envelope region of HCV 
presents a problem in developing a vaccine using this region. Although a 
vaccine against an individual isolate is theoretically possible the 
hypervariability of E2 coupled w ith the presence of so many viral strains 
means that the development of a universal envelope-based vaccine against 
HCV is unlikely.
1.8.3. NS2 protein.
The non-structural region of the polyprotein is processed by two 
viral encoded proteases. The first of these proteases cleaves between the C- 
terminus of NS2 and the N-terminus of NS3 and is encoded by amino acids 
from both these non-structural proteins. This protease, designated the 
NS2/3 protease, or C-pro-1, is encoded between amino acids 827 and 1207 of 
the virus polyprotein (Reed et ah, 1995). This protease encompasses the C- 
terminus of NS2 and all the NS3 serine protease domain (181 amino acids). 
This 380 amino acid region can process itself when expressed as a single 
construct (Reed et ah, 1995). Two amino acids essential for protease activity 
are located in the NS2 region (His-952 and Cys-993). Mutations that 
inactivate the NS3 serine protease have no effect on NS2/3 protease action 
(Grakoui et ah, 1993a) illustrating that the NS2/3 protease cleavage event is 
independent of the serine protease activity.
Cleavage occurs between the leucine and alanine residues at the 
following amino acid sequence - KGWRLL/APIT. Although the sequence 
APIT is present at other positions in the HCV polyprotein (five in HCV-H), 
the sequence RLLA is not found, and processing is not observed at these 
sites. The NS2/3 cleavage site amino acid sequence is highly conserved for 
different strains of HCV from positions P5 to P61. Cleavage takes place 
between PI and P I7 with the 5 residues upstream (P1-P5) and 6 residues 
downstream (Pl'-P6') being highly conserved. Mutations at PI and P I1 are 
well tolerated except for the introduction of acidic residues and proline. The 
amino acid preferences at PI and P I1 are similar to those of neutral metallo- 
proteases that cleave next to hydrophobic amino acids. As NS2/3 is an
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autocatalytic protease, amino acid substitutions and deletions that inhibit 
processing may disrupt proper folding of the autoprotease, the cleavage 
site, or both. It has also been demonstrated that NS2/3 cleavage can take 
place in trans. An NS2/3 protease, inactivated by mutation of His-952 or 
Cys 993, could be cleaved in mammalian cells when coexpressed w ith a 
functional NS2, providing the substrate contained the N-terminal portion of 
NS3. Similarly an NS2/3 substrate with a C-terminal deletion in NS3 could 
be processed when cotransfected with an NS3 fragment containing the N- 
terminal 181 amino acids (Reed et al., 1995). This observation suggests that 
the two regions interact to from a functional autoprotease. NS2/3 contains a 
zinc ion which has been demonstrated to have a structural rather than a 
catalytic role. The structural requirement is explained by its ability to be 
replaced by a cadmium or cobalt ion. Ubiquitous soluble factors may also 
be required for efficient proteolysis (Pieroni et al, 1997). The presence of 
microsomal membranes has been shown to stimulate the activity of the 
N S2/3 protease and are believed to act by assisting the proper folding of the 
precursor (Santolini et al., 1995). The NS2/3 protease of different HCV 
strains is stimulated to different degrees by the presence of membranes. 
The NS2/3 protease of HCV-J is unaffected by the presence of m em branes 
whereas that of HCV-BK is entirely dependent on membranes. The 
targetting of the NS2/3 precursor to membranes is dependent on the (Signal 
Receptor Particle) SRP-SRP receptor machinery.
After the NS2 protein has been processed from the polyprotein it is 
observed to be a transmembrane protein. Analysis has shown that the C- 
terminal region of NS2 is translocated in the ER lumen. The way in which 
this protein interacts with the targetting machinery or how it is inserted 
into the ER shows some strange features. NS2 contains no long stretches of 
hydrophobic amino acids that resemble a signal sequence an d /o r a 
transmembrane domain. It is speculated that the signal sequence is located 
downstream  of the cleavage site, within NS3. Targetting to and 
translocation across the ER membrane are distinct events with the NS2 
being translocated entirely posttranslationally (Santolini et al, 1995). In an 
in vitro assay non polar detergents have also been shown to stimulate 
protease activity and are also thought to promote proper folding of the 
precursor. The action of detergents is believed to bypass the SRP-SRP 
machinery and so removes the necessity for microsomal membranes for in 
vitro processing for some HCV strains (Pieroni et al, 1997). The function of 
NS2, once released from the polyprotein is unknown. The analagous 
cleavage takes place inefficiently in the cytopathic pestiviruses (e.g. BVDV) 
but is not observed in the non-cytopathic strains (Collett, 1992). The 
NS2B/NS3 site in flaviviruses is processed efficiently (Chambers et al, 1991) 
but the NS2B protein is equivelant to the NS4A protein of HCV (i.e. it acts as 
the NS3 serine protease cofactor).
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1.8.4. The NS3 protein.
The NS3 protein (70kDa) of HCV can be split into two distinct 
domains. The N-terminus encodes a serine protease (Hijikata et al., 1993a; 
Bartenschlager et ah, 1994; Lin et ah, 1994b; Tanji et ah, 1994b; Failla et ah,
1995) as illustrated in Fig. 1.5. The C-terminal domain encodes an 
NTPase/RNA helicase. This feature is also seen for the flavivirus NS3 
protein (Wengler and Wengler, 1991; Warrener et ah, 1993) and the 
pestivirus p80 protein (Tamura et ah, 1993).
The serine protease.
Serine proteases are a group of enzymes that hydrolyse peptide 
bonds in proteins. Many proteases are present as domains in large 
multifunctional proteins whereas others are smaller polypeptide chains. 
Proteases belong to one of four families: serine, cysteine, aspartic, or 
metallo proteases. Classification of a protein into one of these families 
depends on the nature of the most prominent functional group in the active 
site. Enzyme catalysis begins with the bonding of enzyme and substrate to 
form a reversible enzyme-substrate complex (ES). Once formed, ES can 
either be fully catalysed to give enzyme and products or revert to the 
reactants. This reaction can be summarised by the equation below:
Km kcat
E + S --------► ES «-------- E + P<   ►
The dissociation constant of the ES complex back to E + S is called Km 
and describes the affinity of the enzyme for the substrate. The second step 
of the reaction from ES to E + P occurs with a rate constant called kcat, or the 
turnover number. The turnover number is defined as the maximum 
num ber of substrate molecules converted to product per active site of the 
enzyme per unit time. For simple reactions, kcat is the rate constant for the 
chemical conversion of the ES complex to free enzyme and products. These 
definitions are only valid when the concentration of the enzyme is very 
small in comparison to the substrate i.e. the rate of formation of the first few 
percent of the product before the substrate has been depleted and enough 
products have been produced that they can interfere w ith the catalytic 
reaction. The maximum rate of reaction is reached when the enzyme is 
saturated with substrate and is defined as Vmax. The substrate concentration 
when the half maximal rate (Vmax/ 2) is achieved is also known as Km. The 
rate constant that refers to the properties and reactions of the free enzyme
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and free substrate is called the specificity constant (kCat/Km). This describes 
the specificity of an enzyme for competing substrates.
The ES complex undergoes several rearrangements to one or several 
transition states before the products are obtained. These rearrangem ents 
require energy. The energy required to bring free enzyme and substrate to 
the highest transition state is called the activation energy of the reaction. In 
the absence of enzyme the substrate also proceeds through transition states 
to give products but in the absence of enzyme the activation energy is 
significantly higher. Enzymes can reduce the activation by several different 
methods. They can provide catalytically competent groups for a specific 
reaction mechanism, bind several substrates in an orientation appropriate to 
the reaction being catalysed and use the differential binding energy of the 
substrate in its transition state compared with its normal state. The 
activation energy for the conversion of ES to E + P is lower if the enzyme 
binds more tightly to the transition state of S than to its normal structure, 
i.e. it is catalytically advantageous for the enzyme to be complementary to 
the transition state of the substrate than to the normal structure of the 
substrate.
Catalysis by serine proteases occurs in two steps. The first step 
produces a covalent bond between Ci of the substrate and the hydroxyl 
group of the reactive serine residue of the enzyme. To produce this acyl- 
enzyme intermediate the reaction must first go through a negatively 
charged, transition state intermediate. In this intermediate the bonds of Ci 
have a tetrahedral geometry as opposed to the planar geometry in the 
peptide group. During this step the peptide bond is cleaved, one peptide 
product diffuses away while the remaining peptide is attached to the 
enzyme in the acyl-enzyme intermediate (Fig. 1.6.).
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Fig. 1.6. The acylation step of catalysis by serine proteases. 
The oxygen atom of the catalytic serine residue binds to the 
carbon atom of the peptide bond to form the negatively charged 
tetrahedral intermediate while the histidine residue accepts the 
hydrogen atom. The nitrogen atom of the peptide bond 
subsequently accepts the hydrogen atom from the histidine 
residue to form a stable cleavage product that is released from the 
enzyme. Hydrogen bonding is illustrated by broken lines.
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In the second step of the reaction the acyl-enzyme intermediate is 
hydrolysed by a water molecule to release the second peptide product. This 
product has a complete carboxy-terminus and the serine residue of the 
enzyme is restored. This step, known as deacylation, also occurs through a 
negatively charged tetrahedral transition state intermediate (Fig. 1.7.).
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Fig. 1.7. The deacylation step of catalysis by serine proteases. The 
oxygen atom of the water molecule binds to the enzyme-substrate 
complex at the carbon atom to form the negatively charged
tetrahedral intermediate. The histidine residue of the catalytic
triad accepts the hydrogen atom from the water molecule. The 
second cleavage product is released before the serine residue 
accepts the hydrogen atom from the positively charged histidine 
to reform the stable catalytic triad conformation. Hydrogen 
bonding is illustrated by broken lines.
Serine proteases have four essential structural features that facilitate 
the catalysis mechanism. The most important feature is that of the catalytic 
triad, consisting of three side chains from apspartate, histidine and serine 
residues. The histidine residue is a general base that can accept the proton
from the hydroxyl group of the reactive serine residue allowing the
formation of the covalent tetrahedral transition state. The aspartic acid 
stabilises the correct tautomer of histidine, orienting it so that it is able to 
accept the proton during catalysis (Fig. 1.8.).
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Fig. 1.8. The catalytic triad of the serine pro tease. The 
aspartic acid residue forms a hydrogen bond with the histidine 
residue, orienting the histidine so that it can hydrogen bond with 
the catalytic serine residue.
The negatively charged transition state intermediate is tightly bound and 
stabilised by groups that can form hydrogen bonds with the negatively 
charged oxygen atom at Ci. These groups are located in a region known as 
the oxyanion hole. The positive charge that develops on the histidine after 
it has accepted a proton also stabilises the negatively charge transition state. 
A loop region of the enzyme forms a short antiparallel p sheet, mediated by 
hydrogen bonding, to main chain atoms of the substrate to give nonspecific 
binding between enzyme and substrate. Most serine proteases have no 
strict substrate specificity but many show a preference for a particular side 
chain before the scissile bond as seen from the N-terminus of the substrate. 
The preferred side chain is oriented to fit into a pocket of the enzyme called 
the specificity pocket. Serine protease catalysis was discussed by Branden 
and Tooze in An Introduction to Protein Structure (1991), Chapter 15.
The NS3 protein of HCV was found to contain the catalytic motif of a 
trypsin-like serine protease (Miller and Purcell, 1990). The order and 
spacing of the catalytic triad are conserved between different HCV 
sequences: His-57, Asp-81 and Ser-139 (amino acid numbering from the start 
of the NS3 protein). The important amino acid regions of serine proteases 
can be divided into four separate "boxes" or regions. The first three boxes 
each contain an amino acid that contributes to the catalytic triad, present in a 
characteristic spatial pattern. Mutation of amino acids in the catalytic triad 
results in inactivation of the serine protease (Hijikata et al., 1993a; Manabe et 
al., 1994). Box 4 contributes to substrate binding. These features are 
observed for HCV NS3 (Bartenschlager et al., 1993).
The shape of the HCV serine protease specificity pocket is 
determined by main-chain atoms and by a phenylalanine ring (Pizzi et al., 
1994). This indicates that PI in the substrate has to have a short side chain 
(Cys or Ser) to fit into the very hydrophobic pocket. The sulfhydryl group 
of cysteine has been shown to interact favourably with the aromatic ring 
system of phenylalanine (Bode et ah, 1984). The amino acid at PI in the
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substrate is restricted to a short, polar or aliphatic side chain to perm it 
cleavage (Leinbach et al, 1994). Within the substrate P6 is observed to be a 
conserved acidic amino acid with serine or alanine at PI' (Grakoui et a l, 
1993b; Pizzi et a l, 1994; Leinbach et a l, 1994; Komoda et al., 1994).
Processing by the NS3 protease involves a num ber of features. NS3 
associates with the HCV NS4A protein and is anchored by it to the 
endoplasmic reticulum (Satoh et al, 1995). W ithout NS4A, NS3 is usually 
found in the cytoplasm. The NS4A protein also acts as a cofactor in NS3- 
m ediated processing events (Failla et al, 1994; Bartenschlager et al, 1994). 
Association of NS3 to the ER membrane through NS4A results in maximal 
protease activity. ER membrane association of the NS3/NS4A complex may 
play a role in replicase function (Lin and Rice, 1995). The first 20-30 am ino 
acids of NS3 are required for interaction with NS4A (Failla et a l, 1995; H an et 
a l, 1995; Satoh et a l, 1995). Association with NS4A stabilises the NS3 protein 
(Satoh et al, 1995) although association may have to take place at an early 
stage of expression to create an active protease (Overton et al., 1995). The 
degree of interaction with NS4A seems to vary between different strains of 
HCV (Muramatsu et al, 1997). In some strains of HCV, NS3 is found 
localised, to a minor degree, in the nucleus. This nuclear localisation has 
been observed to be stimulated by the presence of p53, either through 
interaction with p53 to form a complex that is transported to the nucleus or 
by p53 augmenting the expression of a nuclear transporter protein that 
binds NS3 (Muramatsu et al, 1997).
The Zn2+ ion has shown to have an indirect role in NS3 protease 
function in that it stabilises the correct conformation of the enzyme (Hahm 
et al, 1995; Han et al, 1995). The Zn2+ binding site has a structural 
composition that utilises the sulfhydryl groups of cysteine residues and the 
imidazolyl group of a histidine residue. There are four residues involved: 
Cys-97, Cys-99, Cys-145 and His-149 (Stempniak et al, 1997). The histidine 
residue is less important than the three cysteine residues in Zn2+ binding.
This binding motif CXC CXXXH is similar to the proposed Zn2+ binding
motif in enterovirus and rhinovirus proteins. The structural role of the zinc 
atom is to stabilise the NS3 domain but also to enable recognition of the 
NS3 region as a substrate for NS2/3 activity (Stempniak et al, 1997). The 
addition of Zn2+ during protease folding stimulates the basal level of 
polyprotein processing by NS3 (Stempniak et al, 1997). Inhibition of 
protease activity by Cu2+ seems to occur near to or at the active site of the 
protease (Han et al, 1995). The C-terminal region of NS3 that encodes the 
NTPase/RNA helicase can be deleted with no effect on protease activity 
(Failla et a l, 1995; Hahm et a l, 1995).
Crystallization of the protease domain of HCV has been shown to be 
difficult due to its poor solubility and tendency to aggregate. The three- 
dimensional structure of the 189 amino acid protease domain was 
determined for a type 2b isolate (HCV BK) by Love et al (1996). The 
protease domain folded into two six-stranded P barrels, similar to those 
observed for trypsin-like serine proteases despite having virtually no 
sequence similarity with proteases containing a trypsin-like fold. A 30 
amino acid stretch at the N-terminus precedes the first p barrel. This is
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significantly larger than in most proteases in their active states. The 
secondary structure formed by this region is reminiscent of the short p 
strand found in many cellular proteases. The spatial arrangement of strands 
within the p barrels is similar to that observed for other trypsin-like 
proteases w ith the exception that the loops connecting the strands are 
relatively short. The two p barrel motifs comprise 140 amino acids of the 
NS3P domain. After the p barrel structure there is one turn of a  helix (4 
amino acids) that resembles the first turn of the C-terminal helix found in 
cellular proteases. This region is followed by a disordered polypeptide 
stretch. The crystal structure is illustrated in Fig. 1.9. The crystal structure 
also confirmed the involvement Cys-97, Cys-99, Cys-145 and His-149 in the 
binding of Zn2+ within the protease domain. The three cysteine residues 
contribute a partial tetrahedral geometry around the zinc ion. The fourth 
member of the tetrahedral coordination is a water molecule located w ithin 
hydrogen bond distance to the histidine residue. The zinc ion serves to 
anchor the turn  at pD2-pE2 to the interbarrel loop implying a structural role 
for the metal. The catalytic triad, the oxyanion hole and strand pE2 
(forming one side of the specificity pocket) have the same relative spatial 
positions as seen in other trypsin-like proteases. A classic catalytic triad 
configuration would exist during substrate cleavage by the protease 
domain. The amino acid sequence around the catalytic serine residue is part 
of the conserved GXSGG motif seen in trypsin-like serine proteases. The 
oxy anion hole is nearly identical to that observed in other proteases. The 
pC2-pD2 loop (containing one turn of a  helix) situated before the oxyanion 
hole may add conformational stability at the binding site utilising the 
region of a  helical structure.
A shallow, nonpolar specificity pocket is formed primarily by the 
side chains of Phe-154, Ala-157 and Leu-135. From the crystal structure it has 
been proposed that the side chain of PI in the substrate (OH or SH) will 
interact w ith the electron-rich k clouds on the aromatic ring of Phe-154. 
Amino acids P2-P6 of the cleavage site will form P sheet antiparallel 
hydrogen bonds with strand pE2. This extensive backbone interaction 
would allow the acidic side chain at P6 on the substrate to interact with Arg- 
161 and Lys-165. These interactions also compensate for the apparent lack 
of P2-P5 side chain to enzyme interactions due to the short pB2-pC2 and 
pEl-pFl loops of the protease domain. Phe-154 was shown to be the m ain 
determinant of substrate specificity for the SI pocket by Koch and 
Bartenschlager (1997). The position of Phe-154 at the bottom of the pocket 
would determine the specificity of the PI residue by restricting the length of 
the PI amino acid residue that can fit in the pocket and defines the 
interaction of the residue with the aromatic ring of Phe-154. Ala-157 is
located underneath Phe-154 and plays a very minor role in determining the 
SI pocket whereas Leu-135 plays a structural role (Koch and Bartenschlager, 
1997). The SI binding pocket is illustrated in Fig. 1.10.
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Fig. 1.9. Overall folding of HCV NS3P (taken from Love et 
al., 1996). View into the active site in the asymmetric unit 
with catalytic triad residues labeled by the single amino acid 
code. Secondary structural elements are colour-coded 
yellow for (3 strand, green for a  helices, and blue for coil, p 
strands in the trypsin-like barrels (A1-F2) are labelled in the 
standard convention. Catalytic residues are shown in 
sphere and cylinder representation, with spheres colour- 
coded green for carbon, blue for nitrogen, and red for 
oxygen.
HS
Leu 135
Phe 154
Ala 157
Fig. 1.10. Hypothetical model of the SI specificity binding pocket of the 
NS3 serine proteinase. The SI pocket is defined by the dotted line and 
containd the PI side chain of the wild type cysteine residue. Model 
adapted from Koch and Bartenschlager (1997).
The crystal structure of the protease domain was also determined 
when bound to the NS4A cofactor (Kim et al., 1996). In this case there were a 
num ber of slight differences to that observed for the NS3 protease dom ain 
alone. The complex adopted a chymotrypsin-like fold consisting of two 
domains, each containing a twisted P sheet incorporating a "Greek key" 
motif. The C-terminal domain (amino acids 1120-1206) consists of a six- 
stranded p barrel followed by a structurally conserved a  helix. The core of 
this barrel is packed w ith hydrophobic residues emanating from all six 
strands of the P barrel. The N-terminal domain (amino acids 1027-1119) 
contains an eight stranded P barrel with one strand donated from the NS4A 
cofactor. The C-terminal domain contains the tetrahedrally coordinated 
zinc ion and the catalytic serine residue of the catalytic triad whereas the 
histidine and aspartate are located in the N-terminal domain. The NS4A 
peptide (amino acids 21-39) used in this modelling formed hydrogen bonds 
with the N-terminal region or one of the strands from its main-chain 
carbonyl and amide groups from Val-23 to Leu-31. From this analysis it has 
been shown that NS4A should be considered as an integral structural 
component of the complex, supporting the observation that NS4A stabilises 
NS3 (Satoh et al, 1995). W ithin NS4A several residues found buried in the 
core of NS3P are critical for complex formation with NS3 (Val-23, Ile-25, Ile- 
29 and Leu-31). This corroborates with what has been observed in previous 
NS4A analyses (1.8.6.). Activation of NS3 by NS4A may be a result of 
incorporation of NS4A into the N-terminal domain p sheet. When 
incorporated NS4A stabilises the NS3 structure between residues 1030 and 
1034 through main-chain hydrogen bonds. The crystal structure of the 
NS3P/NS4A complex is illustrated in Fig. 1.11.
The NTPase/RNA helicase domain.
The RNA helicase family can be divided into a number of 
subdivisions. One of these groups called the DEAD box family contains 
three subfamilies: DEAD, DEAH and DEXH (Koonin, 1991). The HCV NS3 
protein has an Asp-Glu-Cys-His sequence and is thought to be a member of 
the DEXH protein family.
The basal NTPase activities of HCV, flavivirus and pestivirus NS3 
proteins are all unaffected by pH, MgCh and monovalent cation 
concentrations when expressed as protein fragments lacking the N-term inal 
protease domain. In the presence of a polynucleotide stimulator a clear pH 
optim um  of 6.5 was observed. In addition to this there is an optim um  
MgCh concentration of 2.5mM in the presence of 0.35mM ATP (Suzich et al, 
1993). All the Flaviviridae NTPases tested were capable of hydrolysing NTP 
and dNTP substrates. Both HCV and pestivirus (BVDV) NTPases were 
stimulated by poly(U) to a degree higher than that for other 
polyribonucleotides. HCV was alone however in its equal stimulation by 
both poly(U) and poly(dU). The HCV enzyme required a higher
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Fig. 1.11. Stereo ribbon diagram of the NS3P: NS4A complex 
(taken from Kim et al., 1996). View into the active site cleft of the 
enzyme. The N-terminal domain of the complex is on the left and 
the C-terminal domain on the right. Secondary structural elements 
are labelled according to convention used for chymotrypsin. Side- 
chains of active site residues His-1083, Asp-1107, and Ser-1165, 
along with Zn2+ ligands Cys-1123, Cys-1125, and Cys-1171 are 
displayed in ball-and-stick representation. Zn2+ is coloured cyan 
and its H20  ligand red. The p strand formed by NS4A is shown in 
magenta.
concentration of poly(U) to achieve the half-maximal level of stimulation in 
comparison to both pestivirus and flavivirus NTPases (Suzich et ah, 1993). It 
has been shown that the NS3 protein interacts with the NS4A protein to 
form a stable complex with observed effects on protease activity (see The 
serine protease). The NS34A complex has an optimal NTPase pH between 
7.5 and 8.5 in contrast to an optimal pH 6.5 for the helicase domain alone 
(Morgenstern et al., 1997). The catalytic efficiency of the NTPase function 
was stimulated to a similar extent by saturation with poly(U) for both the 
NS3 NTPase alone and the NS34A complex. This is not true for saturation 
with poly(C) and poly(A) that stimulated the NS34A complex NTPase 
activity significantly more than for the NTPase alone. The NS3-4A complex 
was also significantly more sensitive to polynucleotide stimulation than the 
NTPase alone (Morgenstern et al., 1997).
RNA helicases are involved in important cellular functions, such as 
RNA splicing, ribosome assembly and translational initiation as well as 
viral RNA helicases functions in viral replication, transcription and protein 
translation. The C-terminal domain of HCV NS3 has an RNA helicase 
activity that uses ATP as an energy source (Kim et al., 1995; Tai et ah, 1996).
As for the NTPase experiments, a C-terminal fragment only was used 
to assay RNA helicase activity. A full length NS3 protein may have a higher 
level of enzymatic activity. The functional domain required for 
NTPase/RNA helicase activity is 400 amino acids in length between amino 
acids 1209 and 1608. Of these amino acids two regions (amino acids 1562- 
1608 and 1193-1224) are believed to be important for correct conformation of 
the protein (Kim et ah, 1997a). The helicase activity occurs in a 3' to 5' 
direction along the RNA template and binds to single-stranded but not 
blunt-ended dsRNA (Tai et ah, 1996; Kim et ah, 1997a). The C-terminal 135 
amino acids and the N-terminal 32 amino acids of the helicase domain are 
not required for RNA binding (Kim et ah, 1997a). The RNA helicase can 
unwind the native 5'NTR of HCV in a 5' to 3' direction. The directionality of 
the unwinding of the 5'NTR may be due to the presence of secondary 
structures or sequence within this region. The ability of the 5'NTR to direct 
the helicase in this direction means that in natural HCV infection the 
helicase can act in a bidirectional manner. The HCV NS3 helicase also could 
unwind DNA-RNA and DNA-DNA substrates and so exhibits DNA helicase 
activity (Tai et ah, 1996). This DNA helicase activity may affect cellular 
nucleic acid structures or activities and so may be relevant in viral 
pathogenesis. The HCV helicase is very similar to two cellular helicases, 
NDH II and NPH II, except that NDH II can also bind dsRNA and is 
stimulated by, rather than sensitive to, salt concentration. The presence of 
poly(U) and poly(A), which both stimulate NTPase activity, inhibit RNA 
helicase function, possibly by inhibiting the binding of the enzyme to 
substrate. Similarly the presence of polynucleotides inhibits the RNA 
helicase function of the NS34A complex possibly due to binding 
competition between poly(U) and duplex RNA for the same or overlapping 
sites within the NS3 region.
RNA helicases contain eight conserved motifs, four of which have 
been shown to play an important role. Closest to the N- terminus of RNA
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helicases is the A motif. This motif has the basic amino acid sequence of 
AXXXXGKT/S and is required for ATP binding, ATP hydrolysis and RNA 
unw inding (Walker et al., 1982). The second motif is the DEAD box element. 
The first aspartic acid of this element binds to Mg2+ through a water 
molecule (Pai et al., 1990) and this metal ion binds to the ATP bound to the A 
motif. In the C-terminus of RNA helicases there are two important motifs. 
An S/TAT sequence is believed to play a role in RNA unwinding and the 
H/QRXGRXXR motif is believed to play a role in ATP hydrolysis and RNA 
unwinding.
Point mutations were introduced into these four motifs within an 
active NS3 construct (Kim et al., 1997b). This construct encoded the C- 
term inal region of NS3 and produced a fully functional RNA 
helicase/ ATPase. M utation of the conserved lysine residue within motif A 
reduced NTPase activity by 95% in the absence of poly(U) and by 50% in the 
presence of poly(U). This mutation completely abolished RNA helicase 
activity.
W ithin the DECH motif of the HCV NS3 a variety of amino acid 
substitutions were carried out. The effect on activity depended on the 
charge of the amino acid introduced and the interactions of these residues 
with other amino acids.
The HCV NS3 contains a threonine residue at the first amino acid of 
the S/TAT motif. Substitution of this threonine residue with an alanine 
residue had little effect on the NTPase activity in the absence of poly(U) 
although this activity was not influenced by the presence of poly(U). The 
RNA helicase activity was approximately half of the wild type. The eIF-4a 
RNA helicase SAT motif was important in the RNA unwinding reaction and 
the contrast in these results implies that the TAT motif may play a lesser 
role in RNA unwinding than the SAT motif (Kim et al., 1997b).
Enzymatic activity was demonstrated to be highly dependent on the 
presence of the glutamine residue at the start of the fourth motif. Further 
m utational analyses of additional residues throughout the conserved motifs 
dem onstrated that the strictly conserved amino acids were of a higher 
importance for enzymatic activity than the less conserved amino acids.
1.8.5. A novel method for the inhibition of NS3 function.
A strategy developed for in vitro genetic selection has led to the 
isolation of nucleic acids that have the ability to bind to specific target 
proteins. Using this strategy, nucleic acid molecules, isolated from a pool of 
random  nucleic acids, are obtained that have a high affinity with a target 
protein. After repeated rounds of selection and amplification, the end 
products isolated are tight-binding oligonucleotide ligands called aptamers 
(Kumar et al., 1997).
A pool of 1014 random  oligonucleotides (120 nucleotides in length) 
was analysed for binding to the HCV NS3 protein. During this selection 
cycle a non-specific competitor (tRNA) and a specific competitor (10G-1
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RNA, a small aptamer that binds to NS3 isolated by Urvil et al., 1997) were 
included to increase the stringency of the selection. The selection cycle was 
repeated six times until 14% of the aptamers present bound to the NS3 
protein. All the NS3-binding aptamers were cloned and then were grouped 
together to give four classes of NS3-specific aptamers (Kumar et al, 1997). 
The secondary structures of these NS3 specific aptamers are illustrated in 
Fig. 1.12.
Two aptamers, G6-16 and G6-19, inhibited processing in vitro by 
approximately 50%, moderate inhibition was observed with G6-8 and no 
inhibition of NS3 protease activity by G6-12. The lack of inhibition of 
protease activity by G6-12 is consistent with its low binding efficiency to the 
NS3 protease domain alone. G6-16 and G6-19 bound specifically to the NS3 
protease domain.
None of the NS3 specific aptamers had any effect on the NS3 ATPase 
activity. In contrast G6-12, G6-16 and G6-19 completely inhibited the 
helicase activity of the NS3 protein (Kumar et al., 1997).
1.8.6. The NS4A protein.
The NS4A protein is a short, 54 amino acid protein of approximately 
6 kDa (Tomei et al., 1993). The function of NS4A is primarily as a cofactor for 
catalysis by the NS3 serine protease. NS4A interacts with NS3 to form a 
stable complex which is subsequently localised to the ER membranes (Failla 
et al, 1995; Satoh et al., 1995). In the absence of NS4A, NS3 is located in the 
cytoplasm. Although NS4A is responsible for localising the protease 
complex to membranes its activation effect is essentially independent of 
membranes (Koch et al., 1996).
The NS4A protein is composed of three distinct domains: an N- 
terminal hydrophobic domain, a central hydrophobic domain and an acidic 
C-terminal domain (Bartenschlager et al, 1995b) as illustrated in Fig. 1.13. 
The central domain of NS4A is responsible for the interaction with NS3 
(Koch et al, 1996; Steinkuhler et al, 1996a; Steinkuhler et ah, 1996b). The 
minimal domain required for this activation of NS3 was isolated to a central 
12 amino acid stretch (Lin et al., 1995; Bartenschlager et al., 1995b; Butkiewicz 
et al., 1996). Within this region hydrophobic residues, specifically Ile-29, are 
critical in the role of NS4A as the NS3 cofactor (Lin et al., 1995; Butkiewicz et 
al., 1996). Mutation of residues such as Val-24, Ile-25, Val-26, Val-30 and Leu- 
31 to Ala inhibited cofactor activity whereas the alanine substitution for 
Cys-22 and Arg-28 showed little or no effect (Butkiewicz et al., 1996). The 
region exhibits a high propensity for the formation of a (3 strand-like 
structure (Butkiewicz et al., 1996). The N-terminal domain of NS4A does not 
seem to be im portant in cofactor activity (Hamatake et al., 1996; Koch et al.,
1996). This domain is very hydrophobic and has the potential to span the 
lipid bilayer once and so may be important in the membrane anchoring of 
NS3/NS4A complexes to the ER (Bartenschlager et al., 1994). Overall a weak
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interaction at multiple sites between NS4A and NS3 is sufficient for protease 
complex formation (Lin et al., 1995; Koch et al., 1996).
The presence of NS4A is essential for some of the processing events 
mediated by the NS3 protease, whereas at other sites NS4A merely increases 
the efficiency of NS3 mediated catalysis (Bartenschlager et al., 1994; Lin et al., 
1994b). The presence of NS4A may induce conformational changes in NS3 
that favour substrate hydrolysis, and NS4A may contribute directly to 
substrate binding by interacting with the polyprotein substrate (Lin et al., 
1997). NS4A forms a detergent-stable compex with the NS4B5A substrate 
and this complex formation requires key residues on NS4A (Lin et al., 1997). 
NS4A may act as a mediator between the NS3 protease and the NS4B5A 
substrate to bring them into close contact with each other as binding occurs 
both with and without NS3. Three residues within the central domain of 
NS4A that are essential for interaction with NS3 (Val-23, Ile-25 and Iso-29) 
are also essential for the interaction with the NS4B5A substrate (Lin et al.,
1997). The multisubunit complex between NS4A and the NS4B5A substrate 
may also involve residues from NS3 and may also involve cellular 
components. It has been demonstrated that NS4A from subtype la  can 
stimulate proteolysis by subtype lb  NS3 and vice versa (Butkiewicz et al.,
1996). The effect of NS4A on the NS3 protein is similar to that of NS2B in 
flaviviruses and plO in pestiviruses (Lin et al., 1994b).
1.8.7. The NS4B protein.
The NS4B protein is a 261 amino acid, relatively hydrophobic, 27kDa 
protein. It is located between amino acids 1712 and 1972 of the HCV Gla. 
polyprotein. The function of the NS4B protein of HCV is not known at this 
time. It plays no role in the processing of the polyprotein and thus may 
have a function in the replication of the HCV genome.
1.8.8. The NS5A protein.
The NS5A protein is encoded between amino acids 1973 and 2419. 
The NS5A gene is observed to produce two proteins of 56 and 58 kDa in size. 
Analysis has shown that both proteins are phosphorylated and that p58 is a 
hyperphosphorylated form of p56 (Tanji et al., 1994a). There are three serine 
residues that are targetted for hyperphosphorylation at positions 2197, 2201 
and 2204 and hyperphosphorylation at these residues is dependent on the 
presence of NS4A (Tanji et al., 1995). Amino acids 2135 to 2139 of NS5A are 
im portant for NS4A-mediated hyperphosphorylation (Asabe et al., 1997). 
There are two regions within the NS5A protein that are involved in basal 
phosphorylation (in the absence of NS4A). The first region falls between 
amino acids 2200 and 2250 and the second between amino acid 2350 and the 
C-terminus of the NS5A protein (Tanji et al., 1995). Basal phosphorylation of
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the 2200-2250 region may be greatly enhanced by deletion of the C-terminus 
of NS5A. Both these phosphorylation events take place after the NS5A has 
been processed from the viral polyprotein. A nuclear localisation-like 
signal has been identified at the C-terminus between amino acids 2326 and 
2334 (PPRKKRTVV). A diagram showing the amino acid positions w ithin 
the NS5A protein is illustrated in Fig. 1.14.
Both forms of NS5A are detected in the nuclear periplasmic 
membrane fraction although no trace of either form was detected within the 
nucleus (Tanji et al., 1995). The phosphorylation pattern of the NS5A protein 
between diverse HCV types is maintained. Phosphorylation is mediated by 
cellular serine/threonine kinases with characteristics similar for both in vivo 
and in vitro experiments (Reed et al., 1997). The kinase involved is believed 
to be a member of the CMGC kinase family (consisting of CKII and proline- 
directed kinases; CDK, MAPK and GSK3). Phosphorylation takes place 
mostly on serine residues although there is a low level of threonine 
phosphorylation. The C-terminus of NS5A is acidic, containing a large 
num ber of proline and serine residues, which agrees with the features 
observed for phosphorylation by CMGC kinases. There are a num ber of 
reasons why phosphorylation of the NS5A protein is believed to be 
m ediated by cellular kinases. NS5A phosphorylation takes place in the 
absence of any viral proteins and NS5A itself does not contain any motifs 
associated w ith eukaryotic kinases. In vitro phosphorylation exhibits a 
preference for Mn2+ and is inhibited by Ca2+ (although Ca2+ may already be 
bound by the enzyme) (Reed et ah, 1997).
One of the proposed functions of NS5A is that it forms part of the 
replication complex for HCV. This theory is based on the observation that 
it can be coprecipitated with both NS2 and NS5B (the HCV polymerase). 
Alternatively, NS5A has also been linked with having a function in 
resistance to treatm ent with interferon. In 1995, Enomoto et al. showed that 
sensitivity to interferon-a therapy varied between different HCV isolates. 
Analysis of the interferon-resistant HCV types showed that a 40 amino acid 
stretch in the NS5A region, from amino acid 2209 to 2248, contained a 
unique amino acid change at amino acid 2218, that was exclusive to IFN- 
resistant HCV sequences. This region was identical to that observed in the 
prototype HCV type lb  sequence and was designated the interferon 
sensitivity determ ining region (ISDR). Further characterisation has shown 
that 13% of patients who had 1-3 amino acid changes from the wild type 
(HCV-J) sequence in this region were resistant to interferon treatment. One 
hundred percent of patients who had greater than 4 amino acid changes 
were complete responders (Enomoto et al., 1996). Patients treated w ith 
interferon-p instead of interferon-a also showed a correlation between 
amino acid sequence in the ISDR of different HCV isolates and interferon-p 
resistance (Kurosaki et al., 1997). NS5A has been shown to repress the IFN- 
induced protein kinase, PKR, which is a mediator of IFN-induced antiviral 
resistance through a direct interaction with the protein kinase catalytic 
domain (Gale et al., 1997). This mechanism may be one by which HCV 
avoids the antiviral effects of IFN. However, one report by Zeuzem et al.
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(1997) did not find any link between the amino acid sequence in the ISDR 
and interferon resistance, as did a report by Khorsi et al (1997). An NS5A 
fragm ent deleted at its N-terminus had the ability to activate transcription 
in yeast cells w hen fused to GAL4 DNA binding domain. Amino acids 130- 
352 of NS5A were critical. This region contained two acidic domains and a 
proline-rich region that have been shown to be involved in the function of 
several transcriptional activators (Tanimoto et al, 1997).
1.8.9. The NS5B protein.
Analysis of the HCV polyprotein sequence by Miller and Purcell 
(1990) predicted that the C-terminal region of NS5B encoded an RNA- 
dependent RNA polymerase (RdRp) which was responsible for replication 
of the viral genome. Four motifs (A-D) within the NS5B protein have been 
shown to play a role in polymerase function (Lohmann et al., 1997) and are 
shown positionally within NS5B in Fig. 1.15. Motif A, which probably plays 
a role in NTP binding and catalysis, is characterised by the presence of an 
invariant aspartic acid residue and is essential for enzymatic activity. 
M utation of motif B, containing an invariant glycine residue, results in little 
or no RdRp activity. Motif C, consisting of the distinctive GDD sequence 
associated w ith polymerases, is sensitive to mutation at the central aspartic 
acid residue but tolerates mutation of the flanking residues, albeit with a 
lower enzymatic activity. The conservative mutation of arginine to lysine 
w ithin motif D enhanced the activity of the enzyme by 50% (Lohmann et al, 
1997). The presence of the arginine residue that reduces RdRp catalytic 
activity within NS5B may explain the low replication levels of HCV in vivo. 
It should be noted that the polymerase assay used in these experiments did 
not involve any other of the viral proteins.
The RdRp activity of HCV was shown to be dependent on Mg2+ ions, 
had an optim um  pH of 7.5 and was tolerant to variations in salt 
concentration (Behrens et al., 1996). Polymerase activity was shown to act by 
a "copy-back" mechanism on the input RNA. It was also shown not to be 
restricted to RNA molecules containing the HCV 3'UTR (Behrens et al., 1996; 
Lohmann et al., 1997). The RdRp uses the 3/-terminal OH group as a prim er 
for polymerisation producing the complementary strand copy of the input 
RNA. When the 3 '-terminal OH was blocked, a DNA or RNA 
oligonucleotide primer could be used to initiate polymerisation (Behrens et 
al, 1996; Lohmann et al, 1997). Polymerisation was observed for both 
homo- and heteropolymeric RNA molecules of up to several hundreds of 
nucleotides in length. The "copy-back" mechanism may be a common 
feature of RNA polymerising enzymes. The observation that the HCV 
RdRp had the ability to replicate unrelated RNAs suggests that the NS5B 
able to carry out viral RNA replication and that there must be a specific 
feature that directs replication of the HCV genome. The restriction of RNA 
synthesis exclusively to HCV viral templates must require viral a n d /o r 
cellular proteins. NS5B produced from the viral polyprotein was m ore
27
Fig. 1.15. 
Schem
atic 
representation 
of the 
NS5B 
protein. The 
positions 
of the 
am
ino 
acid 
m
otifs 
A 
to 
D 
are 
indicated.R
esidues m
arked 
by 
asterisks are 
highly 
conserved 
am
ong 
HCV 
isolates. 
Capital letters indicate 
residues highly 
conserved 
am
ong 
plus-strand 
RNA 
virus 
polym
erases and 
residues underlined 
and 
bold 
are 
residues highly 
conserved 
am
aong 
all viral polym
erases. 
Diagram 
taken 
from 
Lohm
ann 
et al. (1997).
id
0
H —*
H >
oaa
Cn
VOM
220 
283 
317 
345
efficient at RNA synthesis than NS5B expressed as a single construct 
(Behrens et al., 1996). This feature may be due to more accurate NS5B folding 
w hen it is expressed as part of the HCV polyprotein. Alternatively one or 
more of the viral non-structural proteins may act as cofactors for NS5B 
directed RNA synthesis.
The NS5B protein is also believed to encode a terminal nucleotide 
transferase (TNTase) which incorporates UMP preferentially at the 3' end of 
the input RNA (Behrens et al., 1996). Although this feature has also been 
observed for other viral RdRps the HCV NS5B protein was not purified to 
homogeneity. The TNTase activity may be due to a cellular enzyme that is 
co-purified or associated with NS5B. That the TNTase activity was 
approximately the same, irrespective of the level of the RdRp activity, backs 
up the observation that there may not be an endogeneous TNTase function 
(Lohmann et al., 1997). The NS5B protein is unstable when expressed in cells 
(Lin et al., 1994b). This observation may be a feature of regulation w ith 
NS5B probably being degraded through a cellular pathway as it is stable in 
reticulocyte lysates.
1.9. Polyprotein processing.
The polyprotein of HCV encodes both the structural and non- 
structural proteins. The structural proteins, located at the N-terminus of the 
polyprotein, are cleaved away from the polyprotein by the action of host- 
encoded signal peptidases located in the ER lumen (Hijikata et al., 1991b; 
Tomei et al., 1993). Host signal-peptidase mediated processing of the 
structural region is also seen for flaviviruses and pestiviruses with small 
differences between each genus (C.M. Rice, 1996). The non-structural region 
is processed by two proteases encoded within the virus polyprotein. The 
junction between the C-terminus of NS2 and the N-terminus of NS3 by a 
zinc-dependent metallo-protease encoded by the C-terminus of NS3 and the 
N-terminal third of NS3 (1.8.3.), The remaining cleavage sites within the 
polyprotein are processed by the NS3 serine protease (Grakoui et al., 1993b; 
Bartenschlager et al., 1993; Tomei et al., 1993; Manabe et al., 1994). The major 
cleavage pathway of the non structural region of the HCV polyprotein is 
shown in Fig. 1.16.
The presence of uncleaved NS2 sequence at the N-terminus of NS3 
inhibits subsequent NS3 protease activity (D'Souza et al., 1994). The helicase 
dom ain of NS3 can be deleted with no inhibitory effect on the serine 
protease activity (Bartenschlager et al., 1994; Hahm et a l, 1995). Processing of 
the non-structural region in this way is similar to flaviviruses and 
pestiviruses. In flaviviruses NS3 is responsible for most of the processing 
within the non-structural regions with the exception of the NS4A/NS4B site 
which is processed by a signal peptidase (Chambers et al, 1993; Lin et al., 
1994a; Preugschat et al, 1991; Speight et al., 1988). The pestivirus non- 
structural region is processed by p80 except for the p80 N-terminus. The 
enzyme responsible for this cleavage has not been determined. Both the
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flavivirus NS3 and the pestivirus p80 are analagous to the NS3 protein of 
HCV. In flaviviruses a cofactor NS2B is required for processing by the 
protease. HCV NS3 has a cofactor, NS4A, whose effect on processing varies 
from site to site.
Processing at the NS3/NS4A site was shown to occur 
intramolecularly (in cis) whereas the remaining processing events at 
NS4A/NS4B, NS4B/NS5A and NS5A/NS5B occur intermolecularly (in trans) 
by Bartenschlager et al. and Tomei et al. in 1993. These processing features 
are similar to that seen for flaviviruses and pestiviruses. The NS2A/NS2B 
and NS2B/NS3 processing events take place in cis whereas the NS4B/NS5 
cleavage site is processed in trans in flaviviruses. For pestiviruses both the 
N and C-termini of p80 are produced from intramolecular cleavage events 
while the rem aining cleavage sites downstream of p80 are processed 
intermolecularly. Once released from the polyprotein all HCV proteins are 
associated, more or less, with membranes although a small amount of NS3 
and NS5A can be isolated in the membrane-free fraction (Hijikata et al., 
1993b). The non-structural proteins may form a complex possibly 
containing the replicatory machinery and even the roots that hold the 
genome on the surface of the ER during replication.
Analyses of the NS3-mediated cleavage sites have given the 
following consensus sequences at each site:
P6 P5 P4 P3 P2 PI / PI'
NS3/NS4A D L E V /IV /M T s
NS4A/NS4B D E M E E C A/S
NS4B/NS5A E C X X P C S
NS5A/NS5B E/D D V V C C S
This analysis gives a consensus cleavage site sequence as:
E /D X X X X C /T  S/A
All the cleavage sites processed in trans contain a cysteine residue at 
PI whereas the only cleavage site processed in cis, NS3/NS4A, has a 
threonine residue at PI. For all the cleavage sites an acidic residue is 
present at P6 with serine or alanine present at PI'. No basic residues are 
found between P7 and P2' for any of the cleavage sites (Kolykhalov et al.,
1994). From further in vitro analysis the minimal domain required for 
processing falls between P4 and FI' and residues immediately N and C-
terminal to these amino acids may be essential for efficient cleavage 
(Komoda et al., 1994).
As for HCV the pestivirus structural proteins (NPro, C, E1™, El and E2) 
are released from the polyprotein mostly by cellular enzymes (Elbers et al., 
1996; Rumenapf et al., 1993). The non-structural region downstream of the 
NS3 is processed by the NS3 serine protease at NS3/NS4A, NS4/NS4B, 
NS4B/NS5A and NS5A/NS5B (Xu et a l ,  1997; Tautz et a l ,  1997).
The only conserved residues at the NS3 mediated cleavage sites are a 
leucine at PI and either a serine, alanine or asparagine residue at PI'. The 
residue at position 216 within the protease defines the depth of the PI 
specificity pocket. For the pestivirus bovine viral diarrhoea virus (BVDV) 
the residue at position 216 is a glycine which results in a deeper binding 
pocket than that observed for HCV. An asparagine residue at position 190 
limits the w idth of the specificity pocket (Xu et a l ,  1997).
As for HCV, pestivirus NS3 protease mediated processing is 
stimulated by the presence of a cofactor, NS4A. Processing at the 
NS4B/NS5A and NS5A/NS5B sites requires the presence of NS4A. The 
pestivirus NS4A protein is a relatively acidic, 64 amino acids peptide. It has 
a hydrophobic N-terminus and a highly charged, acidic C-terminus sim ilar 
to the HCV NS4A. The BVDV NS4A has a number of conserved acidic 
residues within the central region, differing from the hydrophobic central 
region of the HCV NS4A (Xu et a l ,  1997).
The NS3 serine protease of flaviviruses processes the non-structural 
region of the polyprotein both upstream and downstream of the NS3 
protein. The flavivirus NS3 protease processes at NS2A/NS2B, NS3/NS4A 
and NS4B/NS5. The consensus cleavage site for these processing events is 
G(A)RR /  S(G). The PI and P2 residues are highly conserved, basic amino 
acids and the P I' residue always contains a short side chain.
The flavivirus NS3 serine protease also uses a cofactor, located 
upstream of the NS3, NS2B (Zhang et a l, 1992). The NS2B cofactor is 
essential for cleavage at all the NS3 protease-dependent sites (Chambers et 
al., 1993). The highly charged, central region of this protein is responsible 
for cofactor function (Chambers et a l ,  1993).
For all three genera of the Flaviviridae the cleavage sites processed by 
the NS3 serine protease contain amino acids with short side chains at the PI' 
position.
110. HCV replication.
The replication of the HCV genome has not been well characterised 
due to the absence of an efficient tissue culture system for propagating the 
virus. The replication of RNA in other members of the Flaviviridae has been 
characterised (Fig. 1.17.). For flaviviruses, after the genomic RNA has been 
translated to produce the poly protein, complementary negative-sense RNA 
strands are produced, which are subsequently used as templates to produce 
more genome-length positive-sense RNAs. These positive-sense strands are
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Fig. 1.17. The Flavivirus lifecycle (from C.M. Rice, 1996).
used for translation of the polyprotein, production of additional negative- 
sense RNA strands or are packaged into virions (Brinton et al, 1986; Trent 
and Naeve, 1980; Westaway, 1987). The synthesis of negative-sense RNA 
strands from  the positive-sense genomic RNA occurs through a sem i­
conservative mechanism involving replicative intermediates (RIs) and 
replicative forms (RFs) (Chu and Westaway, 1985; Cleaves et al, 1981). RIs 
are defined as duplex RNA molecules whereas RIs contain both double­
stranded and single-stranded RNA regions (Chu and Westaway, 1985; 
Cleaves et al, 1981). These replication intermediates and replication forms 
are detected in infected cells as well as in vitro in RNA polymerase reactions 
(Bartholomeusz and Wright, 1993; Chu and Westaway, 1985; Grun and 
Brinton, 1986). Regulation of positive and negative strands is believed to 
take place as at the peak of RNA synthesis in infected cells the ratio of 
positive-sense to negative-sense RNA molecules is 10:1 (Cleaves et al, 1981). 
A similar replication process has been postulated for pestiviruses involving 
both RIs and RFs and the same ratio of positive-sense RNA to negative- 
sense RNA has been observed (Gong et a l, 1996).
HCV is assumed to replicate in the same manner as flaviviruses and 
pestiviruses. Full length genomic RNAs from flaviviruses (Kapoor et al,
1995) and pestiviruses (Moorman et al, 1996) have been shown to be 
sufficient to produce infection and infectious virus. Replication of HCV 
RNA transcribed from a molecular clone has been demonstrated by 
Kolykhalov et a l (1997) and Yanagi et a l (1997). Full length HCV transcripts 
containing both the 5' and 3' UTRs were produced under the control of a T7 
prom oter and were introduced by intrahepatic injection into chimpanzees. 
A consensus sequence within the open reading frame was required to give 
HCV replication. The observation that a consensus sequence was required 
suggests that many quasispecies are defective for replication. The length of 
the poly (U/UC) tract varied between different clones but all transcripts 
resulted in HCV replication although a longer tract was preferred 
(Kolykhalov et al, 1997). The HCV RNA was resistant to RNase digestion 
implying that the RNA was packaged. HCV RNA alone is sufficient to cause 
disease in chimpanzees.
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1.11. Aims of this project.
At the time of beginning this project (1994) the NS3 protein was 
known to be responsible for most cleavage events within the non-structural 
region of the HCV polyprotein. The positions of the NS3-mediated 
cleavage sites were known and the basic motif determined.
The objectives of this project were:
1) To develop a simple and efficient assay to study the processing of 
an HCV substrate in trans.
2) To determine the substrate specificity for cleavage in trans by the 
NS3 serine protease.
3) To investigate the protease requirements for cleavage.
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Chapter 2 - Materials and Methods
2.1. Materials.
2.1.1. Enzymes and inhibitors.
Most restriction enzymes, calf intestinal phosphatase (CIP) and Taq 
DNA polymerase were purchased from Boehringer M annheim. T4 DNA 
polymerase and T4 polynucleotide kinase were purchased from N ew  
England Biolabs. T7 RNA polymerase and RNasin were obtained from  
Promega. Sigma supplied RNaseA and lysozyme.
All enzyme reactions were carried out under the reaction 
conditions specified by the manufacturer unless otherwise stated.
2.1.2. Radiochemicals.
Both radiochemicals listed below were produced by Amersham.
[35S] L-methionine (>800 Ci/mmol)
[a35S] dATP (>1000 Ci/mmol)
2.1.3. Synthetic oligonucleotides.
M13/pUC sequencing primer (-40) 17-mer and M13/pUC reverse 
sequencing prim er (-48) 24-mer were supplied by New England Biolabs. 
Other oligonucleotides were synthesised in the Division of Virology on a 
Cruachem PS250 autom ated synthesizer.
2.1.4. Plasmids.
pTF7.5 NS34A produces a single transcript encoding the NS3 gene 
followed by the gene for NS4A, pTF7.5 NS3 expresses NS3 alone, pTM l 
NS5 and pTZ18 NS5 both express the full length NS5 region of HCV. All 
four constructs were supplied by Dr M. McElwee.
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Cloning vectors pTZ18 and pUC119 were purchased from USB, and 
pTM l was obtained from Dr. B. Moss, NIH. Cloning vector pGEM-1 was 
supplied by Promega and pQE30 was supplied by Qiagen Inc.
The plasm id ALL NS3-5s_A encodes the NS3-NS5 region of HCV A 
(containing an inactive serine protease) and was obtained from Dr B.E. 
Clarke at GlaxoWellcome pic.
2.1.5. Bacterial strains.
E. coli strain DH5a (<J)80d/acZAM15, rec A l, end A l, gyr A96, thi-1, 
hsdRV7 (no, mK+) swpE44, relAl, deoR, A(lacZY A-argF) U169) was used for 
propagation of recombinant plasmids.
E. coli strains M15[pRep4] and SGI3009[pREP4] were used for the 
expression of 6-His tagged proteins and were both obtained from Qiagen 
Inc. Both strains are Nals, Str6, r if , lac, arc, gab, mtb, F-, recA+, uvr+.
2.1.6. Virus stocks.
vTF7.3 is a recombinant vaccinia virus that expresses T7 RN A  
polymerase (Fuerst et al., 1986) and was obtained from Dr. B. Moss.
2.1.7. Mammalian cell lines and tissue culture growth media.
CV-1 cells (an African green monkey kidney cell line) were used to 
grow vTF7.3 and for the transfection of plasmid DNAs. The cell line was 
maintained in Dulbecco's modified Eagle's m edium  (DMEM, from Gibco- 
BRL) supplem ented with 10% foetal calf serum (FCS), 100 u n its /m l 
penicillin and 100 un its /m l streptomycin (all from Gibco-BRL). The cell 
line was grown at 37°C in a 5% C 0 2 humidified incubator.
2.1.8. Antibodies and antisera.
The monoclonal antibody SV5-P-k (Hanke et al., 1992) was obtained 
from Dr R. Randall of The University of St. Andrews.
The NS3 antisera (1245 and 717) and NS5 antisera (1040 and Baculo) 
were supplied by GlaxoWellcome.
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2.1.9. Chemicals.
Unless stated otherwise, all chemicals and reagents were obtained 
from Sigma Chemicals Co. or BDH Chemicals Ltd.
En3hance was supplied by DuPont. A m m onium  persulphate and 
temed were supplied by Bio-Rad.
2.1.10. Miscellaneous materials.
GeneClean III and MerMaid nucleic acid purification kits were 
purchased from Bio 101 Inc. X-Omat S X-ray film was obtained from  
Kodak Ltd. And all tissue culture plasticware was supplied by N unc. 
Pansorbin cells were purchased from Calbiochem-Novabiochem and 
OptiMem 1 was obtained from Gibco BRL.
2.2. Manipulation of DNA.
2.2.1. Purification of synthetic oligonucleotides.
Oligonucleotides synthesised Un-house" were supplied as protected 
molecules still coupled to the support matrix. They were de-protected and 
eluted from the column by pushing 1.5ml of ammonia through the 
column between two 2ml syringes at a rate of 0.5ml every 20 minutes. The 
oligonucleotide/am m onia solution was then heated for 5 hours at 55°C to 
remove the base protecting groups and then removed to ice for 5 m inutes. 
The oligonucleotide was dried under vacuum to remove the am m onia
and resuspended in 200jj1 dH20. One millilitre of butanol was added and 
the mixture vortexed for 15 seconds before centrifugation at 13,000 rpm  for 
1 minute. The supernatant was then removed and the pellet dried under 
vacuum  for 5 minutes. The purified oligonucleotide was th en
resuspended in 200pl dLLO.
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2.2.2. Polymerase Chain Reaction (PCR) amplification of DNA.
Amplification of DNA was carried out using Taq DNA polym erase 
and lOx PCR buffer, 50mM MgCl2 and detergent W -l supplied with the 
polymerase by the manufacturer (Boehringer M annheim). The PCR 
reaction mix consisted of the components shown below, the order in  
which they are displayed being that in which the components were added 
to the reaction tube (an 0.5ml microfuge tube).
Nuclease free water
(to a final volume of 50|il) XjLtl
lOx PCR buffer 5.0|il
Detergent W -l 2.5jli1
50mM MgCl2 2.0pl
4 dNTPs (lOmM) l.OjLLl
Upstream  prim er 100 pmol
Downstream prim er 100 pmol
Taq DNA polymerase 0.5jll1
Template DNA (10-50ng/jiil) l.Opl
The reaction mixture was vortexed, centrifuged for 5 seconds before 
the addition of 2 drops of nuclease-free light mineral oil (to overlay the top 
of the reaction mixture). The reaction was then carried out using a Perkin 
Elmer Model 480 thermal cycler. The reaction was carried out at the 
following temperatures, strand separation at 94°C for 30 seconds, prim er 
annealing at 50°C (temperature varies depending on primer ) for 40 seconds 
and strand elongation from primers at 72°C for 120 seconds (time varies 
with length of PCR product) for 30 cycles.
PCR was also carried out using the proof reading enzyme Pju using lOx Pju 
PCR buffer supplied with the enzyme (Stratagene). The reaction was carried 
out as illustrated below.
Nuclease free dEkO 40|il
lOx Pju PCR buffer 5pl
4 dNTPs(lOmM) lp l
lOOpmol upstream  primer lp l
lOOpmol downstream primer lp l
Pju DNA polymerase ljul
Template DNA (10-50ng) ljil
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The actual reaction was carried out in the same manner as for Taq 
PCR reactions w ith a strand separation temperature of 95°C and a strand 
elongation tem perature of 74°C.
PCRs were electrophoresed through a 1% TAE gel and purified using 
a silica matrix (see 2.2.9).
2.2.3. Small scale plasm id DNA preparation by boil lysis.
A 20ml tube containing 5ml of L-broth with lOOjLig/ml ampicillin was 
inoculated w ith a single bacterial colony and incubated with shaking 
overnight at 37°C. One and a half ml of the overnight culture were 
transferred to an 1.5ml microfuge tube and centrifuged at 13,000 rpm  for 30 
seconds. The supernatant was gently removed and the pellet resuspended in 
400 jll1 of STET solution containing 500pg/ml lysozyme. The sample was 
kept on ice for 5 minutes before boiling for 30 seconds and subsequent 
centrifugation at 13,000 rpm  for 15 minutes. The pelleted bacterial debri 
were carefully removed using a sterile toothpick, and 400jll1 of isopropanol 
added to the supernatant. The sample was mixed thoroughly before 
incubation at -20°C for 30 minutes. The microfuge tube was then 
centrifuged at 13,000 rpm  for 10 minutes, the supernatant removed and the 
pellet washed with ice cold 70% ethanol. The DNA pellet was dried under 
vacuum  for 5 minutes before resuspension in lOOpl dEkO.
L-broth: lOg NaCl, lOg Bactopeptone and 5g yeast extract per litre.
STET solution: lOOmM NaCl, lOmM Tris-HCl (pH 8.0), ImM  EDTA (pH 
8.0), 5% Triton X-100.
2.2.4. Large scale preparation of plasmid DNA.
A 20ml universal containing 10ml of L-broth (2.2.3) with lOOjig/ml
ampicillin was inoculated w ith either a single bacterial colony or 2 0 jli1 of a 
glycerol stock. The universal was incubated with shaking at 37°C for 8 
hours. The m edium  was then transferred to a 250ml bottle containing 
100ml L- broth/am picillin  (see above) and the bottle shaken vigorously 
overnight at 37°C. The bacterial culture was then centrifuged at 3,000 rpm  
for 10 m inutes, the supernatant removed and the pellet vortexed before 
resuspension in 5ml Solution 1. Ten millilitres of freshly made Solu tion  
2 were slowly added, the tube inverted 10 times and left to sit at room  
tem perature for 10 minutes before vigorous mixing with 5ml Solution 3.
After incubation on ice for 5 minutes the tube was centrifuged at 
2,500 rpm  for 5 minutes and the supernatant carefully removed to a fresh
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tube before the addition of an equal volume of isopropanol and 
incubation at -20°C for 10 minutes. The tube was centrifuged at 3,000 rpm  
for 10 m inutes, the supernatant decanted and the rem aining pellet 
dissolved in 1.5ml TE buffer. Two ml of ice cold 5M LiCl were added to 
precipitate the RNA and the mixture kept in ice for 5 m inutes before 
centrifugation at 2,500 rpm  for 5 minutes. The supernatant was rem oved 
to a fresh tube containing 2 volumes of ethanol, the solutions mixed and 
then incubated at -20°C for 10 minutes. After a further centrifugation for 
10 m inutes at 2,500 rpm  the supernatant was removed and the pellet 
washed w ith 70% ethanol before resuspension in 0.5 ml TE buffer and
transferral to a 1.5ml microfuge tube. Two pi of RNase A solution and 2pl 
of Proteinase K solution were added and the sample incubated at 37°C for 
15 minutes. The DNA was precipitated by the addition of 0.5 volumes of 
20% PEG/2.5M NaCl and incubation on ice for a further 15 minutes. The 
DNA was pelleted by centrifugation at 13,000 rpm for 10 m inutes, the 
supernatant rem oved and the pellet subsequently dissolved in 0.6ml TE 
buffer.
An equal volum e of phenol/chloroform  was added to the DNA 
solution and the m ixture vortexed thoroughly for 30 seconds before 
centrifugation at 13,000 rpm  for 1 minute. The upper aqueous layer was 
transferred to a microfuge tube containing an equal volume of 
chloroform. The m ixture was again mixed thoroughly and subsequently 
centrifuged at 13,000 rpm  for 1 m inute. The upper aqueous layer was 
again rem oved to a microfuge tube and 2 volumes of ethanol and 0.1 
volum es of 3m NaOAc were added before incubation at -20°C overnight. 
The sample was then centrifuged for 10 minutes at 13,000 rpm, the 
supernatant rem oved and the pellet dried under vacuum  for 5 m inu tes
before resuspension in lOOpl dH 20. The concentration of the plasm id 
DNA was determ ined by measuring the absorbance at a wavelength of 
260nm (A260) assuming that 1 A260 = 50pg/m l for double stranded DNA.
Solution 1: 50mM glucose, 25mM Tris-HCl (pH8.0), lOmM EDTA (pH8.0). 
Solution 2: 0.2M NaOH, 1% (w / v) SDS, freshly made.
Solution 3: 250g KOAc, 150g glacial acetic acid made up to 1 litre with dThO.
TE buffer: lOmM Tris-HCl (pH 8.0), Im M  EDTA (pH 8.0).
RNaseA solution: 10m g/m l pancreatic RNaseA in lOmM Tris-HCl (pH 7.5), 
15mM NaCl, heated at 100°C for 15 minutes to inactivate DNases, cooled 
and stored at -20°C.
Proteinase K solution: 10m g/m l proteinase K dissolved in dH20.
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2.2.5. Restriction enzym e digestion of DNA.
Restriction enzyme digestion of plasmid DNA was done in 20|il
containing 2pl of m iniprep/m axiprep DNA (approximately ljxg), 2pl
relevant lOx reaction buffer, 1 unit of restriction enzyme and 0.5|il of 
lO m g/m l RNase A. The reactions were carried out at the tem perature
appropriate for the restriction enzyme for 2-4 hours. After digestion 2 jll1 of 
loading dye were added and the samples analysed by agarose gel 
electrophoresis through a non-denaturing 1% TBE gel.
Digestion of DNA for cloning purposes, creation of vector
backbones, or of inserts, was carried out in larger volumes, 50-100|il, w ith  
the same relative concentrations of enzyme and buffer. Digestion was 
carried out for a similar time period as illustrated above. The digestion 
products were fractionated through a 1-1.5% agarose TAE gel, depending 
on the size of the DNA band in question. DNA fragments were 
subsequently purified as in 2.2.9.
Partial digestion of DNA was occasionally necessary when an insert 
or vector contained more than one restriction enzyme site when digestion
at one site only was desired. A lOOjil reaction was set up containing all the 
necessary ingredients with the exception of the relevant restriction 
enzyme. Five 1.5ml microfuge tubes were placed on ice and num bered 1- 
5. Thirty microlitres of the reaction mix were transferred to microfuge
tube 1, 20(il into each of microfuge tubes 2 to 4 and the remaining lOjil 
removed to microfuge tube 5. All 5 microfuge tubes were returned to ice.
The required quantity of restriction enzyme (2-5 units /jig  DNA) was added 
to microfuge tube 1, the tube mixed thoroughly and returned to ice. Ten 
microlitres from the sample in tube 1 was added to tube 2, tube 2 was 
mixed thoroughly and then returned to ice. This procedure was repeated
until tube 5, after which each microfuge tube would contain a 20pl 
reaction sample. Each tube was incubated at the relevant tem perature for 
restriction enzyme digestion for 15 minutes before fractionation through a 
TAE agarose gel and purification of the required DNA fragment.
TAE: 40mM Tris-acetate (pH 8.0), ImM  EDTA.
TBE: 90mM Tris-HCl (pH 8.0), 90mM boric acid, ImM EDTA (pH 8.0).
2.2.6. Dephosphorylation of linearised plasmid DNA.
Removal of the 5' terminal phosphates of digested vectors was 
carried out using calf intestinal alkaline phosphatase (CIP). Reactions 
were typically carried out in a total volume of 50pl containing 5(il lOx CIP
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buffer (Boehringer M annheim), 1 unit of CIP per 5pg of DNA and m ade 
up to volum e with dhhO. The reaction was incubated at 37°C for 60 
m inutes before electrophoresis through a 1% TAE agarose gel, purification 
of linearised, dephosphorylated vector by silica matrix adsorption
(2.2.9),and stored at a concentration of lOOng/pi for ligation reactions.
2.2.7. End repair of DNA fragments.
Linearised vectors and DNA restriction enzyme fragments were 
made blunt-ended using T4 DNA polymerase. For PCR products the 
presence of T4 polynucleotide kinase was included to phosphorylate the 
ends of the DNA product. A standard protocol for the blunt-ending and
kinasing reaction used a reaction volume of lOOpl containing 10pl T4 
polynucleotide kinase buffer, 10 units T4 polynucleotide kinase, 10 un its
T4 DNA polymerase, 5pl of a lOmM mix of the 4 dNTPs, lp l lOOmM ATP 
and m ade up to volum e with dhhO. The reaction mix was m ixed 
thoroughly and incubated at 37°C for 60 minutes before analysis by agarose 
gel electrophoresis through a 1-1.5% agarose TAE gel and purification of 
the desired DNA fragment by silica matrix adsorption (2.2.9).
T4 polynucleotide kinase buffer (lOx): 700mM Tris-HCl (pH7.6), lOOmM 
MgCl2, 50mM DTT (NEB).
2.2.8. Agarose gel electrophoresis of DNA.
Electrophoresis of DNA was carried out in horizontal slab gels [BRL 
gel electrophoresis apparatus Model H5 (14 x 11 x 0.5cm) and BRL gel 
electrophoresis Horizon 58 (5.7 x 8.3 x 0.3cm)] containing l-1.5%(w/v)
agarose in 1 x TAE or 1 X TBE containing 0.5pg/ml ethidium  brom ide. 
DNA samples contained 0.1 volumes of loading dye. Electrophoresis was 
carried out at 50-150V in 1 x TAE or 1 x TBE buffer (2.2.5) containing
0.5pg/m l ethidium  bromide.
Agarose gel loading dye: 0.25% (w /v) brom ophenol blue, 0.25% (w /v) 
xylene cyanol, 10% (w /v) Ficoll.
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2.2.9. Purification of DNA from agarose gels by silica matrix adsorption.
The solutions used in this procedure were either part of the 
GeneClean (>200bp DNA fragments) or MerMaid (<200bp DNA fragments) 
kits. DNA fragments resolved by agarose gel electrophoresis were 
visualised by long-wave UV illumination and the DNA fragments excised 
in a gel slice, transferred to an 1.5ml microfuge tube containing 3 vo lum es 
of Nal solution and incubated at 55°C until the agarose slice has 
completely melted. A silica matrix solution (Glassmilk for DNA
fragments >200bp or Glassfog for DNA fragments <200bp) was added, 5pl
for up to 5pg of DNA and lp l for every additional jLtg of DNA and the 
m ixture mixed thoroughly for 10 minutes at room tem perature to bind 
the DNA to the silica matrix. The sample was centrifuged at 13,000 rpm  
for 5 seconds, the supernatant removed and the pellet washed 3 tim es 
w ith an ethanol-based wash solution through repeated 
resuspension/centrifugation steps. The DNA was eluted from the pellet
in 10-100pl dHhO, incubated at 55°C for 5 minutes and centrifuged for 2 
m inutes to pellet the silica matrix. The DNA solution was removed to a 
microfuge tube and stored at -20°C.
2.2.10. Ligation of DNA fragments.
Ligation reactions were carried out in a reaction volume of 20|Lil 
containing 4jil 5x ligation buffer (Gibco BRL), 1 unit T4 DNA ligase, lOOng 
linearised vector, DNA insert and made up to final volume with dTLO. 
DNA inserts were added in 1-14jll1 volumes depending on insert size and 
concentration (a 1:1 molar ratio of vectorrinsert was calculated and insert 
volumes to achieve this value used) and the reactions incubated at room 
tem perature overnight before transformation of competent cells.
2.2.11. Preparation of competent bacterial cells.
Ten millilitres of L-broth (2.2.3) were inoculated with a single
colony of E. coli strain DH5a and incubated with shaking at 37°C 
overnight. One ml of this overnight culture was added to 50ml of L-broth 
in a 250ml conical flask and shaken at 37°C until the cells reached an A550 
of 0.4. The cells were centrifuged at 2,500 rpm for 5 m inutes, the 
supernatant removed and the pellet gently resuspended in 20ml of ice cold 
0.1M CaCh. The suspension was placed on ice for 30 minutes, centrifuged 
at 2,500 rpm for 5 m inutes after which the pellet was resuspended in 5m l 
of ice cold 0.1M CaCh and stored at 4°C.
41
2.2.12. Transformation of competent cells with plasmid DNA.
DNA was added to a 1.5ml microfuge tube containing 200pl of 
com petent cells (see 2.2.11) and the solution gently mixed before 
incubation on ice for 30 minutes. The tube was then placed at 42°C for 90 
seconds before the addition of 600pl of L-broth (2.2.3) and placed at 37°C for 
60 minutes. Four hundred j l l I  of the transformation mix were then spread 
onto an LB agarose plate containing lOOpg/ml ampicillin and incubated 
overnight at 37°C to allow the formation of single colonies.
LB agarose: L-broth plus 1.5% (w /v) agarose.
2.2.13. Double stranded DNA sequencing.
Sequencing of double stranded DNA was based on the  
dideoxynucleotide chain term ination method (Sanger et al, 1977) as 
modified by Tabor and Richardson (1987). A modified T7 DNA 
polymerase lacking 3' to 5' exonuclease activity was used in the m ethod 
described below.
Eight pi (2-5|ig) of plasmid DNA were added to a 1.5ml microfuge 
tube containing 2pl of 2M NaOH and the mixture incubated at room  
tem perature for 10 minutes. Three microlitres of 3M NaOAc, 7p 1 dH20
and 60 j l i 1 ethanol were added, the mixture mixed thoroughly and 
subsequently placed on dry ice for 15 minutes. The sample was th en  
centrifuged at 13,000 rpm for 10 minutes, the supernatant removed and 
the pellet washed with ice cold 70% ethanol before re-centrifugation at
13,000 rpm  for 5 minutes. The supernatant was removed and the pellet 
dried briefly under vacuum before resuspension in lOpl dH20 . Two pi of
annealing buffer and 2pl of primer solution (5ng/pi) were added and the 
sample incubated at 37°C for 20 minutes, then allowed to cool to room
tem perature for at least 10 minutes. Six pi of labelling reaction m ix
(containing 2pl labelling mix, lp l 0.3M DTT, 0.5pl a 35S dATP and 2 units of 
T7 DNA polymerase diluted in enzyme dilution buffer supplied with the 
enzyme) were added to the DNA-primer mix and incubated at room
tem perature for 5 minutes. During the labelling reaction 2.5pl of the four 
dideoxy term ination mixtures (G, A, T, C) were added to four separate 
wells respectively in a 96-well, round bottomed microtitre plate and pre­
heated at 37°C for at least 1 minute. Four and a half microlitres of the  
labelled DNA-primer mix were added to each of the four term ination  
mixes, briefly mixed and centrifuged before incubation at 37°C for 5
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m inutes after which the reactions were arrested by the addition of 5pi of 
STOP mix.
The samples were heated at 75-80°C for 2 m inutes and then 3 jll1 of 
each were loaded onto a 6% polyacrylamide sequencing gel (80ml 6%
sequencing solution, 800pl APS, 80pl TEMED) in the order G, A, T, C. The 
samples were electrophoresed at a constant power of 70 watts, the gel 
transferred to 3MM paper and dried under vacuum  for 2 hours at 80°C. 
The dried gel was then exposed directly onto an X-Omat S film and 
incubated at room temperature for 24-48 hours.
Sequencing annealing buffer: 280mM Tris-HCl (pH7.5), lOOmM MgCb, 
350mM NaCl.
Sequencing dideoxy termination mix: 150mM each dNTP, lOmM MgCb, 
40mM Tris-HCl (pH 7.5), 50mM NaCl, 15pM of relevant dideoxynucleotide.
Sequencing labelling mix: 2pM dGTP, 2(iM dCTP, 2pM dTTP.
Sequencing STOP mix: 95% (v/v) deionized formamide, 20mM EDTA (pH 
7.5), 0.005% (w /v) xylene cyanol, 0.005% (w /v) bromophenol blue.
6% sequencing acrylamide solution: 6% (w /v) acrylamide/0.3% (w /v) bis- 
acrylamide, 7M urea, lx  TBE (ratio 19:1) [Scotlab].
2.2.14. Oligonuceotide directed mutagenesis.
Com plem entary oligonucleotides were designed so that w hen  
annealed they would form a Kpn I /Bst  Eli cassette for ligation into cut
vector. One hundred pg of each Oligonucleotide (lpl) were added to a
0.5ml microfuge tube containing 30pl 150mM NaCl and incubated at 65°C 
for 10 m inutes and slowly cooled to room temperature. The annealed
oligonucleotides were then phosphorylated in a lOOpl reaction containing
lOpl annealed oligonucleotides, lOpl lOx T4 polynucleotide kinase buffer,
IOjllI lOOmM ATP, 5pl T4 polynucleotide kinase and 65jll1 dHzO for 1 h o u r 
at 37°C. The phosphorylated partially double stranded oligonucleotide was 
then purified by silica matrix adsorption (2.2.9) and ligated into cut 
plasmid vector (2.2.10).
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2.3. Expression and purification of 6-His tagged proteins.
The protocols in this section were carried out based on those found in The  
QIAexpressionist, 2nd edition, 1992 (Qiagen Inc.).
2.3.1. Rapid screening and small-scale expression cultures.
The production of competent E. coli strains M15[pREP4] and 
SG13009[pREP4] and their subsequent transformation was undertaken as 
described in 2.3.11 and 2.3.12. A 20ml tube containing 1.5ml L-broth (2.2.5) 
supplem ented w ith lOOmg/ml ampicillin and 25m g/m l kanamycin was 
inoculated w ith a single colony and grown overnight at 37°C with shaking. 
One and a quarter millilitres of the overnight culture were added to a 
20ml tube containing 8.75 ml, pre-warmed L-broth (plus 
am picillin/kanam ycin as above) and incubated at 37°C with shaking for 60 
m inutes until the A6oo was 0.7-0.9. Subsequently 1ml was removed and 
stored (uninduced fraction) before the remaining culture was induced 
with IPTG and returned to 37°C for 3-5 hours. Another 1ml sample was 
removed (induced fraction) before centrifugation at 3,000 rpm  for 3 
minutes and removal of the supernatant.
The cell pellet was resuspended in 200pl buffer A (2.3.4) and the cells 
lysed by gentle mixing. The lysate was subsequently centrifuged at 13,000 
rpm for 10 m inutes before removal of the supernatant to a fresh tube. 
Fifty microlitres of a 50% slurry of Ni-NTA resin were added to the 
supernatant and the sample mixed at room temperature for 30 m inutes. 
The sample was then centrifuged at 13,000 rpm to pellet the resin and the 
supernatant discarded. The resin was washed 3 times with buffer C (2.3.4)
before the addition of 20|ll1 buffer C and gentle mixing for 2 minutes to 
elute the protein from the resin. The mixture was pelleted at 13,000 rpm  
for 10 seconds before careful removal of the supernatant to a fresh tube
containing 5|il 5x SDS PAGE sample buffer. Five x SDS PAGE buffer was 
added to the previous samples taken and all samples analysed on a 
denaturing, 12% SDS polyacrylamide gel (see 2.6.3).
5x SDS PAGE buffer: 15% (v/v) p-mercaptoethanol, 15% (w /v) SDS, 1.5% 
(w /v) bromophenol blue, 50% (v/v) glycerol.
2.3.2. Large scale expression of protein.
A 20ml tube containing 10ml L-broth (plus 100pg/ml ampicillin and 
25pg/m l kanamycin) was inoculated with a single bacterial colony or lOOfil
of a glycerol stock and grown at 37°C overnight with shaking. Fifty 
millilitres of L-broth (containing am picillin/kanam ycin as above) were 
inoculated with 1ml of the uninduced overnight culture and grown at 
37°C with shaking until the A600 was 0.7 - 0.9. IPTG was added to a final 
concentration of l-2mM after which the culture was returned to 37°C for 5 
hours. The cells were pelleted at 4,000g (3,000 rpm) using an SW 27 rotor 
for 10 minutes, the supernatant removed and the pellet stored at -70°C.
2.3.3. Determination of cytosolic or periplasmic location of expressed 
protein.
A 100ml culture was grown as described in 2.3.2 except 1ml of the 
culture was removed before induction with IPTG (uninduced control) and 
lm l removed before centrifugation (induced control). These two samples
were centrifuged at 13,000 rpm and the pellets resuspended in 50 jll1 of 5x 
SDS-PAGE buffer. The rem ainder of the 100ml culture were separated 
into two aliquots and the cells pelleted as in 2.3.2.
To check for cytosolic location one sample was resuspended in 5m l 
sonication buffer, frozen in dry ice/ethanol and subsequently thawed in  
cold water. The cells were sonicated briefly to induce lysis before 
centrifugation at 9,000 rpm for 20 minutes. The supernatant was rem oved 
and stored (soluble protein extract) and the pellet resuspended in 5m l 
sonication buffer (insoluble protein extract).
To check for periplasmic location the remaining pellet was 
resuspended in 10ml 30mM Tris-HCl (pH 8.0)/20% sucrose before addition 
of EDTA to Im M  and incubation at room tem perature for 5-10 m inutes 
with gentle mixing. The sample was centrifuged at 8,000 rpm for 10 
m inutes at 4°C, the supernatant removed and the pellet resuspended in  
10ml ice-cold 5mM MgSCh before stirring for 10 minutes in an ice/w ater 
bath. The sample was recentrifuged at 8,000 rpm for 10 minutes at 4°C and
the supernatant stored (periplasmic extract). Ten pi of all three extracts
were removed to fresh tubes containing 5pl 5x SDS-PAGE buffer and the 
samples heated at 100°C for 5 minutes ( as well as the uninduced and 
induced samples) before loading on a 12% SDS polyacrylamide gel (see 
2.6.3).
Sonication buffer: 50mM Na-phosphate (pH 7.8), 300mM NaCl
2.3.4. Denaturing purification of insoluble proteins.
A 500 ml culture was grown and induced as described in 2.3.2 before 
centrifugation at 9,000 rpm for 20 minutes. The supernatant was rem oved
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and the pellet resuspended in Buffer A at 5ml per gram before stirring at 
room tem perature for 60 minutes. The lysate was then centrifuged at 9,000 
rpm  for 15 m inutes at 4°C and the supernatant removed to a fresh tube 
containing 8ml of a 50% slurry of Ni-NTA resin previously equilibrated in  
Buffer A. The sample was mixed at room tem perature for 45 m inu tes 
before loading into a 4ml column pre-equilibrated with buffer A. The 
column was then washed with 10 column volumes (40ml) of Buffer A and 
5 column volumes of Buffer B. The column was then washed with Buffer 
C until the A280 was <0.01.
The protein was eluted with 15ml Buffer D followed by 15ml Buffer 
E and then 15ml Buffer F, collecting 3ml fractions during each elution.
Twenty pi of each sample were added to a 1.5ml microfuge tube containing
50pl 5X PAGE buffer and half of this sample analysed by SDS-PAGE (2.7.3)
Buffer A : 6M guanidine hydrochloride, lOOmM NaEhPCh, lOmM Tris-HCl, 
pH  adjusted to 8.0.
Buffer B: 8M urea, lOOmM NaH2P 0 4, lOmM Tris-HCl, pH  adjusted to 8.0. 
Buffer C: Same composition as Buffer B except pH  6.3.
Buffer D: Same composition as Buffer B except pH 5.9.
Buffer E : Same composition as Buffer B except pH 4.5.
Buffer F: 6M guanidine hydrochloride, 0.2M acetic acid.
2.4. Culture of cell lines and viruses.
2.4.1. Cell Culture.
Confluent monolayers of CV-1 cells were washed w ith 20ml of 
versene followed by 25ml trypsin/versene (1:5). The cells were 
subsequently incubated at 37°C for 5 minutes before suspension in 10ml 
DMEM-10% FCS. One millilitre (approximately 1 x 106 cells) was added to 
a 175cm2 cell culture flask containing 50ml of DMEM-10%FCS and 
incubated at 37°C until confluent.
Trypsin solution: 0.25% (w /v) Difco trypsin dissolved in Tris-saline
solution plus 0.005% (w /v) phenol red.
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Tris-saline: 140mM NaCl, 30mM KC1, 280mM Na2HP0 4 , lm g /  ml dextrose, 
25mM Tris-HCl (pH7.4).
Versene solution: PBS supplemented with 0.6mM EDTA and 0.0015% (w /v) 
phenol red.
2.4.2. Growth and purification of vTF7.3.
A confluent 175cm2 flask of CV-1 cells was inoculated with lOpl of
vTF7.3 stock (lxlO6 p fu /|il) in 5ml DMEM-5% FCS and incubated at 37°C 
for 1 hour w ith agitation every 15 minutes. The m edium  was replaced 
w ith 20ml DMEM-5% FCS and returned to 37°C for approximately 2 days 
until cytopathic effects were visible. The infected cells were centrifuged at
3,000 rpm  and resuspended in 4ml lOmM Tris-HCl pH  9.0 at 4°C. The cells 
were disrupted by 3 cycles of freeze thawing (5 m inutes in dry ice, 5 
m inutes at 37°C) before the nuclei were pelleted at 10,000 rpm  for 5 
m inutes at 4°C and the supernatant removed to a sterile tube. The pellet 
was resuspended in 4ml lOmM Tris-HCl pH 9.0, recentrifuged and the two 
supernatants combined. One tenth volumes of trypsin so lu tion  
(2.5mg/ml) was added and the sample incubated at 37°C for 30 m inu tes 
with frequent mixing. Four millilitre aliquots were then layered onto  
12ml 36% (w /v) sucrose in lOmM Tris-HCl pH9.0 and centrifuged at 13,000 
rpm  in an SW29 rotor for 80 minutes at 4°C. The supernatant was 
discarded and each pellet was resuspended in 1ml of ImM Tris-HCl pH  9.0, 
aliquoted and stored at -70°C.
2.4.3. Titration of vTF7.3 stock virus.
Thirty-five mm petri dishes containing 1 x 106 CV-1 cells were 
infected with dilutions of vTF7.3. Dilutions were carried out in a total
volum e of 1ml PBS and duplicate lOOpl volumes (for each dilution from  
10'5 to 10'9) were used for titration. The cells were incubated at 37°C for 60 
m inutes to allow the virus to adsorb with gentle agitation every 15 
m inutes. The inoculum was removed, 2ml DMEM-5%FCS added and the  
cells incubated at 37°C for 2 days. Then the medium was rem oved and the  
cells gently covered with CIDEX (a commercial glutaraldehyde preparation 
diluted 1:1 with PBS) for 3-4 hours to fix the cells. The CIDEX was 
removed and the cells stained with Giemsa for 10 m inutes before w ashing 
w ith tap water. Virus plaques were visible as clear regions w ithin the 
purple-stained cell monolayer.
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PBS: 170mM NaCl, 3.4mM KC1, lOmM H P04, 1.8mM KH2PO4 (pH 7.2), 
6.8mM CaCh, 4.9mM MgCh.
Giemsa stain: 1.5% (w /v) Giemsa in glycerol, heated at 50°C for 2 hours 
and diluted w ith an equal volume of methanol.
2.5. Introduction of nucleic acids into mammalian cells.
2.5.1. Preparation of cationic liposomes.
Cationic liposomes were prepared using a method based on that 
described by Rose et al. (1991). Dimethyldioctadecyl ammonium brom ide 
(DDAB) was diluted in chloroform to 4m g/ ml and 1ml added to a 20ml tube 
containing 1ml of dioleoyl-a-phopsphatidyl ethanolamine (DOPE: 
lO m g/m l in chloroform). After mixing, the chloroform was removed by 
evaporation w ith a gentle stream of nitrogen. Lyophilization was carried 
out for a further 4 hours to remove any further traces of chloroform and the 
dried lipids resuspended in 10ml sterile cfflhO through sonication in a 
sonicating water bath. The lipids were further sonicated on ice using a 
soniprobe set at maximum power until the suspension cleared. The final 
lipid solution had a ratio 1:2.5 w t/w t for DDAB:DOPE and was stored at 4°C 
for up to one month.
2.5.2. Liposome mediated transfection of nucleic acids into mammalian 
cells.
Sub-confluent monolayers of CV-1 cells in 35mm petri dishes 
(approximately 5x10s cells per dish) were infected with the recom binant 
vaccinia virus vTF7.3 using a m.o.i. of 5 p.f.u. per cell for 30 m inutes at 
37°C. The inoculum  was removed and the cells washed with 1ml of 
OptiMem before addition of the DNA transfection mix. The required
plasm id DNA (1-20 pg) in 250 pi OptiMem was combined w ith 15pl of
liposomes in 250pl OptiMem and the tube mixed thoroughly. This 
transfection mix was left to stand for 10-20 minutes before addition to the  
cell monolayer and incubation at 37°C for 3 hours. One ml of DMEM-10% 
FCS was added and the cells returned to 37°C for 12 hours.
The m edium  was replaced with 2ml of m edium  lacking 
m ethionine for 30 m inutes at 37°C before replacement with 1ml of
methionine free m edium  containing 50pCi of [35S] L-m ethionine/m l for 2 
hours at 37°C. After radio-labelling the cells were washed in ice cold PBS 
(2.4.3) before the addition of either 200pl protein dissociation mix (cell
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lysate sample) or IOOjllI 0.5% SDS to lyse the cells. The cell lysate was th en  
removed using a 2ml syringe and transferred to a 1.5ml microfuge tube for 
storage at -20°C or immunoprecipitation.
M ethionine free medium: Eagles A, Eagles B w ithout methionine.
Eagles A: 0.23g CaCb, 0.23g MgSCh, 0.1ml conc. HC1 in 1 litre dEbO.
Eagles B w ithout m ethionine: 500ml salts, 400ml amino acids m inus 
methionine, 32ml vitamins made up to 1 litre with dEbO.
Salts: 102.4g NaCl, 6.4g KC1, 2.4g, NaEbPCh, 72g glucose, 16ml 0.01% ferric 
nitrate, 4.68g L-glutamine, 16ml (1,600,000 units) penicillin, 1.6g 
streptomycin, 16ml 0.02% antimycotic made up to 1 litre with dEbO.
Am ino acids m inus m ethionine: 0.84g L-arginine mono HC1, 0.384g L- 
histidine mono HC1, 1.048g L-isoleucine, 1.048g L-leucine, 1.462g L-lysine 
mono HC1, 0.66g L-phenylalanine, 0.952g L-threonine, 0.16g L-tryptophan, 
0.724g L-tyrosine, 0.936g L-valine, 0.07g inositol, 0.48g L-cysteine, 55g 
NaHCOs dissolved in 700ml dEbO and heated to 50°C before addition of 
30ml 1 % phenol red and made up to a final volume of 1 litre with dEbO.
Vitamins: 2g choline chloride, 2g folic acid (dissolved in 200ml 1M NaOH), 
2g nicotinamide, 2g pantothenic acid/Ca salt, 2g pyridotal HC1, 2g thiamine 
HCL (aneurine), 0.2g riboflavine, made up to 4 litres with dEbO.
Protein dissociation mix: lOOmM Tris-HCl (pH 6.8), 4% (w /v) SDS, 200mM 
P-mercaptoethanol, 20% (v/v) glycerol, 0.2% (w /v) bromophenol blue.
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2.5.3. Polyethlyleneimine mediated transfection of nucleic acids into 
mammalian cells.
This transfection protocol is taken from that described in Boussif et 
al. (1995). The transfection of nucleic acids into m am m alian cells using 
polyethyleneim ine (PEI) used the same basic method as illustrated above 
(2.5.2) w ith the only difference being the preparation of the DNA
transfection mix. The required plasmid DNA (l-20pg) was added to a
1.5ml microfuge tube containing I O O j l l I  150mM NaCl. Sterilised PEI
solution was added to another 1.5ml microfuge tube also containing lOOjil 
150mM NaCl. PEI 800kDa (Fluka) was used as a lOmM m onom er aqueous 
stock solution [9mg of the 50%(w/v) commercial solution diluted in 10ml
of dH20] and was neutralised with HC1 before filtration through a 0.2pm 
Millipore. The am ount of PEI added was directly proportional to the
am ount of plasmid DNA to be introduced (3jnl of PEI per ljug plasm id 
DNA). The two microfuge tubes were mixed thoroughly and left for 10 
m inutes at room tem perature, the contents combined, mixed thoroughly  
and left for 10 m inutes at room temperature. The DNA transfection m ix 
was then added to vTF7.3 infected cells (after the 1ml OptiMem wash)
with 500|il OptiMem and the cells incubated at 37°C for 4 hours. The rest 
of the method is exactly as described above (2.5.2).
2.6. Protein Analysis.
2.6.1. Immunoprecipitation of proteins.
This m ethod of im m unoprecipitation was based on a m ethod by 
Kolykhalov et al. (1994). The cell lysate (2.5.2) was heated at 100°C for 5 
minutes, diluted 1:5 in im m unoprecipitation (IP) buffer and stored on ice 
for 30 minutes to 2 hours. The sample was then centrifuged at 13,000rpm 
for 15 m inutes to pellet the cell debris and the supernatant removed to a 
1.5ml microfuge tube. Fifty microlitres of formalin-fixed S. aureus bearing 
protein A (Pansorbin) was added to the supernatant and the sample m ixed 
w ith rotation at 4°C for 30 minutes before re-centrifugation at 13,000rpm 
for 5 minutes. The supernatant was gently removed, transferred to a
microfuge tube containing 2\xl of specific monoclonal antibody and rotated 
overnight at 4°C.
Sixty microlitres of Protein A Sepharose suspension (lOOmg in 800jnl 
IP buffer) was added to the sample and a further 30 m inute rotation at 4°C 
carried out The sample was then centrifuged at 13,000rpm for 30 seconds,
washed three times in 0.5M LiCl/O.lM Tris pH 7.5 and 70)0,1 pro tein
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dissociation mix added. The sample was stored at -20°C or analysed by 
SDS-PAGE (2.6.3).
Immunoprecipitation (IP) buffer: 50mM Tris-HCl (pH 7.6), 200mM NaCl, 
Im M  EDTA, 0.1% (v/v) Triton X-100, lm g /m l BSA.
2.6.2. Coupled in v i tro  transcription/translation reactions.
Cell free protein synthesis was carried out using the TnT coupled 
transcription/translation system from Promega. The reactions were set up  
on ice in accordance with the protocol supplied.
Tn T Rabbit reticulocyte lysate 12.5|xl
Tn T Reaction buffer 2.0pl
Tn T T7 RNA polymerase 0.5pl
Amino acid m ixture m inus m ethionine 0.5pl
[35S] L-Methionine 2 . 0 ] l l 1
RNasin (40 un its/p l) 0.5pl
DNA template (lpg) ypl
Nuclease free dH 20  (to a final volume of 25jxl) xpl
The reaction was carried out at 30°C for 60 minutes and then 70 jll1 
protein dissociation mix (2.5.2) were added. The sample was stored at - 
20°C or analysed by SDS-PAGE (2.6.3)
2.6.3. SDS polyacrylamide gel electrophoresis (SDS-PAGE) of proteins.
Proteins were separated by electrophoresis through a polyacrylamide 
gel containing SDS with the discontinuous buffer system of Laemmli (1970). 
The gel apparatus and glass plates were assembled following the 
manufacturers instructions. A 12% acrylamide resolving gel mix was used 
containing 14.4ml 30% acrylamide solution, 16.8ml 1M Tris-HCl pH 8.8, 
12.9ml dH20, 450pl 10% SDS, 450 jll1 10% APS and 50pl TEMED, with the 
TEMED added immediately before pouring the gel. A gap at the top of the 
gel plate was left to allow for addition of the stacking gel (approximately 
twice the depth of the comb). The resolving gel was immediately overlaid 
with 1ml isopropanol to leave a smooth interface after polymerisation. 
After the gel had polymerised the surface isopropanol was poured off, the 
stacking gel (1ml 30% acrylamide solution, 630pl 1M Tris-HCl pH 6.8, 8m l
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dH 20 , lOOjul 10% APS, 100|LLl 10% SDS and IOjllI TEMED) was added on top 
of the set resolving gel surface and a comb inserted to form loading wells 
for the protein samples. After polymerisation the comb was removed, the 
gel placed in the electrophoresis apparatus and the reservoirs filled w ith 
running buffer.
Protein samples were heated at 100°C for 5 minutes before loading 
into the wells, as were low range molecular weight protein markers (to 
allow determ ination of the protein sizes of the samples). The gel was run at 
45mA until the bromophenol blue reached the bottom of the resolving gel 
after which the gel was removed from the apparatus and immersed in Gel 
Fix for 1 hour. The Gel Fix was then replaced by En3hance for 45 m inutes 
and then the gel washed 3 times with dH20  before a final 45 minute soak in 
dH20 . The gel was then dried under vacuum for 60 minutes and placed in 
direct contact w ith X-Omat film S and exposed at -70°C for 24-96 hours.
For non-radioactively labelled gels the gel was first immersed in 
0.05% (w /v) Coomassie blue in Gel Fix and destained in Gel Fix for 3-4 
hours before drying under vacuum.
30% acrylamide solution: 30% (w /v) acrylamide/0.8% bis-acrylamide (ratio 
37.5:1) [Scotlab].
Gel Fix: 50% (v/v) methanol, 10% (v/v) acetic acid, 40% (v/v) dH20 .
2.6.4. Q uantitation of cleavage efficiency.
A dried SDS-PAGE gel was placed in direct contact with a Molecular 
Dynamics phosphor screen and placed at room temperature overnight. The 
screen was loaded into a Molecular Dynamics Phosphorlmager and the 
image incorporated into a computer file. The ImageQuant software was 
used to analyse the scanned image. A background value was taken before 
determ ination of both uncleaved substrate and cleavage product band 
intensities. The size of the background value box was the same size as the 
boxes used for substrate and cleavage products. The background value was 
subtracted from the experimental values before any calculations were 
carried out. The efficiency of cleavage was calculated as a percentage as 
illustrated below.
Cleavage product A + cleavage product B x 100 
Cleavage products + uncleaved substrate
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Chapter 3 - Construction of HCV 
protein expression clones
3. Introduction.
The aim of this study was to characterise the HCV NS3 serine 
pro tease. To study the catalytic activity and requirements of the NS3 
protease an efficient system for NS3 mediated cleavage was necessary. Once 
an assay of this nature had been developed the characterisation of substrate 
and protease requirements could be carried out.
Before a protease assay could be developed sources of the HCV serine 
protease and a suitable HCV substrate were required. The HCV serine 
protease is encoded within the N-terminal region of the NS3 protein 
(Hijikata et al., 1993a; Bartenschlager et al., 1994; Lin et al., 1994b; Tanji et al., 
1994b; Failla et al., 1995). It had been demonstrated that the NS3 protein 
associates with the NS4A protein to form a complex with optimal catalytic 
activity (Failla et al., 1994; Bartenschlager et ah, 1994). A construct that 
expressed the NS3 serine protease was required and in addition, it was 
considered that inclusion of the NS4A protein would result in a m ore 
efficient protease.
The first cleavage site processed by the NS3 protease in trans during 
polyprotein processing is the NS5A/NS5B cleavage site. This processing 
event is efficient and quick. For these reasons the NS5 protein was chosen as 
a substrate for the frans-cleavage assay.
This chapter describes approaches to generate the reagents required 
for a fnms-cleavage assay for the NS3 serine protease. The protease was 
expressed in bacteria, by in vitro transcription/ translation and transiently in 
transfected mammalian cells. The substrate was expressed by in vitro 
transcription/ translation or transiently in transfected mammalian cells.
3.1. HCV cDNA clones available in the laboratory.
A number of HCV plasmid constructs were available in the 
laboratory when I started the project. Two plasmids encoding the NS3 
protease region had been constructed: the full length NS3 gene (encoding 
amino acids 1027 to 1657 of the HCV Gla poly protein) and the NS34A gene 
(encoding amino acids 1027 to 1709) had been cloned, under control of the 
T7 promoter, into pTF7.5. The NS34A construct contained the full NS3 gene 
and almost the entire NS4A region with just 2 amino acids missing from the 
C-terminus of NS4A. The gene encoding the full length NS5 protein 
(consisting of amino acids 1973 to 3011 of the HCV Gla polyprotein), under
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control of the T7 promoter, was cloned into pTZ18 and pTMl. pTMl 
contains the EMCV IRES element that directs cap-independent translation 
and results in a higher level of protein expression. These constructs are 
illustrated in Fig. 3.1.
3.2. Construction of substrate clones.
It had been reported that the NS5B protein of HCV was unstable 
when expressed in mammalian cells (Lin et al., 1994b). The NS5B protein is 
not further processed by HCV-encoded enzymes, and thus may be degraded 
by a cellular pathway. To determine the level of processing with respect to 
the uncleaved substrate (2.6.4) it would be more accurate if both cleavage 
products were identifiable. Quantitation of the level of processing was 
calculated by dividing the total of the cleavage product intensities by the 
total of cleaved and uncleaved band intensities. The intensity of each band 
was determined by the number of (radioactively labelled) m ethionine 
residues within the protein. The sum of the intensities of the two cleavage 
products would equal the intensity of the single substrate band (as the 
uncleaved substrate contains the same number of methionine residues as the 
two cleavage products). This method of quantitation is "quasi-quantitative" 
as the calculation uses steady state levels of substrate and products. If only 
one cleavage product was identifiable the estimation of processing would 
be increasingly inaccurate.
It was thought that an NS5 substrate truncated at both the N- and C- 
termini might produce a stable NS5B product that was less susceptible to 
degradation. A truncated NS5 substrate (519 amino acids in length) 
consisting of residues 2105 to 2623 of the HCV Gla poly protein was 
constructed. This substrate still contained the NS5A/NS5B cleavage site but, 
after processing by the NS3 serine protease, would give smaller cleavage 
products (including perhaps a stable NS5B protein).
No efficient antiserum  against the NS5 region was available in the 
laboratory at the time so an epitope tag derived from the SV5 P and V 
proteins (Hanke et al., 1992) was introduced at both termini of this truncated 
NS5 substrate. A specific monoclonal antibody (SV5-P-k) recognises this 
sequence and would enable identification of both cleavage products. The 
epitope tag consists of the 15 amino acid sequence:- Ser Gly Lys Pro lie Pro 
Asn Pro Leu Leu Gly Leu Asp Ser Thr
PCR primers were designed containing a suitable restriction enzyme 
site for cloning (Xba I or Nco I for the 5'primers and Pst I for the 3' prim er) 
followed by the epitope tag sequence and 15 nucleotides complementary to 
the terminal sequence of the desired NS5 region. The nucleotide sequence 
encoding the epitope tag was changed between the 5' and 3' PCR prim ers 
(maintaining the required amino acid sequence) to ensure that no 
mispriming took place during PCR. The truncated, epitope-tagged NS5 
substrate (designated tNS5T) was cloned into pTZ18 and subsequently into 
pTMl. The ?>' PCR primer used was identical for production of both PCR
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products and contained a Pst I restriction enzyme site for cloning into both 
pTZ18 and pTMl. An Xba I site was used in the 5' PCR primer for cloning 
into pTZ18 and an Nco I site used in the 5' PCR primer for cloning into 
pTMl. The Nco I site contains an ATG codon that is used as the initiation 
codon for translation by the EMCV IRES element in pTMl. As the PCR 
producing the pTMl tNS5T insert was carried out using pTZ18 tNS5T as a 
template a smaller 5' PCR primer was sufficient. The PCR primers used are 
illustrated in Fig. 3.2.
After cloning of correctly sized inserts the tNS5T constructs were 
sequenced from both the 5' and 3' ends to confirm that no mutations had 
been introduced during PCR
Attempts were made to produce a full length NS5 substrate with the 
epitope tag identified by the SV5-P-k antibody at either terminus. This 
would enable detection of a full length NS5B protein and confirm whether 
this protein was unstable. Attempts to produce this substrate were 
unsuccessful.
Having developed a truncated substrate (tNS5T) identifiable using 
the specific monoclonal antibody (SV5-P-k) two antibodies against the NS5 
region were supplied by Dr B.E. Clarke (GlaxoWellcome). These antibodies 
could be used to identify both the truncated NS5 substrate and the full 
length NS5 substrate. These antibodies were used for im m unoprecipitation 
of cell lysates expressing the NS5 construct. The ability of these antibodies 
to identify the HCV Gla NS5 protein and that of SV5-P-k to identify the 
tNS5T substrate is illustrated in Fig. 3.3. The NS5 protein was 
im m uneprecipitated by the NS5(Baculo) antisera only and tNS5T was 
detected using the SV5-P-k antibody. Both NS5 proteins could be used for 
fnms-cleavage analysis as the baculovirus-derived NS5 antibody (which 
recognises the C-terminus of NS5A) identifies the full length HCV Gla NS5 
substrate and the SV5-P-k antibody identifies the tNS5T substrate.
3.3. Construction of protease expressing clones.
Although the HCV serine protease was shown to be encoded w ithin 
the N-terminal region of the NS3 protein (Hijikata et al., 1993a; 
Bartenschlager et al., 1994; Lin et al., 1994b; Tanji et al., 1994b; Failla et al., 
1995) it was not known whether this region, expressed w ithout the C- 
term inus of NS3, folded in a manner that still permitted catalytic activity. 
The DNA sequence encoding the protease domain (designated NS3P) would 
produce a protein consisting of the first 190 amino acids of NS3 (amino acids 
1027 to 1216 of the HCV Gla polyprotein). This sequence was cloned into 
pTM l and the bacterial expression vector pQE30. The NS3P sequence cloned 
into pTM l would be suitable for expression in vitro or in mammalian cells. 
The NS3P sequence cloned into pQE30 would be used to express the protein 
fragm ent in bacterial cells and the protein product purified. This purified 
NS3P protein could be added to substrate expressed either in vitro or in vivo 
to determine whether it had suitable catalytic activity. The PCR prim ers
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Fig. 3.3. Identification of full length  and  trunca ted  NS5 
pro te ins  using  different antisera. vTF7.3 infected CV-1 cells 
w e re  transfected  w ith  p T M l NS5 (lanes 1 and  2), p T M l 
tNS5T (lane 4) or left un transfected  (lane 3). Radiolabelled 
cell extracts w ere  p rep a red  11 hours  post-transfection  and  
reacted w ith  various antisera. The NS5 (1040) antisera (lane 1) 
failed to detect the full length  NS5, w hereas  NS5 (Baculo) 
de tec ted  the full length  NS5 (lane 2). The trunca ted  NS5 
substra te  w as precipita ted  by the SV5-P-k antibody (lane 4). 
T h e  u n s t r a n s f e c t e d  c e l l  l y s a t e  ( l a n e  3) w a s  
im m uneprec ip ita ted  w ith  the SV5-P-k antibody, illustra ting 
th e  b a c k g r o u n d  p r o te in  p r o d u c t s  r e m a in in g  a f te r  
im m uneprecip ita tion . The NS5 proteins are indicated by an 
arrow. M olecular w eight m arkers  are located at the right of 
the gel.
used in the cloning of these constructs are illustrated in Fig. 3.4. The 3' PCR 
prim er was identical for both reactions and contained a Pst I site for cloning. 
The 5' PCR prim er used for cloning into pTMl contained an Nco I site 
whereas a Kpn I site was used in the 5' primer for cloning into pQE30.
Cloning of the NS3P PCR product into pTMl required partial 
digestion w ith Nco I as an internal site was present within the HCV Gla 
NS3P nucleotide sequence. The PCR product was initially digested with Pst 
I to linearise the plasmid DNA and the vector purified by silica matrix 
adsorption (2.2.9.) before partial digestion with Nco I. The partial digest is 
illustrated in Fig. 3.5. The partial digest containing the 1:400 dilution of the 
enzyme shows a very faint band corresponding to the desired band. In the 
subsequent two reactions the band is more prominent. Once cloned the 5' 
and 3' ends of the insert were sequenced to ensure that no PCR-induced 
m utations had been introduced.
3.3.1. Expression of NS3P in bacteria.
After cloning of the NS3P gene into pQE30 the ends were sequenced 
to check that no PCR-induced mutations had been introduced. The construct 
was checked for protein expression in bacterial cells. After induction w ith 
IPTG the NS3P protein was expressed in both strains used (SG13009[pREP4] 
and M15[pREP4]). Both these bacterial strains allow high level expression. 
SGI3009[pREP4] gives levels of protein expression that can be toxic to the 
cells, but can be useful for the expression of proteins that are expressed 
poorly in M15[pREP4]. The NS3P protein was expressed in both strains w ith 
no observable difference in the level of expression (Fig. 3.6.).
Proteins expressed in bacterial cells may be soluble in the cytoplasm, 
located w ithin cytoplasmic inclusion bodies (insoluble) or secreted into the 
periplasmic space. Many proteins expressed at high levels in bacteria form  
inclusion bodies, while others are well tolerated by the cell and remain in  
the cytoplasm in their native configuration.
After expression of NS3P in bacteria, half the cells were pelleted, 
resuspended in sonication buffer (50mM Na-phosphate pH 7.8, 300mM 
NaCl) and freeze/thaw ed before lysis by sonication. The sample was 
pelleted and the supernatant removed. This supernatant would contain the 
protein if it was soluble within the cell. Once resuspended the pellet would 
contain the protein if it was insoluble. In addition to this analysis, the 
remaining cells were pelleted and resuspended in 30mM Tris-HCl, 20% 
sucrose (pH8.0) before addition of EDTA to Im M  and incubation w ith 
rotation at room tem perature for 10 minutes. The sample was pelleted, the 
supernatant removed and the pellet resuspended in ice-cold 5mM MgS0 4  
before stirring at 4°C for 10 minutes. The sample was pelleted and the 
supernatant removed. This supernatant would contain the protein if it was 
secreted into the periplasm (this protein containing sample is called the 
osmotic shock fluid). When all three samples were analysed by SDS-PAGE 
the protein was found to be insoluble (Fig. 3.7.).
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Fig. 3.5. Partial Nco I digest of the NS3P PCR fragment. 
The o r ig ina l PCR p ro d u c t  w as  b lu n t-e n d e d  before  
ligation into Sma  I cut pTZ18. This construct (pTZ18 
NS3P) w as subsequently  digested w ith  Pst I (to linearise 
the  vector) an d  then  p u r if ied  by silica gel m atrix  
adsorp tion . Partial digests using Nco I w ere  set up  and 
the reactions incubated  at 37°C for 15 m inutes . After 
incubation the digests were analysed th rough  a 1% TAE 
gel. The reactions were loaded correspond ing  to their 
decreasing  enzym e concentration from left to right. The 
top insert b an d  (lanes 4 and 5), indicated by  an arrow , 
corresponds to the full length Nco I /Pst  I NS3P insert.
Fig. 3.6. 
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Fig. 3.7. Expression of the NS3 protease dom ain  in E. coli 
s trains SG13009[pREP4] and M15[pREP4]. For each pair 
of lanes the first lane corresponds to expression in the 
M15[pREP4] s tra in  and the second lane co rresponds  to 
expression in the SG13009[pREP4] strain. The un induced  
cells w ere  loaded  in lanes 1 and 2 and the induced  band  
was seen for bo th  cell lines in lanes 3 and 4. The natu re  of 
the expressed  p ro te in  w as investigated by de te rm in ing  
w h e th e r  the  p ro te in  was found in the soluble fraction 
(lanes 5 and  6), the insoluble fraction (lanes 7 and  8) or 
associated w ith  the perip lasm  (lanes 9 and 10). For both 
s tra in s  the  NS3P p ro te in  p ro d u c t  w as fo und  in the 
insoluble  fraction. The faint band  in the M15[pREP4] 
osmotic shock lane (lane 9) was probably spill over from 
the adjacent lane (insoluble fraction) .
After expression in both bacterial strains the NS3P protein was tested 
for binding to the Ni2+ resin (2.3.1.). The cells were pelleted and resuspened 
in Buffer A (6M GuHCl, 0.1M Na-phosphate, 0.01M Tris-HCl, pH 8.0) before 
mixing w ith a 50% slurry of Ni-NTA resin. After mixing for 30 minutes the 
sample was pelleted and the supernatant removed. The sample was washed 
with Buffer C (8M urea, lOOmM NaH2P 0 4, lOmM Tris-HCl, pH adjusted to 
6.0) before gentle mixing with BufferC/lOOmM EDTA. The EDTA chelates 
the N i2+ ions from the NTA resin and elutes the protein. The samples 
obtained after elution of the protein from the pelleted Ni2+ resin were 
analysed by SDS-PAGE (Fig. 3.8). The NS3P protein expressed in bacteria 
was bound to the Ni-NTA resin and could be purified after expression.
A large scale (500ml) expression of NS3P was carried out. The cells 
were pelleted and resuspened in Buffer A (6M GuHCl, 0.1M Na-phosphate, 
0.01M Tris-HCl, pH 8.0) before mixing with a 50% slurry of Ni-NTA resin. 
After mixing for 45 minutes the resin was loaded onto a column and washed 
with Buffers A-F. The protein was eluted from the column with buffer E (8M 
urea, 0.1M Na-phosphate, 0.01M Tris, pH4.5). Although there was a small 
am ount of NS3P eluted with buffer D (8M urea, 0.1M Na-phosphate, 0.01M 
Tris, pH  5.9) the majority of the NS3P protein was eluted in the first two 
fractions with buffer E (Fig. 3.9.).
To remove any contaminating Ni2+ ions EDTA (a metal ion chelator) 
was added to a final concentration of lOmM. After chelation of the N i2+ ions 
the EDTA was removed from the protein by dialysis in Buffer E (the buffer 
used to elute NS3P from the column) for 4 hours. The purified NS3P protein 
was analysed through a 12% SDS polyacrylamide gel (Fig. 3.10.).
3.4. HCV protease cofactor clone, NS4A.
The cofactor for NS3 serine protease activity was demonstrated to be 
the 54 amino acid NS4A protein (Failla et al., 1994; Bartenschlager et al., 
1994). The NS4A gene (consisting of amino acids 1658 to 1711 of the HCV 
Gla polyprotein) from HCV Gla was amplified by PCR and cloned into 
pTMl using the PCR primers shown in Fig. 3.11. An Nco I site was used in 
the 5' prim er and a Pst I site used in the 3' primer. The cloned gene was 
sequenced completely and shown to be correct. The NS4A protein is 
predicted to have a molecular weight of 6 kDa (Tomei et al, 1993) and hence 
after expression in vitro the protein was not observed by SDS-PAGE on 
either a 12% or a 15% SDS polyacrylamide gel.
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Fig. 3.8. Expression of the NS3 protease dom ain  (NS3P) in 
bacteria and  analysis of b ind ing  to Ni2+ resin. The first lane 
of each pa ir  corresponds to expression in the M15[pREP4] 
stra in  and  the second lane corresponds to expression in the 
SG13009[pREP4] strain. The induced  NS3P band  (lanes 3 
an d  4) w as  seen in ad d it io n  to the b ackground  p ro te in  
b an d s  observed  in the un in d u ced  sam ples (lanes 1 and  2). 
The exp ressed  NS3P is ind ica ted  by  an a rrow . W hen  
expressed in either cell line the NS3P protein  was observed 
to b ind  to the nickel resin (lanes 5 and 6) after the cells had  
been lysed.
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Fig. 3.10. Bacterially expressed NS3P after purification 
an d  co n cen tra t io n .  The c o n ce n tra te d  N S3P w as  
analysed by SDS-PAGE th ro u g h  a 12% gel. The NS3P 
p roduc t is a distinct band  of approxim ately 25kDa and is 
identified by an arrow. M olecular w eigh t m arkers  are 
located at the right of the gel.
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3.5. Summary of HCV expression clones.
Two NS5 clones (full length NS5 and the truncated tNS5T) were 
constructed to provide a substrate in an HCV serine pro tease assay. Three 
protease constructs (pTF7.5 NS34A, pTF7.5 NS3, pTMl NS3P) were produced 
for expression in a T7-RNA polymerase driven system, as well as a construct 
expressing the cofactor, pTMl NS4A. All the HCV constructs (pTF7.5 
NS34A, pTF7.5 NS3, pTMl NS3P, pTMl tNS5T, pTZ18 tNS5T and pTMl NS5) 
were tested for expression by in vitro transcription/ translation and analysed 
by SDS-PAGE through a 12% polyacrylamide gel (Fig. 3.12.).
All the HCV constructs expressed well in vitro. In this system the 
NS34A construct gave two separate bands, a 75 kDa band corresponding to 
uncleaved NS34A and a smaller 70 kDa product corresponding to NS3. The 
NS3P product appeared to be approximately 19kDa. The full length NS5 
substrate band was estimated to be approximately 120 kDa in weight. The 
truncated, epitope tagged NS5 substrate (tNS5T) was seen as a 75-80 kDa 
band. There are a number of additional bands present that are either non­
specific by-products of the TNT system or breakdown products.
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Fig. 3.12. E xpress ion  of HCV p ro te in s  by  in vitro 
t ransc r ip t io n /tran s la t io n .  The HCV pro te in  cD N A s w ere 
cloned w ith in  a variety of plasm ids, all of w hich  gave a high 
level of protein  expression in vitro. Three substrate  reactions 
w ere  loaded  at the righ t of the gel (lanes 4, 5, 6). The 
protease  reactions were loaded at the left of the gel (lanes 1, 
2, 3). The NS3P band  was observed to have a slightly smaller 
m olecular w eigh t than predicted. There were a nu m b er of 
bands in addition to the HCV protein bands (the HCV bands 
are indicated by an arrow). These additional pro tein  bands 
w e re  e i th e r  p r o d u c e d  n o n -s p e c i f ic a l ly  d u r i n g  th e  
t r a n s c r ip t io n / t r a n s la t io n  reac tio n  or w e re  b re a k d o w n  
products . The molecular w eight m arkers are located at the 
right of the gel.
Chapter 4 - Development of an 
assay for protease activity
4.1. Proteolytic activity of NS3 serine protease using in v i t r o  
transcription/translation systems.
The use of the coupled in vitro transcription/translation system (TnT) 
from Promega was found to be efficient for the expression of both substrate 
and protease constructs separately (Fig. 3.12.). It had not been determ ined 
whether, having expressed a suitable substrate in vitro, a separately 
produced NS3 protein could process in trans. The ability of the NS3 serine 
protease to process in trans could be investigated either (i) by combining 
lysates after separate transcription/ translation or (ii) by program m ing the 
TnT reactions with both plasmids.
Separate 25pl in vitro transcription/translation reactions (2.6.2) were 
carried out for the NS34A construct and both the full length and truncated 
substrate constructs. After the reactions had been incubated at 30°C for 60 
minutes, lOpl of the substrate reaction were mixed with lOpl of the protease 
reaction and the combined lysates incubated at 37°C for 2 hours. Then 70 pi 
of protein dissociation mix were added and 40pl of the sample analysed by 
SDS-PAGE (12% gel). The results of this experiment are shown in Fig. 4.1. 
No cleavage of either substrate, as evidenced by the appearance of sm aller 
cleavage products, was observed. The length of the incubation and the 
incubation tem perature were varied but no cleavage products were 
observed.
One microgram of both substrate and protease (NS34A) constructs 
was introduced into the same TnT reaction and incubated at 30°C for 180 
minutes. The reaction was terminated by addition of 70pl protein 
dissociation mix and half the sample analysed by SDS- PAGE through a 12% 
SDS polyacrylamide gel (lanes 6 and 7, Fig. 4.1.). As for the combination of 
substrate and protease Tn T lysates no evidence of cleavage was observed.
As coupled transcription/ translation trans-cleavage reactions had not 
been successful it was investigated whether separate transcription and 
translation reactions would enable processing in trans. mRNAs were 
transcribed from linearised substrate and protease vectors and purified 
before separate translation reactions were carried out in rabbit reticulocyte 
lysates. Ten microlitres of the substrate reaction were mixed with 10pl of 
the protease reaction and the sample incubated at 37°C for 2 hours. Seventy 
microlitres of protein dissociation mix were added to the reaction and 40 jll1 
of the sample analysed by SDS-PAGE through a 12% SDS polyacrylam ide
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Fig. 4.1. In vitro trans -cleavage assay using coupled transcription/translation 
system (TnT). The HCV protease and substrate proteins were expressed in 
vitro by coupled transcription/translation. Both the full length NS5 (lane 1) 
and tNS5T (lane 2) were expressed individually and are indicated by a black 
arrow. The NS34A construct produced a full length NS34A and a smaller, 
cleaved NS3 product (lane 3). The protease bands are indicated by white 
arrows. When protease and substrate were produced by separate TnT 
reactions and the lysates combined no cleavage products were observed 
(lanes 4 and 5). When both protease and substrate were produced in the 
same TnT reaction no cleavage products were observed (lanes 6 and 7). 
Molecular weight markers are illustrated at the right of the gel.
gel. The quality of the proteins produced by this method was lower than 
was observed for coupled transcription/ translation. The level of expression 
of the HCV proteins was lower than the coupled transcription/ translation 
reactions and there was also a significantly higher background. Processing 
of the substrate was not visible using separate transcription and translation 
reactions (lanes 4 and 5, Fig. 4.2.).
An alternative approach was to use the bacterially expressed NS3 
protease domain, which had been purified and concentrated (3.3.), to cleave 
substrates produced by in vitro transcription/translation. The catalytic 
activity of this concentrated protease fragment was not known. 
Introduction of this protein to a lysate containing in vitro expressed 
substrates could result in fnms-cleavage. The purified, bacterially expressed 
NS3P was added in increasing amounts to TnT reactions of both the full 
length and the truncated NS5 substrates. After the addition of the purified 
protease the samples were incubated at 37°C for 2 hours before the addition 
of 70 pi protein dissociation mix and analysis by SDS-PAGE. The results 
(Fig. 4.3.) show that neither substrate was processed when the purified 
protease was added to substrate expressed in vitro.
Trans-cleavage of the HCV NS5A/NS5B substrates by the HCV NS3 
serine protease was not observed using any in vitro protein expression 
system. Co-expression of substrate and protease proteins in a TnT reaction, 
combination of protease and substrate-containing lysates produced by TnT 
or RRL reactions or the addition of bacterially expressed NS3P to in vitro 
expressed substrates all failed to produce fnzns-cleavage. As no assay 
involving in vitro expression of HCV proteins had been successful an 
alternative m ethod was investigated.
4.2. Proteolytic activity of the NS3 serine protease in mammalian cells.
vTF7.3 is a recombinant vaccinia virus encoding T7 RNA polymerase. 
Afcer infection of mammalian cells vTF7.3 expresses a large am ount of T7 
RNA polymerase in the cytoplasm of the infected cell. It has been 
demonstrated that introduction of plasmids containing genes under control 
of the T7 prom oter can result in a high level of expression of the encoded 
proteins (Fuerst et a l, 1986). Mammalian cells (CV-1 or BHK) were infected 
wi:h vTF7.3 and subsequently transfected with plasmids encoding the 
substrate and protease cDNAs under control of the T7 promoter. Successful 
introduction of plasmid DNA by this method resulted in a high level of 
expression of the HCV proteins (Fig. 4.4.). When the truncated NS5 substrate 
was cotransfected with the NS34A serine protease two additional protein 
bands were produced of the approximate size expected of tNS5T cleavage 
products. As these protein bands were only produced after cotransfection of 
the substrate w ith NS34A they were identified as being tNS5AT and tNS5BT. 
The 549 amino acid tNS5T substrate was processed into a 331 amino acid 
NS5A product of approximately 50 kDa (tNS5AT) and a smaller, 218 am ino
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Fig. 4.2. In vitro trans-c leavage  assay  u s in g  s e p a ra te  
transcrip tion  and  transla tion  reactions to p ro d u ce  the HCV 
proteins. The full leng th  NS5 (lane 1), tNS5T (lane 2) and  
NS34A complex (lane 3) w ere  expressed poorly after separate  
transcr ip tion  and transla tion  from cDNAs. W hen  substra te  
and  p ro tease  lysates w ere  com bined  (lanes 4 an d  5) no  
cleavage p ro d u c ts  w ere  observed . The qua lity  of p ro te in  
p ro d u c t io n  w a s  s ig n if ic a n t ly  lo w er  th a n  for c o u p le d  
transcrip tion /transla tion  reactions.
Fig. 4.3. 
In 
vitro 
trans-cleavage 
assay 
using 
bacterially-expressed, purified 
N
S3P. 
Both 
substrates 
w
ere 
expressed 
in 
vitro 
by 
coupled 
transcription/translation. 
Increasing 
am
ounts 
(0.5, 1, 2, 5 
and 
10 
pg) 
of 
bacterially 
expressed, purified 
NS3P 
were 
added 
to 
both 
substrates 
and 
after 
incubation 
at 
37oC 
the 
lysates 
were 
analysed 
by 
SD
S-PA
G
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No 
cleavage 
products 
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Fig. 4.4. Trans-cleavage of the trunca ted  NS5 substra te  
(tNS5T) by coexpressed  NS34A. Plasm id D N A s w ere  
transfected  into CV-1 cells infected w ith  vTF7.3. At 11 
hou rs  post-transfection the cells were  labelled w ith  35S- 
m e t h i o n i n e  fo r  2 h o u r s ,  l y s e d  a n d  t h e n  
im m u n e p re c ip i ta ted  w ith  the SV5-P-k an tibody . This 
protocol was carried ou t in all subsequent trans-cleavage 
experim ents. W hen expressed alone in m am m alian  cells 
the tNS5T substra te  w as no t  p rocessed  (lane 1). W hen  
tNS5T w as  co tran sfec ted  w ith  NS34A tw o  c leavage  
p ro d u c ts  w ere  p ro d u ced  (the 50kDa tNS5AT and  the 
30kDa tNS5BT). Despite the evidence of frflrzs-cleavage a 
significant am oun t of unprocessed substrate rem ained(lane 
3). In lane 2, unstransfected cells were im m uneprecipita ted  
to de term ine  the background  pro te in  bands observed for 
this procesdure. The positions of molecular w eight m arkers 
are located at the right of the gel.
acid, 28 kDa NS5B protein. In this initial fnms-cleavage experiment 5pg of 
substrate (tNS5T) DNA was cotransfected with 5pg of the NS34A construct.
Although the NS34A protease complex processed the tNS5T substrate 
there was still a significant quantity of unprocessed substrate remaining. To 
attem pt to optimise the level of processing mediated by the protease 
construct the protease construct was titrated against a constant am ount of 
substrate. 5pg of substrate (tNS5T) was cotransfected with increasing 
amounts of the protease construct (Fig. 4.5.). As the amount of NS34A DNA 
increased the level of processing increased until reaching an optimal level 
of processing when 5|ig of NS34A plasmid DNA was transfected. Any 
further increase in the quantity of protease DNA transfected had little effect 
on the am ount of uncleaved substrate in comparison to the cotransfection 
with 5pg protease DNA. The efficiencies of processing observed w ith 
different quantities of NS34A are tabulated below.
Cotransfection Relative % Cleavage 
efficiency
tNS5T + 2pg NS34A 6
tNS5T + 5pg NS34A 17
tNS5T + 1 Ojixg NS34A 20
tNS5T + 15jLLg NS34A 24
Table 4.1. Titration of NS34A when cotransfected with 5pg tNS5T 
cDNA. Increasing quantities of pTF7.5 NS34A were cotransfected 
with pTM l tNS5T and after protein coexpression the relative % of 
substrate cleaved determined. As the amount of NS34A 
coexpressed increased the level of processing increased however 
there was very little increase in processing efficiency when m ore 
than 5pg NS34A was cotransfected.
Quantitation of the level of processing was calculated by dividing the 
total of the cleavage product intensities by the total of cleaved and 
uncleaved band intensities. The intensity of each band was determined by 
the num ber of (radioactively labelled) methionine residues within the 
protein. The sum of the intensities of the two cleavage products w ould 
equal the intensity of the single substrate band (as the uncleaved substrate 
contains the same num ber of methionine residues as the two cleavage 
products). This m ethod of quantitation is "quasi-quantitative" as the 
calculation uses steady state levels of substrate and products. The level of 
processing efficiency was estimated as a percentage (cleaved substrate as a 
percentage of total substrate). The calculations for the values obtained in 
Table 4.1. are illustrated in Table 4.2.
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Cotransfection +2ngNS34A +5^ ig NS34A +10pg NS34A +15^g NS34A
tNS5T 78408 76354 51917 36397
tNS5AT 3146 8821 6845 6213
tNS5BT 1588 6484 6346 5278
Total Substrate 83142 91659 65108 47888
Relative % Cleavage 
Efficiency
6 17 20 24
Table 4.2. Calculation of relative % cleavage efficiencies.
The intensities of the uncleaved substrate and cleavage products 
were determined using ImageQuant. The relative % cleavage 
efficiency was calculated by dividing the sum of the cleavage 
product intensities by the total substrate intensity and the 
m ultiplying this value by 100.
It was considered that the transfection protocol might be inefficient at 
introducing two plasmids into the same cell when large quantities of DNA 
were used. Alternatively, the level of processing observed could be the most 
efficient possible and any further increase in protease would have no effect 
on cleavage efficiency.
The am ount of protease DNA that gave the highest level of 
processing (5pg) was maintained as a constant and the substrate DNA 
titrated. Cotransfections were carried out using different quantities of 
substrate DNA from l-5|ng (Fig. 4.6.). As the quantity of substrate cDNA 
transfected decreased the amount of substrate protein expressed decreased. 
The am ount of NS34A remained constant, but in comparison with the 
substrate the ratio of protease:substrate increased. The lower the quantity of 
substrate DNA transfected the more cleavage products were produced 
relative to unprocessed substrate. Thus there was an increase in the 
efficiency of processing when the quantity of the substrate present fell 
(when the quantity of protease was unchanged). The relative % cleavage for 
these assays is illustrated below.
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Cotransfection Relative % Cleavage 
Efficiency
ljug tNS5T + NS34A 46
2pg tNS5T + NS34A 17
3 jig tNS5T + NS34A 22
4jLLg tNS5T + NS34A 17
5|ig tNS5T + NS34A 14
Table 4.3. Titration of tNS5T when cotransfected with 5pg NS34A 
cDNA. Increasing quantities of substrate cDNA were
cotransfected with a fixed amount of pTF7.5 NS34A. The less 
substrate cotransfected, the less substrate expressed and the 
higher the ratio of proteaseisubstrate. As the ratio of 
protease:substrate increased a higher relative % of cleavage 
efficiency was obtained.
Further titration of the assay was carried out using lp g  of substrate 
DNA and varying the amount of protease DNA (Fig. 4.7.). When 5|ig of 
protease DNA was cotransfected the substrate was processed with the 
highest level of efficiency. Any further decrease in the amount of protease 
DNA cotransfected resulted in a fall in the efficiency of processing. The 
processing efficiencies are tabulated below.
Cotransfection Relative % Cleavage 
Efficiency
tNS5T + lpg  NS34A 12
tNS5T + 2pg NS34A 32
tNS5T + 3pg NS34A 29
tNS5T + 4pg NS34A 32
tNS5T + 5 jig NS34A 42
5pgtNS5T + 5pg NS34A 21
Table 4.4. Titration of NS34A when cotransfected with lp g  
tNS5T. Increasing quantities of pTF7.5 NS34A were cotransfected 
with an unchanging amount of pTMl tNS5T. As the ratio of 
protease:substrate increased the relative % cleavage efficiency 
increased.
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Standard parameters for the cotransfection protocol were established 
w ith ljL ig  of substrate DNA cotransfected with 5pg of protease DNA. This 
protocol gave an optimal level of substrate processing with approxim ately 
40-45% of the substrate processed in different experiments.
To determine if the efficiency of processing by the protease could be 
im proved the duration of the incubation step of the transfection protocol 
(after addition of the plasmid DNA to the cells) was extended from 11 to 15 
hours after transfection (Fig. 4.8.).
W hen the length of the incubation step after transfection was 
increased, the efficiency of processing increased by a significant amount. 
The increase in the efficiency of processing of the tNS5T substrate increased 
from approximately 45% to 75%, resulting in significantly less substrate 
rem aining uncleaved.
To confirm that processing of the substrate was mediated by the NS3 
protease, an inactive NS3 serine protease construct, ALL NS3-5s_A was used 
as a negative control. This construct was supplied by Dr B. E. Clarke 
(GlaxoWellcome) and encodes the NS3-NS5 region of the type lb  HCV-A 
genome w ith a serine residue in the catalytic triad of the NS3 serine 
protease changed to an alanine residue, that abolishes protease activity 
(D'Souza et at., 1994, 1995). When the full length or the truncated NS5 
substrate was cotransfected with the inactive serine protease no cleavage 
products were observed (Fig. 4.9.). All the previous experiments w ith 
respect to the characterisation of the fnms-cleavage assay were carried out 
using the tNS5T substrate only as this was the only substrate that could be 
detected by immuneprecipitation. The NS5 antibody required for the 
identification of the full length NS5 and NS5A was unavailable until this 
time. The previous characterisation of the frans-cleavage assay had only 
been possible with the tNS5T substrate.
A comparison of different transfection protocols was carried out to 
see whether any further optimisation of the level of processing could be 
achieved. The standard transfection protocol used cationic liposomes 
whereas it was reported that the positively charged polyethylene im ine 
(PEI) was a highly efficient vector for the transfection of plasmid DNA into 
cells (Boussif et a l, 1995). Transfections were carried out with lp g  of tNS5T + 
5ju.g NS34A cotransfected into vTF7.3 infected CV-1 cells. For one reaction 
the DNA was transfected with cationic liposomes and for the other PEI was 
used. The experiments were carried out in tandem, the lysates 
immuneprecipitated and then analysed through a 12% SDS polyacrylam ide 
gel (Fig. 4.10.). No significant difference in processing efficiency was 
observed w hen either cationic liposomes or PEI were used to introduce the 
plasmid DNA into the mammalian cells.
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Fig. 4.8. Optimisation of processing. vTF7.3 infected 
CV-1 cells were left untransfected w ith DNA (lane 1) or 
transfected w ith tNS5T (lane 2) or tNS5T + NS34A (lane 
3). For the original protocol the cells were labelled with 
35S-methionine 11 hours post-transfection , lysed and
im m uneprecipita ted  with the SV5-P-k antibody before 
analysis by SDS-PAGE. The incubation period of the 
protocol (after introduction of the plasm id DNA) was 
increased from 11 to 15 hours  and this resulted in a 
significantly lower am ount of unprocessed substrate. 
The efficiency of processing was increased from 45% to 
75%. Molecular w eight m arkers are indicated on the
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Fig. 4.9. C om parison  of processing betw een an active and  an 
inactive NS3 pro tease . CV-1 cells infected w ith  vTF7.3 w ere 
transfected w ith  various combinations of HCV plasm id DNAs. 
The tNS5T substra te  w as transfected alone (lane 2), w ith  5pg 
NS34A (lane 3) or w ith  5|ig NS234 [Ser-Ala] (lane 4). The NS5 
substra te  w as transfected alone (lane 5), w ith 5pg NS34A (lane 
6) or w ith  5 |ig  NS34A [Ser-Ala] (lane 7). Fifteen hours  p o s t­
transfection  the  cells w ere  labelled w ith  35S-methionine for 2 
h o u rs  , lysed and  then  im m uneprec ip ita ted  w ith  the relative 
antibodies. Both substra tes  w ere  processed w hen  they w ere  
coexpressed w ith  NS34A (lanes 3 and 6). W hen the substrates 
w ere  coexpressed  w ith  the inactive protease  NS234[Ser-Ala] 
no c leavage p ro d u c ts  w ere  observed  (lanes 4 and  7). The 
tNS5T p ro te in  b an d s  are indicated by w hite  arrow s and  the 
NS5 p ro te in  b a n d s  ind ica ted  by black arrow s. M olecular 
w eight m arkers  are illustrated on the right.
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Fig. 4.10. C o m p ariso n  of different transfection m ethods. The 
HCV p lasm ids  w ere  in troduced  into cells using either cationic 
liposom es or po lye thy lene  imine (PEI). vTF7.3 infected CV-1 
cells w e re  t ran s fec ted  w ith  p la sm id s  an d  15 h o u rs  p o s t ­
transfection  the  cells w ere  labelled w ith  35S-methionine for 2 
hours. The cell lysates were im m uneprecip ita ted  w ith  the SV5- 
P -k  a n t i b o d y  b e fo re  a n a ly s is  by  SD S-PA G E. T he  
im m u n ep rec ip ita ted  control (vTF7.3 infected cell lysate) w as 
loaded  in lane 1. The tNS5T substra te  w as transfected alone 
(lane 2) or w ith  NS34A (lane 3) using cationic liposomes. tNS5T 
was also transfected either alone (lane 4) or w ith  NS34A (lane 5) 
us ing  PEI. U sing  either transfection m ed ium  the sam e level of 
p rocess ing  w as  observed  (lanes 3 and  5). M olecular w e ig h t 
m arkers  are located at the right of the gel.
4.3. Summary.
An assay was developed for the analysis of cleavage mediated in trans 
by the NS3 serine protease. One microgram of the relevant HCV substrate 
cDNA was cotransfected with 5|ig of NS34A cDNA into mammalian cells. 
The method of DNA introduction (Liposomes or PEI) did not appear to 
affect the efficiency of the cleavage reaction. After transfection of the 
plasmid DNAs the time of incubation before labelling was optim ised 
resulting in a significantly increased quantity of cleavage products produced 
relative to the unprocessed substrate. The cleavage products obtained were 
confirmed as being produced by NS3 serine protease-mediated cleavage.
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Chapter 5 - Mutagenesis of the 
NS5A/NS5B cleavage site
5.1. Development of a cassette for mutagenesis within the tNS5T substrate.
Mutagenesis of the NS5A/NS5B cleavage site required the 
development of an efficient system for the introduction of specific 
mutations. The alteration of amino acids within the cleavage site would 
provide an insight into the substrate requirements for processing by the 
NS3 serine protease. To study the importance of amino acids close to the 
NS5A/NS5B cleavage site a small cassette encompassing the cleavage site 
was introduced. This cassette, encoded in the tNS5T cDNA, would allow the 
production of tNS5T substrates containing mutated NS5A/NS5B cleavage 
sites, altered at the nucleic acid level to produce specific amino acid 
mutations, in an easy and straight-forward manner.
Two naturally occurring restriction enzyme sites, one either side of 
the cleavage site, were present within the tNS5T cDNA. A Sal I site situated 
45 nucleotides upstream of the cleavage site and a Sac II site situated 47 
nucleotides downstream of the cleavage site were contained within the 
nucleotide sequence of the tNS5T cDNA. When the tNS5T cDNA was 
digested with both these enzymes a double-stranded 86bp insert was 
removed. Construction of a corresponding m utant cleavage site cassette 
(for introduction into the digested vector) required the ligation of two 
synthetic oligonucleotides of considerable size. The quality of synthesis of 
oligonucleotides decreases as the size of the oligonucleotide increases. The 
deprotection of the bases used becomes inefficient and a mixed population 
of oligonucleotides would be created as opposed to the desired 
oligonucleotide. This fact, coupled with the expense, would make the 
construction of a cassette of this size infeasible.
By introducing silent mutations in the nucleotide sequence (that 
would not alter the amino acid sequence of the encoded polyprotein) two 
restriction enzyme sites closer to the NS5A/NS5B cleavage site could be 
created. A Kpn I site could be introduced 19 nucleotides upstream  of the 
cleavage site and a Bst Eli site could be introduced 30 nucleotides 
downstream. These two restriction enzyme sites, when digested, would 
produce a double-stranded 49bp insert with sticky ends.
To introduce the silent mutations by PCR two primers were 
designed. The 5' primer contained the Sal I site in the tNS5T cDNA and the 
new Kpn I site. The 3' primer contained the Sac II site in the tNS5T cDNA 
and the new Bst Eli site (Fig. 5.1.). After PCR amplification the product was 
digested with Sal I and Sac II. The digested product was ligated into Sal 
1/ Sac II digested pTMl tNS5T (Fig. 5.2.). The PCR product was sequenced to
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Fig. 5.2. PCR mutagenesis of the NS5A/NS5B cleavage site. The 
conserved restriction enzyme sites are illustrated by a blue X and 
the introduced restriction enzyme sites by a green X
check that no additional mutations had been introduced during the PCR 
reaction. Once the insert had been ligated into the tNS5T gene the presence 
of a compression m ade it difficult to determine whether the nucleotide 
sequence had been amplified correctly. This region was re-sequenced using 
the Sequenase DNA sequencing kit, using dITP instead of dCTP to overcome 
the problems associated with compression. When the region was sequenced 
in this m anner the compressed sequence was readable and this confirmed 
that the sequence of the PCR product was correct (Fig. 5.3.). The DNA 
sequence determ ined by the Sequenase method of DNA sequencing 
contained an unreadable region of sequence but this region was confirmed 
as correct by the standard method of sequencing.
pTM l contains a Kpn I site in the vector outwith the multiple cloning 
site and so could not be used for the initial mutagenesis step without 
carrying out a partial digest. Despite varying the DNA and restriction 
enzyme concentrations the partial digest always favoured the Kpn I site in 
pTM l and so made cloning into this vector impossible. pTZ18 also contains 
a site within its multiple cloning site and so pTZ18 tNS5T could not be used 
for the initial cloning step. Therefore the tNS5T cDNA containing the 
additional restriction enzyme sites was subcloned into pGEM-1, a vector 
lacking a Kpn I site and so suitable for the introduction of the mutated 
NS5A/NS5B cleavage sites. Hence mutagenesis was initially carried out 
using pGEM tNS5T and then the mutated cleavage site subcloned into pTMl 
tNS5T (as protein expression from cDNAs cloned within pTMl was 
significantly higher). The tNS5T cDNA contains a Bam HI site 75 nucleotides 
upstream  of the NS5A/NS5B cleavage site and an Eco RI site 605 nucleotides 
downstream. The pGEM tNS5T containing the mutated cleavage site was 
digested with Bam HI/Eco  RI to produce a 680bp insert that was ligated into 
Bam HI/Eco RI digested pTMl tNS5T.
The expression of the three tNS5T constructs (pTZ18 tNS5T, pTMl 
tNS5T, pGEM tNS5T) containing the cleavage site with the Kpn l/B s t Eli sites 
introduced was checked. The introduction of the additional restriction 
enzyme sites, which had no effect on the amino acid sequence, also had no 
effect on protein expression. All three constructs were also co-expressed 
with NS34A to ensure that the "altered" tNS5T substrate was still processed 
by the NS3 serine protease (Fig. 5.4.). Although the tNS5T substrate was 
expressed from all the vectors the level of expression from the pTMl tNS5T 
plasmid was significantly higher than for the other vectors.
5.2 Mutagenesis of conserved residues within the cleavage site motif
The cleavage sites processed by the NS3 serine protease all essentially 
have the same amino acid motif. For the HCV Gla polyprotein this motif 
has been shown to consist of a conserved acidic P6 residue (aspartic or 
glutamic acid), a cysteine or threonine residue (both these amino acids 
contain the sulfhydryl group -SH) at PI and a serine residue at PI'.
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Fig. 5.4. C o m p a r iso n  of su b s tra te  exp ress ion  from  
d iffe ren t  p la sm id s  transfec ted  in m a m m a lia n  cells. 
vTF7.3 in fec ted  CV-1 cells w e re  tran s fec ted  w ith  
d i f fe re n t  p la sm id s  e n c o d in g  the  tNS5T su b s tra te .  
Fifteen h o u rs  post-transfection the cells w ere  labelled 
w ith  35S-m ethionine for 2 hours  before lysis and  then
im m u n ep rec ip ita t io n  w ith  the SV5-P-k antibody . In 
a d d i t io n  to u n tran s fec ted  cells (lane 1), the  tNS5T 
substra te  w as  expressed  from pTZ18 (lanes 2 and  3), 
pT M l (lanes 4 and 5) and  pGEM-1 (lanes 6 and 7). The 
levels of expression of the substrate  varied  dep en d in g  
on the vector. The tNS5T substrate  was expressed at the 
h ighest level w h en  expressed from p T M l (lanes 4 and  
5). W hen  the substrate  w as cotransfected w ith  NS34A 
cleavage p roduc ts  were  p roduced(lanes  3, 5 and 7). As 
the level of expression w as higher from the pT M l tNS5T 
construct (lane 5) processing w as observed m ore clearly 
than  for the o ther vectors (lanes 3 and  7). M olecular 
weight m arkers  are located at the right of the gel.
P6 P I P I '
D (E) X X X X C (T) /  S
The cleavage site is processed between the PI residue and the P I7 
residue. The importance an d /o r essential nature of these amino acids was 
not known. The threonine residue at P I7 is only observed for the NS3/NS4A 
cleavage site. This site is the only one processed in cis by the NS3 serine 
protease w ithin the HCV polyprotein
For mutagenesis of amino acids at the NS5A/NS5B cleavage site two 
complementary oligonucleotides containing the necessary nucleotide 
changes were annealed together. Annealing of these oligonucleotides 
produced the cassette required for ligation into the tNS5T gene. For each of 
the single amino acid changes at P6, PI or P I7 the 57 to 37 oligonucleotide 
was designed to give three possible amino acid changes at each codon. This 
was achieved by using a mixture of three nucleotide precursors in the 
synthesis at a specific position within the nucleotide sequence. For each 
codon targetted, the first nucleotide was replaced by a mixture of the other 
three nucleotides. As the first nucleotide of the codon primarily determ ines 
the amino acid encoded this mutagenesis method would produce three 
alternative amino acids at each position. A complementary oligonucleotide 
encoding the wild type sequence was annealed to the m utant 
oligonucleotides to form the cassette containing the m utant cleavage site 
(Fig. 5.5.).
All nine possible mutants were obtained using this procedure, and 
the DNAs were checked to ensure that no extra mutations had been 
introduced. These clones were transfected into mammalian cells both w ith 
and w ithout the protease construct to determine expression and processing 
by the NS3 serine protease (Figs. 5.6.-5.12.). Each set of positional m utants 
(P6, PI and P I7) was analysed in duplicate to ensure that the results obtained 
were consistent and that there was no aberrations.
The effect of m utating the P6 residue of the NS5A/NS5B cleavage site 
was investigated (Figs. 5.6. and 5.7.). The replacement of the wild type P6 
glutamic acid with glutamine or lysine produced a cleavage site that was 
still processed by the NS3 serine protease but with a lower level of 
efficiency. The introduction of a STOP codon at P6 produced a truncated 
NS5A substrate that did not contain the NS5A/NS5B cleavage site and was 
not processed by NS3.
The replacement of the wild type cysteine residue at PI produced 
cleavage sites that were unsuitable for cleavage by the NS3 serine protease 
(Figs. 5.8. and 5.9.). When a serine residue was introduced at PI there was a 
low level of processing but replacement with arginine or glycine resulted in 
the abolition of processing.
The effect of m utating the P I7 residue on processing depended on the 
amino acid introduced (Figs. 5.10. and 5.11.). Cleavage sites containing 
threonine and alanine were processed whereas the cleavage site w ith 
proline at P I7 was not cleaved. In Fig. 5.12. all nine mutants were analysed
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Fig. 5.6. Mutation of the P6 amino acid in the NS5A/NS5B cleavage site 
within the tNS5T substrate. CV-1 cells were infected with vTF7.3 before 
transfection either with HCV plasmids (lanes 2 to 9) or without DNA as a 
control (lane 1). In lane 2 the wild type tNS5T substrate was expressed 
alone and in lane 3 the substrate was coexpressed with NS34A. A tNS5T 
substrate containing a glutamine residue at P6 was transfected alone (lane 
4) or with NS34A (lane 5). A tNS5T substrate with a STOP codon at P6 was 
transfected with (lane 7) or without (lane 6) NS34A. A tNS5T substrate 
containing a lysine at P6 was transfected alone (lane 8) or with NS34A (lane 
9). Fifteen hours post-transfection the cells were labelled with 35S- 
methionine for 2 hours before cell lysis and immuneprecipitation with the 
SV5-P-k antibody. Both the substrates containing P6 Gin and P6 Lys were 
processed by NS34A (lanes 5 and 9) albeit with different efficiencies. The 
tNS5T substrate containing the STOP codon at P6 produced a truncated 
substrate that did not contain the NS5A/NS5B cleavage site. This substrate 
was not processed by NS34A. Molecular weight markers are located at the 
right of the gel.
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F i g .  5 . 7 .  Repeat analysis of mutation of the P6 amino acid in the NS5A/ 
NS5B cleavage site within the tNS5T substrate. CV-1 cells were infected 
with vTF7.3 before transfection either with HCV plasmids (lanes 2 to 9) or 
without DNA as a control (lane 1). In lane 2 the wild type tNS5T substrate 
was expressed alone and in lane 3 the substrate was coexpressed with 
NS34A. A tNS5T substrate containing a glutamine residue at P6 was 
transfected alone (lane 4) or with NS34A (lane 5). A tNS5T substrate with a 
STOP codon at P6 was transfected with (lane 7 )  or without (lane 6) NS34A. 
A tNS5T substrate containing a lysine at P6 was transfected alone (lane 8) or 
with NS34A (lane 9). Fifteen hours post-transfection the cells were labelled 
with 35S-methionme for 2 hours before cell lysis and immuneprecipitation 
with the SV5-P-k antibody. Both the substrates containing P6 Gin and P6 
Lys were processed by NS34A (lanes 5 and 9) albeit with different 
efficiencies. The tNS5T substrate containing the STOP codon at P6 
produced a truncated substrate that did not contain the NS5A/NS5B 
cleavage site and so was not processed by NS34A. Molecular weight 
markers are located at the right of the gel.
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Fig. 5.8. Mutation of the PI residue in the NS5A/NS5B cleavage site 
within tNS5T. CV-1 cells were infected with vTF7.3 before transfection 
either with HCV plasmids (lanes 2 to 9) or without DNA as a control (lane 
1). In lane 2 the wild type tNS5T substrate was expressed alone and in 
lane 3 the substrate was coexpressed with NS34A. A tNS5T substrate 
containing a serine residue at PI was transfected alone (lane 4) or with 
NS34A (lane 5). A tNS5T substrate containing an arginine residue at PI 
was transfected with (lane 7) or without (lane 6) NS34A. A tNS5T 
substrate containing a glycine at PI was transfected alone (lane 8) or with 
NS34A (lane 9). Fifteen hours postransfection the cells were labelled with 
35S-methionine for 2 hours , lysed and then immuneprecipitated with the
SV5-P-k antibody before analysis by SDS-PAGE. None of the mutant 
substrates were processed by NS34A (lanes 7 and 9) with the exception of 
the PI Ser tNS5T substrate that was processed to a small degree (lane 5). 
Molecular weight markers are indicated on the right.
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Fig. 5.9. Repeat of the mutational analysis of the PI residue in the NS5A/ 
NS5B cleavage site within tNS5T. CV-1 cells were infected with vTF7.3 
before transfection either with HCV plasmids (lanes 2 to 9) or without 
DNA as a control (lane 1). In lane 2 the wild type tNS5T substrate was 
expressed alone and in lane 3 the substrate was coexpressed with NS34A. 
A tNS5T substrate containing a serine residue at PI was transfected alone 
(lane 4) or with NS34A (lane 5). A tNS5T substrate containing an arginine 
residue at PI was transfected with (lane 7) or without (lane 6) NS34A. A 
tNS5T substrate containing a glycine at PI was transfected alone (lane 8) 
or with NS34A (lane 9). Fifteen hours postransfection the cells were 
labelled with 35S-methionine for 2 hours , lysed and then 
immuneprecipitated with the SV5-P-k antibody before analysis by SDS- 
PAGE. None of the mutant substrates were processed by NS34A (lanes 7 
and 9) with the exception of the PI Ser tNS5T substrate that was 
processed to a small degree (lane 5). Molecular weight markers are 
indicated on the right.
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Fig. 5.10. Mutation of the PI' amino acid in the NS5A/NS5B cleavage site 
within the tNS5T substrate. CV-1 cells were infected with vTF7.3 before 
transfection either with HCV plasmids (lanes 2 to 9) or without DNA as a 
control (lane 1). In lane 2 the wild type tNS5T substrate was expressed 
alone and in lane 3 the substrate was coexpressed with NS34A. A tNS5T 
substrate containing a threonine residue at PI' was transfected alone (lane 
4) or with NS34A (lane 5). A tNS5T substrate containing an alanine residue 
at PI' was transfected with (lane 7) or without (lane 6) NS34A. A tNS5T 
substrate containing a proline at PI' was transfected alone (lane 8) or with 
NS34A (lane 9). Fifteen hours postransfection the cells were labelled with 
35S-methionine for 2 hours , lysed and then immuneprecipitated with the
SV5-P-k antibody before analysis by SDS-PAGE. The effect of an amino 
acid substitution at PI' depended on the amino acid introduced. A tNS5T 
substrate containing an alanine at PI' was processed at almost wild type 
efficiency (lane 7). A threonine at PI' resulted in a substrate processed less 
efficiently (lane 5) whereas a substrate containing proline at PT was not 
processed. The molecular weight markers are indicated on the right.
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Fig. 5.11. Repeat analysis of mutation of the PI' amino acid in the NS5A/ 
NS5B cleavage site within the tNS5T substrate. CV-1 cells were infected 
with vTF7.3 before transfection either with HCV plasmids (lanes 2 to 9) or 
without DNA as a control (lane 1). In lane 2 the wild type tNS5T substrate 
was expressed alone and in lane 3 the substrate was coexpressed with 
NS34A. A tNS5T substrate containing a threonine residue at PI' was 
transfected alone (lane 4) or with NS34A (lane 5). A tNS5T substrate 
containing an alanine residue at PI' was transfected with (lane 7) or 
without (lane 6) NS34A. A tNS5T substrate containing a proline at PI' was 
transfected alone (lane 8) or with NS34A (lane 9). Fifteen hours 
postransfection the cells were labelled with 35S-methionine for 2 hours , 
lysed and then immuneprecipitated with the SV5-P-k antibody before 
analysis by SDS-PAGE. The effect of an amino acid substitution at PI' 
depended on the amino acid introduced. A tNS5T substrate containing an 
alanine at PI' was processed at almost wild type efficiency (lane 7). A 
threonine at PI' resulted in a substrate processed less efficiently (lane 5) 
whereas a substrate containing proline at PI' was not processed. The 
molecular weight markers are indicated on the right.
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by SDS-PAGE after co-transfection with NS34A to illustrate the effects of all 
the m utations together.
The replacement of the acidic amino acid at P6 with either the basic 
lysine residue or the uncharged polar glutamine resulted in a significant fall 
in the efficiency of processing. The introduction of a stop codon upstream  of 
the cleavage site resulted in a slightly truncated NS5A protein that did not 
contain the NS5A/NS5B cleavage site. This protein was included as a 
negative control in the analysis to demonstrate that the system was 
functioning correctly. Mutation of the PI cysteine residue resulted in the 
abolition of processing except for a cysteine to serine substitution where a 
small am ount of processing was observed at this site.
The effect of substitution at the PI7 amino acid depended on the 
amino acid change. Substitution with the nonpolar proline residue 
completely abolished processing whereas replacement with alanine still 
perm itted a significant degree of processing. Slightly greater inhibition of 
processing resulted from replacement of the PI' serine residue with the 
uncharged, nonpolar threonine residue.
The efficiency of processing at these m utant cleavage sites was 
estimated, w ith respect to wild type cleavage efficiency, in Table 5.1.
Amino Acid Substitution Relative % Cleavage 
Efficiency
Wild Type 100
P6 Glu - Gin 30
P6 Glu - Lys 15-25
PI Cys - Ser <10
PI Cys - Arg 0
PI Cys - Gly 0
PI' Ser - Thr 30-40
PI' Ser - Ala 55-60
PI' Ser - Pro 0
Table 5.1. M utation of the amino acids comprising the cleavage 
site motif. The relative effect on cleavage with respect to the wild 
type is illustrated. Mutation of the P6 residue significantly 
inhibited the level of processing. An even stronger inhibitory 
effect was observed when the PI residue was replaced. The effect 
of m utation at the PI' residue depended on the amino acid 
introduced.
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Chapter 6 - Investigation of 
potential cleavage sites within the 
HCV Gla polyprotein
6.1. Determination of potential cleavage sites within the HCV Gla 
polyprotein.
Only four sites within the HCV polyprotein are cleaved by the NS3 
serine protease. Processing at these sites is essential for the generation of 
the HCV non-structural proteins downstream of NS3. If the NS3 serine 
protease cleaved at any other site within the HCV polyprotein it had yet to 
be reported. The amino acid sequence of the HCV Gla polyprotein was 
examined to determine whether there were any other cleavage sites that 
could potentially be processed by the NS3 serine protease. All the sites 
cleaved by the NS3 serine protease have an aspartic or glutamic acid residue 
followed by a cysteine or threonine residue six residues downstream and a 
serine residue seven residues downstream. The HCV Gla polyprotein was 
searched for this cleavage site motif using the Stringsearch program. The 
results of the search for D(E) X X X X C(T) S are illustrated in Table 6.1.
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Position Sequence Location
1652 -1658 DLEWTS NS3/NS4A
1706 -1712 DEMEECS NS4A/NS4B
2967 -1973 DCTTPCS NS4B/NS5A
2167 - 2173 DVAVLTS In NS5A
2415 - 2421 EDWCCS NS5A/NS5B
2779 - 2785 DLELITS In NS5B
2781 - 2787 ELITSCS In NS5B
Table 6.1. Cleavage site motif search with HCV Gla. The HCV 
Gla polyprotein was searched for any amino acid sequence that 
corresponded to the NS3 cleavage site motif. As well as the 
cleavage sites processed to give the non-structural proteins, three 
additional, potential cleavage sites were identified within the NS5 
region of the polyprotein. A potential cleavage site motif sim ilar 
to the NS3/NS4A cleavage site, in that it contained a threonine 
residue at PI, was located within NS5A. The threonine residue at 
this position is unique to the NS3/NS4A cleavage site, a site that 
is processed in cis. Two potential cleavage sites within the NS5B 
region were found that overlap each other by five amino acids.
One site contained a threonine residue at PI and the other 
contained a cysteine residue at PI (as is seen for the majority of 
cleavage sites, all of which are processed in trans).
6.2. Investigation of processing at the potential cleavage site within NS5A.
Cleavage at the first of these potential cleavage sites within the HCV 
Gla polyprotein would produce a truncated NS5A protein with its N- 
term inus at amino acid 2173. The N-terminus of the tNS5T substrate is at 
amino acid 2105, 68 amino acids upstream of this theoretical cleavage site. If 
the potential cleavage site was cleaved within tNS5T by NS3 then two NS5A 
cleavage products could be generated, depending on how efficiently this 
potential site was processed. These two NS5A products, although relatively 
similar in size, could be differentiated by immuneprecipitation using two 
different antibodies. The SV5-P-k antibody would only identify the full 
length tNS5AT product as the epitope tag it recognised was present at the N- 
term inus of the tNS5T substrate. If processing occurred at the potential 
cleavage site then the epitope tag would be attached to the small 68 amino 
acid protein generated by this cleavage event. The NS5(Baculo) antibody 
against the C-terminal region of the NS5A protein (supplied by 
GlaxoWellcome) would identify both the truncated NS5A proteins.
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Duplicate cotransfections were carried out in vTF7.3 infected CV-1 
cells. The tNS5T substrate cDNA and either the NS3 or the NS34A construct 
were cotransfected together. The potential cleavage site resembled the 
NS3/NS4A cleavage site as it contained a threonine at PI. As the NS3/NS4A 
cleavage site is processed in cis by NS3 alone the cotransfections were 
carried out using the HCV Gla NS3 construct as well as the NS34A construct. 
After radiolabelling with 35S-methionine, the cells were lysed and each pair 
of extracts (tNS5T + NS3 and tNS5T + NS34A) were im m uneprecipitated 
with either the SV5-P-k antibody or the NS5(Baculo) antibody. The 
imm uneprecipitated lysates were analysed by SDS-PAGE (Fig. 6.1.). The 
substrate was only cleaved only when it was cotransfected with NS34A. The 
NS5A cleavage products identified by both the SV5-P-k antibody and the 
NS5A(Baculo) antibody were the same size. No additional NS5A band was 
detected. These results show that only the NS5A/NS5B cleavage site was 
processed by the NS3 serine protease within the tNS5T substrate. Cleavage 
at this site was observed to take place by Markland et a\, 1996.
6.3. Investigation of the potential "trans"  cleavage site in NS5B.
The other two potential cleavage sites, at amino acids 2779 - 2785 and 
2781 - 2787, were situated downstream of the C-terminus of the tNS5T 
substrate (amino acid 2623). Whether these potential cleavage sites were 
processed within NS5B could not be determined using the tNS5T substrate. 
The full length NS5B protein, which contains these theoretical sites, was 
reported to be unstable when expressed in cells. The instability of the NS5B 
protein may be due to proteolysis by cellular-encoded enzymes (Lin et al, 
1994b). As no efficient antibody against the NS5B protein was available in 
the laboratory this protein could not be detected by im m uneprecipitation 
even if it was stable, and so the full length NS5 substrate could not be used 
to investigate processing at these potential sites. As the assay for NS3 serine 
protease activity analysed processing in trans the cleavage site containing 
the cysteine residue at PI (ELITSCS) was chosen for study.
An amino acid comparison was carried out between this potential 
cleavage site (including the flanking amino acids) and the cleavage sites 
processed by NS3 within the HCV Gla polyprotein (Fig. 6.2.). An am ino 
acid sequence comparison between all HCV isolates showed that the 
potential cleavage site (ELITSCS) was present in every genotype at the same 
position.
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Fig. 6.1. Analysis of processing of the tNS5T substrate and 
determination whether processing occurs at a potential site. vTF7.3 
infected CV-1 cells were transfected with HCV cDNAs (lanes 2 to 6) or 
remained untransfected as a control (lane 1). Fifteen hours post­
transfection the cells were labelled with 35S-methionine for 2 hours, lysed 
and then immuneprecipitated before analysis by SDS-PAGE. The tNS5T 
substrate was transfected alone (lane 2). In lanes 3 and 4 the tNS5T 
substrate was cotransfected with NS34A. For lane 3 the substrate was 
immuneprecpitated with the SV5-P-k antibody but for lane 4 the 
substrate was detected by the NS5 (Baculo) antiserum. In lanes 5 and 6 
the tNS5T substrate was cotransfected w ith NS3 and 
immuneprecipitated with either SV5-P-k (lane 5) or NS5 [Baculo] (lane 
6). The theoretical cleavage site within NS5A is situated close to the C- 
terminus of the tNS5T substrate. If the potential cleavage site was 
cleaved a smaller tNS5AT product would be identified by the NS5A/ 
NS5B antibody and not by the SV5-P-k antibody. No additional cleavage 
product was observed when the substrate was cotransfected with either 
NS3 or NS34A (lanes3, 4, 5, 6). The molecular weight markers are located 
at the right of the gel.
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Fig. 6.2. Sequence comparison between the observed sites 
cleaved in trans by the NS3 serine protease and the potential site 
in NS5B. The amino acids constituting the cleavage site motif are 
illustrated in bold.
As for the mutagenesis of the NS5A/NS5B cleavage site within tNS5T, 
two complementary oligonucleotides were designed. Each oligonucleotide 
encoded the NS5A/NS5B cleavage site with the wild type sequence from P5 
- P2 (D W C ) replaced with LITS.
Following successful cloning into tNS5T and confirmation by 
sequencing, the tNS5T substrate containing the mutated cleavage site (tNS5T 
LITS) was cotransfected with NS34A into vTF7.3 infected CV-1 cells to 
determine whether this substrate was processed (Fig. 6.3.) using the 
standard trans-clea.va.ge assay. When tNS5T LITS was coexpressed w ith 
NS34A no cleavage products were detected. When quantitation of 
processing was carried out a very small amount of processing was detected 
but this value was negligible. The lack of processing at the NS5A/NS5B site 
was seen despite the presence of the consensus amino acids at P6, PI and PI'. 
These three amino acids at P6, PI and PI' had been previously suggested to 
be sufficient to define a cleavage site suitable for processing by the NS3 
serine protease.
When leucine, isoleucine, threonine and serine were present at 
positions P5 to P2 in the NS5A/NS5B cleavage site, this site could not be 
cleaved by the NS3 protease. The effect on the cleavage site could be due to 
an individual amino acid or a cumulative effect of more than one residue. 
The amino acid sequences of NS3 processed cleavage sites were examined to 
determine whether any of these four amino acids were present in different 
HCV subtypes or genotypes (Table 6.2.).
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Fig. 6.3. Analysis of processing of the tNS5T substrate 
containing the P5 - P2 substitution from Asp, Val, Val, 
Cys to Leu, Iso, Thr, Ser (LITS). CV-1 cells w ere  
infected w ith  vTF7.3 before transfection w ith  tNS5T 
(lane 2), tNS5T + NS34A (lane 3), tNS5T LITS (lane 4) 
or tNS5T LITS + NS34A (lane 5). Fifteen hours  pos t­
t ra n s fe c t io n  the  cells w e re  labe lled  w i th  35S- 
m e t h i o n i n e  fo r  2 h o u r s  , l y s e d  a n d  
im m u n e p re c ip i ta ted  w ith  the SV5-P-k antibody , as 
w ere  un transfected  cells (lane 1). All these sam ples 
w e re  a n a ly se d  by  SDS-PAGE. The tNS5T-LITS 
su b s tra te  w as  no t c leaved by coexpressed  NS34A 
(lane 5). The molecular w eight m arkers are located at 
the right of the gel.
Position Within Cleavage Site Amino Acids Present Within 
Site
5 E, C, S, Y, D, G, L
4 M ,P ,S ,T ,V ,I,E
3 E, T, V, I, A, S, V
2 E, P, C, V
Table 6.2. Cleavage sites processed by the NS3 serine protease 
were compared from HCV genotypes 1-6. The amino acids found 
at positions 5, 4, 3 and 2 are shown above. The amino acids 
illustrated in bold correspond to those found at the highly 
conserved NS3/NS4A cleavage site (the only site processed in cis 
w ithin the HCV polyprotein).
The presence of the LITS amino acid sequence from P5 to P2 in an NS3 
protease cleavage site was not found in any HCV polyprotein for all six 
genotypes. A leucine at P5, an isoleucine at P4 and a threonine at P3 were 
all present individually. A serine residue at P2 was not seen in any other 
cleavage site. The presence of this residue could have a detrimental effect 
on the form ation of a cleavage site, resulting in a site that could no longer 
be processed by the NS3 serine protease.
Another feature of the potential cleavage site was the presence of a 
serine residue at the P2' position (Fig. 6.2.). Of the cleavage sites processed 
in trans by the NS3 protease only the NS4A/NS4B cleavage site in certain 
genotypes contained a serine residue at P2'. For these cleavage sites the PI' 
residue is always an alanine residue. Some NS3/NS4A cleavage sites 
contain a serine residue at both PI' and P2', but as this site is processed in cis 
it is possible that the flanking residues are not as influential as they are for 
the fnms-cleavage sites. Although the P2' serine residue was not included in 
the initial potential cleavage site analysis the effect of this amino acid at P2' 
was investigated. It was hypothesised that these serine residues could be 
phosphorylated, inhibiting access to the cleavage site to NS3, although no 
analyses were carried out to determine whether these residues were actually 
phosphorylated.
To analyse the effect of a serine at P2, two approaches were used. The 
first potential cleavage site was constructed in tNS5T with the wild type 
NS5A/NS5B amino acid sequence from P6 to PI' except for a serine residue 
at P2. A second potential cleavage site was constructed with the LITS amino 
acid sequence in tNS5T LITS substituted at P2 with the wild type cysteine 
residue to give the amino acid sequence LITC from P5 to P2. These two 
constructs (tNS5T P2S and tNS5T LITC) were cloned and sequenced. A wild 
type NS5A/NS5B cleavage site with a serine residue at P2' was constructed 
to give the substrate tNS5T P2'S. These cleavage sites are illustrated below.
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P2 C ys-S er SEAGT EDWSC/SMSY
LITC SEAGT ELITCC/SMSY
P2' Met -Ser SEAGT EDWCC/SSSY
As well as these substrates an additional substrate was constructed 
with the LITCY amino acid sequence from P5 to PI (tNS5T LITCY). This 
cleavage site was the result of a mistake during oligonucleotide synthesis. 
This substrate was also included in these experiments. All four of these 
substrate clones were cotransfected with NS34A into vTF7.3 infected CV-1 
cells and the cells radiolabelled, lysed and immuneprecipitated before 
analysis by SDS-PAGE (Figs. 6.4., 6.5.).
The tNS5T substrate with the wild type P2 cysteine residue of the 
NS5A/NS5B cleavage site replaced with a serine residue was cleaved with a 
much lower efficiency in comparison to the wild type when it was 
coexpressed with NS34A. The tNS5T LITC substrate with the wild type 
cysteine residue substituted at P2 of the cleavage site was processed at an 
observable, but far from optimal, level. Little processing was observed for 
the substrate containing the ELITCYS cleavage site. The tNS5T P2'S 
substrate was cleaved by coexpressed NS34A but the efficiency of processing 
was only slightly higher than that observed for tNS5T P2S. The efficiency of 
processing estimated for these substrates is summarised below.
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F i g .  6.4. Analysis of the effects on processing after further 
mutagenesis of the theoretical LITS cleavage site. CV-1 cells were 
infected with vTF7.3 before transfection with tNS5T (lane 2), tNS5T + 
NS34A (lane 3), tNS5T LITS (lane 4), tNS5T LITS + NS34A (lane 5), 
tNS5T LITC (lane 6), tNS5T LITC + NS34A (lane 7), tNS5T P2 Ser(lane 
8), tNS5T P2 Ser + NS34A (lane 9), tNS5T P2' Ser (lane 10), tNS5T P2' 
Ser + NS34A (lane 11), tNS5T LITCY (lane 12) or tNS5T LITCY + 
NS34A (lane 13). Fifteen hours post-transfection the cells were 
labelled with 3 5S m ethionine for 2 hours, lysed and 
immuneprecipitated with the SV5-P-k antibody before analysis by 
SDS-PAGE , as were untransfected cells (lane 1). The introduction of 
the wild type cysteine residue at P2 within the LITS cleavage site 
resulted in detectable processing of the substrate (lane 7), albeit at 
significantly lower levels compared to the wild type substrate. The 
introduction of a serine residue at either P2 or P2' had an inhibitory 
effect on the susceptibility to processing of the NS5A/NS5B cleavage 
site (lanes 9 and 11 respectively). The introduction of the tyrosine 
residue at PI of the LITC cleavage site had an inhibitory effect on 
susceptibility to processing (lane 13). The molecular weight markers 
are located at the right of the gel.
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Cleavage Site Relative % Cleavage Efficiency
Wild Type 100
LITS 0
P2 Cys - Ser 45-50
LITC 20-25
LITCY <10
P2' Met - Ser 60
Table 6.3. Cleavage of substrates containing cleavage sites 
derived from the potential LITS cleavage site. The tNS5T LITC 
substrate was processed at 25% the level of wild type efficiency. 
The tNS5T substrates that contained a serine residue at either P2 
or P2' of the NS5A/NS5B cleavage site were processed with an 
efficiency approximately 50% of wild type for both substrates. 
The tNS5T LITCY substrate was cleaved at a low level.
As the tNS5T P2S and tNS5T LITC substrates were cleaved, the serine 
residue at P2 of the LITS cleavage site was not entirely reponsible for the 
abolition of cleavage. The remaining three amino acids within the LITS 
sequence are all present individually in other cleavage sites. As cleavage 
sites containing these amino acids alone are cleaved the presence of m ore 
than one of these amino acids (i.e. the presence of a pair or a combination of 
three or four amino acids) could influence the cleavability of a site. Three 
further tNS5T substrates were constructed that contained NS5A/NS5B 
cleavage sites derived from the potential LITS cleavage site. These three 
substrates were constructed by replacing first the P5 and P4 amino acids 
(tNS5T DVTS), then P4 and P3 (tNS5T LVVS) and finally P3 and P2 of the 
LITS sequence (tNS5T LIVC) as illustrated below.
Wild Type SEAGT EDWCC/SMSY
LITS SEAGT ELITSC/SMSY
DVTS SEAGT EDVTSC/SMSY
L W S SEAGT ELWSC/SMSY
LIVC SEAGT ELIVCC/SMSY
These new substrate constructs were cloned and sequenced before 
being studied in the standard fnms-cleavage assay (Figs. 6.6., 6.7.). All three 
substrates that contained these potential cleavage sites were cleaved, albeit 
at low levels. When the tNS5T LITS substrate contained the wild type amino 
acids at P5 and P4 (tNS5T DVTS), this substrate was processed poorly. The 
tNS5T LVVS substrate was processed with a similar efficiency to the tNS5T 
DVTS substrate whereas the tNS5T LIVC substrate was processed with a
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Fig. 6.6. M utagenesis of the potential LITS cleavage site w ith in  
the  tN S5T substra te .  vTF7.3 infec ted  CV-1 cells w e re  
transfected w ith tNS5T (lane 2), tNS5T + NS34A (lane 3), tNS5T 
LITS + NS34A (lane 4), tNS5T LIVC + NS34A (lane 5), tNS5T 
LVVS + NS34A (lane 6), tNS5T DVTS + NS34A (lane 7) or were  
left untransfected  (lane 1). Fifteen hours  post-transfection the 
cells were  labelled w ith  35S m ethionine for 2 hours  before lysis, 
im m u n e p re c ip i ta io n  w ith  the  SV5-P-k antibody a n d  th e n  
analysis by SDS-PAGE. The m ost efficiently processed of these 
m u ta te d  substra tes  con tained  LIVC from P5 to P2 (lane 5), 
followed by LVVS (lane 6) and  the least efficiently processed 
substra te  contained the sequence DVTS at P5-P2 (lane 7). The 
molecular w eight m arkers are located at the right of the gel.
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higher efficiency than the other two substrates (tNS5T DVTS and tNS5T 
LVVS). The efficiency with which these substrates were processed by the 
NS3 serine protease is estimated in Table 6.4.
Cleavage Site Relative % Cleavage 
Efficiency
Wild Type 100
UTS 0
DVTS -15
LVVS 10-20
LIVC 25-35
Table 6.4. The efficiencies with which tNS5T substrates 
containing derivatives of the potential LITS cleavage site were 
processed. The introduction of the wild type aspartic acid and 
valine residues at P5 and P4 to produce tNS5T DVTS created a 
substrate that was processed at 15% of the wild type tNS5T. The 
effect of replacing the P4 and P3 amino acids with the wild type 
valines produced a substrate (tNS5T LVVS) processed m arginally 
higher than the previous substrate. When valine and cysteine 
were introduced at P3 and P2 to give tNS5T LIVC the largest 
increase in processing efficiency was observed. The substrate was 
processed with a slightly higher efficiency compared to the tNS5T 
LITC substrate. All three substrates were processed at a 
significantly lower level than the wild type substrate, tNS5T.
A cleavage site was constructed with only the m utant leucine residue 
at P5 of the cleavage site maintained from the original potential cleavage 
site (LITS). This cleavage site was cloned into the tNS5T cDNA and the new 
m utant substrate (tNS5T LVVC) introduced into the frans-cleavage assay. 
This substrate and all the previous substrates were cotransfected w ith 
NS34A into vTF7.3 infected CV-1 cells and the efficiencies with which these 
substrates were processed compared. After radiolabelling with 35S- 
methionine the cells were lysed and immuneprecipitated with the SV5-P-k 
antibody before analysis by SDS-PAGE. All the substrates constructed to 
investigate the potential LITS cleavage site were included to give a full 
picture of the analysis (Fig. 6.8.). The tNS5T LVVC substrate containing the 
wild type amino acids from P4 to P2 was processed at a significantly lower 
level of efficiency in comparison to tNS5T. The relative percentage of 
cleavage efficiency by which these substrates were cleaved is summ arised 
in Table 6.5.
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Cleavage Site Relative % Cleavage 
Efficiency
Wild Type 100
LITS 0
LITC 20-25
LIVC 25-35
LVVS 10-20
DVTS -15
L W C 15-25
P2 Cys - Ser 45-50
P2' Met - Ser 60
Table 6.5. Relative % cleavage efficiencies of tNS5T 
substrates with their NS5A/NS5B cleavage sites altered to 
investigate the potential LITS cleavage site. No significant 
increase in efficiency was observed between the LIVC substrate 
and the L W C  m utant substrate as expected with no significant 
structural change between isoleucine and valine.
6.4. Analysis of different cleavage sites within the assay system.
The NS3 serine protease is responsible for cleavage at three other 
sites (NS3/NS4A, NS4A/NS4B, NS4B/NS5A) as well as cleavage at 
NS5A/NS5B. Analysis of processing at these sites would provide a m ore 
complete insight into the substrate specificity for cleavage by NS3. Antisera 
against the NS4 region of the HCV Gla polyprotein was not available in the 
laboratory so development of suitable NS4A/NS4B and NS4B/NS5A 
substrates w ould require the addition of the SV5 epitope tag to the term ini 
of these proteins. The NS4A protein is also small and difficult to detect by 
SDS-PAGE. The NS34A protein undergoes self-processing in vitro. It was 
decided to introduce the three unstudied cleavage sites (NS3/NS4A, 
NS4A/NS4B, NS4B/NS5A) from P6-PT into the tNS5T substrate in place of 
the NS5A/NS5B cleavage site.
Oligonucleotides were designed, as for the previous mutagenesis of 
the NS5A/NS5B cleavage site, encoding the NS3/NS4A, NS4A/NS4B and 
NS4B/NS5A cleavage sites so that these sequences could be introduced into 
the tNS5T substrate. These substrates would allow a comparison betw een 
the different cleavage sites and the relative efficiency of processing by the 
NS3 serine protease. All three cleavage sites were cloned and sequenced to 
create three new substrates: tNS5T 34A, tNS5T 4A4B, tNS5T 4B5A. Due to an 
error during oligonucleotide synthesis a substrate containing an additional 
cleavage site was obtained encoding the NS4B/NS5A cleavage site w ith a 
glutamic acid residue at P6 instead of an aspartic acid (tNS5T 4B5A P6E).
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This additional substrate was included in the experiment and all four 
substrates were cotransfected with NS34A into vTF7.3 infected CV-1 cells. 
After radiolabelling with 35S-methionine, the cell lysates were 
immuneprecipitated with the SV5-P-k antibody before analysis by SDS- 
PAGE. The experiments were repeated to ensure there were no 
discrepancies in the results obtained (Figs. 6.9., 6.10.).
When the tNS5T 34A substrate was coexpressed with NS34A no 
cleavage products were observed. The tNS5T 4A4B substrate was processed 
less efficiently than tNS5T and tNS5T 4B5A was cleaved at a lower efficiency 
than tNS5T 4A4B. The tNS5T 4B5A substrate with its P6 residue substituted 
w ith a glutamic acid was cleaved with a similar efficiency to the tNS5T 4B5A 
substrate.
The relative processing efficiencies obtained are illustrated in Table
6 .6 .
Cleavage Site Relative % Cleavage 
Efficiency
NS5A/NS5B 100
NS3/NS4A 0
NS4A/NS4B 45-50
NS4B/NS5A 20-25
NS4B/NS5A (P6 E) 20-30
Table 6.6. Relative cleavage efficiencies of tNS5T substrates that 
contained the four cleavage sites processed within the F1CV 
poly protein. The altered NS4B/NS5A cleavage site was also 
encoded within the tNS5T substrate. The NS3/NS4A cleavage site 
was not processed in trans when it was substituted for the 
NS5A/NS5B cleavage site within tNS5T. The cleavage sites that 
were processed in trans w ithin the HCV poly protein were all 
cleaved when present within the tNS5T substrate, albeit w ith 
varying efficiencies. The NS4A/NS4B cleavage site was processed 
at an efficiency 50% of that seen for the NS5A/NS5B cleavage site. 
Both the NS4B/NS5A and the NS4B/NS5A (P6 E) were cleaved by 
the NS3 serine protease at approximately 25% of the efficiency 
with which the NS5A/NS5B cleavage site was processed.
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Chapter 7 - Analysis of the NS3 
serine protease
7.1. Influence of the N-terminus of NS3 on protease activity.
The standard protease assay required the cotransfection of a suitable 
substrate construct w ith the NS34A protease construct. To further determ ine 
the protease requirement for this assay alternative protease constructs were 
tested. Dr M.J. McElwee provided a construct encoding the NS234A region 
of the HCV Gla polyprotein (amino acid 737 to 1709) within pTZ18. The 
poly protein encoded begins 73 amino acids upstream of the NS2 N-terminus 
and encompasses the p7 protein, NS2, NS3 and all but the last 2 amino acids 
of NS4A. This construct contained a point mutation within the NS2 region 
that inactivated the NS2/3 protease. When the NS234Mut polyprotein was 
expressed by coupled in vitro transcription/ translation it produced an NS3 
protein w ith the NS2 protein still attached at the N-terminus (Dr M. J. 
McElwee, unpublished data). The presence of the p7 protein had no effect on 
NS2/3 protease activity as a similar construct was cloned, containing a 
single amino acid change in NS2, that produced an active NS2/3 protease. 
The NS234Mut protein expressed in vitro was cleaved to release the NS4A 
protein whereas the NS2/NS3 cleavage event did not take place. The effect 
of having the NS2 protein still attached to the N-terminus of NS3 on the 
fnms-cleavage activity of NS3 was not known.
NS5 and tNS5T were cotransfected with NS34A (as a positive control) 
or NS234Mut into vTF7.3 infected CV-1 cells. After radiolabelling with 35S- 
methionine the cells were lysed, immuneprecipitated with the relevant 
antisera and analysed by SDS-PAGE (Fig. 7.1.). Both substrates were 
processed when coexpressed with NS234Mut showing that additional 
sequence at the NS3 N-terminus did not inactivate the serine protease 
activity of NS3. Coexpression of the substrate with NS234Mut did not result 
in the same level of processing as coexpression with NS34A. As 5jn.g of each 
protease construct was used in the cotransfections and the NS234Mut 
construct has a larger insert, the relative amount of NS3 produced would be 
lower for the NS234Mut construct. However no titration was carried out to 
determine whether NS3 with NS2 still attached was as proteolytically active 
as NS3 alone.
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7.2. A bility of different protease constructs to process in trans.
The full length NS3 and the protease domain (NS3P) cDNAs were 
cloned w ithin pTF7.5 and pTMl respectively. These protease constructs, as 
well as the NS4A cofactor gene cloned within pTMl, could be used in the 
fnms-cleavage assay to determine the protease requirements for cleavage in 
trans. Both NS3 and NS3P were cotransfected with tNS5T in the presence or 
absence of NS4A into vTF7.3 infected CV-1 cells. After radiolabelling w ith 
35S-methionine the immuneprecipitated cell lysates were analysed by SDS- 
PAGE (Fig. 7.2.). Only cotransfection of tNS5T with NS34A resulted in the 
production of cleavage products. Even when the full length NS3 construct 
was cotransfected w ith NS4A and tNS5T, no cleavage products were 
detected.
To determine whether the use of different cell lines could influence 
the requirem ents for processing the cotransfections were carried out using 
tNS5T as a substrate and the different combinations of protease constructs in 
a liver-derived cell line, FIuH7. In addition to using an alternative cell line 
both transfection methods (cationic liposomes and PEI) were used (Fig. 7.3.). 
As for the analysis carried out in CV-1 cells, only cotransfection of the 
substrate w ith NS34A resulted in the fnms-cleavage. The result of the 
cotransfections were the same whether cationic liposomes or PEI were used 
to introduce the DNA into the cells.
An NS3 construct was supplied by Dr B. E. Clarke (GlaxoWellcome) 
which had been shown to process an NS5 substrate in the absence of the 
NS4A cofactor. This construct encoded the full length NS3 gene (derived 
from the type lb  HCV-A genome) in the vector pTM3. This plasmid, like 
pTMl, contained the EMCV IRES element that directs cap-independent 
translation. Both the PICV Gla NS34A construct and the GlaxoWellcome 
NS3 construct were cotransfected with tNS5T into vTF7.3 infected CV-1 cells 
to determine their catalytic activity in trans. After the cells were labelled 
with 35S-methionine the cells were lysed, immuneprecipitated with the SV5- 
P-k antisera and analysed by SDS-PAGE (Fig. 7.4.).
Both proteases processed the tNS5T substrate. A comparison of 
processing efficiencies could have been carried out between the HCV Gla 
NS34A and the FICV-A NS3 but this comparison would not have been 
informative as the HCV Gla NS34A was expressed from pTF7.5, a vector 
containing the T7 promoter only. The HCV-A NS3 construct was expressed 
from pTM3, a vector that contains the EMCV IRES element that boosts 
protein expression. The pTM3 HCV-A NS3 construct would produce 
significantly higher levels of protease than the pTF7.5 HCV Gla NS34A 
construct. The difference in the level of processing between protease 
constructs w ould be influenced by the increased ratio of protease to 
substrate molecules for the HCV-A NS3. For a direct comparison of the two 
proteases the genes would have to be cloned in the same plasmid.
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Fig. 7.2. A nalysis of cleavage of tNS5T w h en  coexpressed  
w ith  different com binations of proteases. CV-1 cells infected 
w ith  vTF7.3 w ere not transfected w ith  DNA (lane 1) or were  
transfected w ith  tNS5T alone (lane 1), tNS5T + NS34A (lane 3), 
tNS5T + NS3 (lane 4), tNS5T + NS3 + NS4A (lane 5), tNS5T + 
NS3P (lane 6), tNS5T + NS3P + NS4A (lane 7). Fifteen hours  
p o s t- t ra n s fe c t io n  the  cells w e re  rad io lab e l led  w ith  35S- 
m eth ion ine  for 2 hours , lysed and im m uneprec ip ita ted  w ith  
the  SV5-P-k antibody before analysis by SDS-PAGE. O ne 
m icrogram  of the tNS5T substrate  was cotransfected w ith  5pg 
each  of the  d i f fe ren t  p ro te a s e a n d  co facto r c o n s tru c ts .  
P rocessing  of the su b s tra te  w as only  observed  w h e n  the 
s u b s t r a te  w as  co tran sfec ted  w ith  NS34A (lane 3). The 
molecular w eight m arkers are located at the right of the gel.
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Fig. 7.4. C om parison  of processing of the tNS5T substrate  
by  H C V  G la NS34A an d  H C V -A  NS3 (su p p l ie d  by  
GlaxoW ellcome). CV-1 cells infected w ith  vTF7.3 w ere left 
un transfected  (lane 1) or w ere  transfected w ith tNS5T alone 
(lane 2), tNS5T + HCV Gla NS34A (lane 3) or tNS5T + HCV- 
A NS3 (lane 4). Fifteen hou rs  post-transfection  the cells 
w e r e  l a b e l l e d  w i t h  35S - m e th io n in e ,  ly s e d  a n d  
im m u n e p r e c ip i ta te d  w i th  the  SV5-P-k antibody before 
analysis by  SDS-PAGE. Both proteases processed the tNS5T 
su b s tra te  (lanes 3 and 4). The ability of the HCV-A NS3 
p ro tease  to process the substrate  in the absence of NS4A is in 
con trast to the results obtained w ith  the HCV Gla NS3. The 
m olecular w eigh t m arkers are located at the right of the gel.
The amino acid sequence of the two NS3 genes were compared. The 
ability of the GlaxoWellcome NS3 alone to process the substrate and not the 
HCV Gla NS3 could be due to a difference in the amino acid sequence 
betw een the two proteases. An amino acid sequence comparison between 
the protease domains of the two NS3 constructs was carried out (Fig. 7.5.).
Many of the amino acid changes were either conservative (ie one 
small, non-polar residue for another) and /o r observed in other HCV 
isolates, i.e. for a number of the amino acid differences observed, the amino 
acid was present in different HCV isolates. In the HCV Gla amino acid 
sequence there was a positively charged lysine residue next to the aspartic 
acid of the catalytic triad. In the HCV-A sequence this residue was a 
glutamine. In other HCV isolates this amino acid was predominantly a 
glutam ine residue although glycine residues and leucine residues were 
found in each of two isolates. The lysine residue could have an inhibitory 
effect on the NS3 serine protease activity that was only overcome in the 
presence of NS4A. For this reason an NS3 construct containing this lysine 
residue substituted with a glutamine residue was constructed.
Dr. M.J. McElwee provided an NS34A construct with this lysine 
residue (at amino acid 1106) substituted with the glutamine residue 
observed for the majority of other HCV isolates . This construct had been 
designated NS34A[K-Q]. As for the wild type NS34A this protease, when 
expressed in rabbit reticulocyte lysates, underwent cleavage in cis to 
produce NS3 from the NS34A complex. The NS3 gene contained a Sal I site 
approximately 130bp upstream of the codon encoding the relevant lysine 
residue and a Sac I site approximately 1270bp downstream. Digestion of the 
NS34A[K-Q] DNA with these restriction enzymes produced a 1400bp insert 
that contained the lysine to glutamine substitution encoded within the 
nucleotide sequence. This insert was ligated into Sac 1 /Sal I digested pTF7.5 
NS3 to create pTF7.5 NS3[K-Q]. The ability of this new protease to process 
the substrate was determined as well as the wild type protease construct and 
the NS34A[K-Q] construct. All these constructs were cotransfected w ith 
tNS5T into vTF7.3 infected CV-1 cells. The cells were radiolabelled with 35S- 
methionine, lysed, immuneprecipitated with the SV5-P-k antibody and 
analysed by SDS-PAGE (Figs. 7.6. and 7.7.).
The single mutation from the lysine residue to the glutamine residue 
(adjacent to the aspartic acid of the catalytic triad) enabled the HCV Gla NS3 
to process tNS5T in the absence of NS4A. NS3[K-Q] processed tNS5T with an 
efficiency approximately 50% of that observed for wild type NS34A.
The HCV-A NS3 contained a glycine residue 11 amino acids 
downstream of the aspartic acid of the catalytic triad (Fig. 7.5.). The arginine 
residue at this position within the HCV Gla NS3 is observed for a number of 
other HCV genotypes. The HCV-A NS3 retained the ability to process 
despite the loss of a highly conserved, positively charged residue at this 
position (twelve isolates have an arginine at this position, three have a 
lysine). The effect of losing this positive charge was investigated to 
determine if there was an effect on the processing activity of the NS3 serine 
protease.
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Fig. 7.5. Sequence comparison between the protease domains of 
the HCV-A and HCV Gla amino acid sequences. The amino acids 
of the catalytic triad are illustrated in red. The amino acids 
differing between the two sequences are shown in green with the 
two "significant" differences (K-Q, R-G) shown in blue.
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Fig. 7.6. A nalysis  of processing  by HCV Gla NS3[K-Q]. 
vTF7.3 infected CV-1 cells were  left untransfected (lane 1) 
o r w ere  transfected w ith  tNS5T (lane 2), tNS5T + NS34A 
(lane 3) or tNS5T + NS3[K-Q] (lane 4). Fifteen hours  pos t­
transfec tion  the  cells w ere  labelled w ith  35S-methionine, 
lysed  and  im m uneprec ip ita ted  w ith  the SV5-P-k antibody 
before analysis by SDS-PAGE. Cotransfection of the tNS5T 
su b stra te  w ith  the NS34A HCV Gla construct resu lted  in 
c leavage of the substra te  (lane 3). W hen NS3 alone w as 
cotransfected  w ith  the tNS5T substra te  no cleavage took 
place. The substitu tion  of a lysine residue by a g lu tam ine  
res idue  adjacent to the aspartic acid of the catalytic triad 
enab led  NS3 alone to process the tNS5T substrate  (lane 4). 
The m olecular w eight m arkers are located at the right of the
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Fig. 7.7. C o m p a r iso n  of the  p ro cess in g  efficiencies of 
p ro teases  con ta in ing  single am ino  acid changes. vTF7.3 
infected CV-1 cells w ere  left untransfected (lane 1) or were  
transfected w ith  tNS5T alone (lane 2), tNS5T + NS34A (lane 
3), tNS5T + NS34A[K-Q] (lane 4), tNS5T + NS3 (lane 5), 
tNS5T + NS3[K-Q] (lane 6 ). Fifteen hours  post-transfection 
the cells w ere  labelled  w ith  35S m eth ion ine , lysed  an d  
im m u n e p re c ip i ta te d  w ith  the  SV5-P-k antibody before  
analysis  by  SDS-PAGE. The only  p ro tease  tha t  d id  no t  
process the tNS5T substrate  w as the wild type NS3 (lane 5). 
A lthough the K-Q substitu tion enabled NS3 to process alone 
(lane 6 ) the w ild  type NS34A (lane 3) was m ore efficient at 
p rocessing  the tNS5T substra te  than  NS34A[K-Q] (lane 4). 
The molecular w eight m arkers are located at the right of the
Four protease constructs were constructed with the arginine to 
glycine m utation introduced into both NS3 and both NS34A constructs. Two 
27 nucleotide complementary oligonucleotides were designed that 
encompassed the region encoding the target amino acid (arginine). Both 
oligonucleotides contained the relevant nucleotide changes from the wild 
type sequence to give a glycine codon 11 amino acids downstream of the 
aspartic acid of the catalytic triad. Two additional oligonucleotide primers 
were supplied by Dr M. J. McElwee. One oligonucleotide (NS3N) 
corresponded to the 5' terminus of the NS3 gene and contained a Bam HI site 
followed by an initiation codon and 21 nucleotides corresponding to the 5' 
terminus of the NS3 gene. The second oligonucleotide (3'Hel) was in the 
complementary orientation to the first and corresponded to the 3' term inus 
of the NS4A gene. This oligonucleotide also contained a Bam HI site and a 
term ination codon preceding 18 nucleotides of the NS4A gene. All four 
primers are illustrated in Fig. 7.8.
Two sets of PCRs using Pfu polymerase were carried out using both 
the NS34A and NS34A[K-Q] plasmids as templates. The first set of PCRs 
were carried out using the NS3N primer and the 3'-5' oligonucleotide 
encoding the R-G substitution. The second set of PCRs used the 3'Hel 
primer and the 5'-3' m utant oligonucleotide (Fig. 7.9.). For both templates a 
1:20 and 1:200 dilution of the plasmid stock DNA was used. The results of 
the first round PCR reactions are illustrated in Fig. 7.10.
Each PCR fragment was purified through a silica gel matrix and 
eluted into 20pl dH20. A second round of PCRs were carried out using the 
NS3N and 3'Hel primers to produce a full length NS34A gene. The purified, 
first round PCR products were diluted in dH20 1:50 and one microlitre of 
this was used as a template. To produce the NS34A[R-G] PCR product the 
PCR fragments amplified from the original wild type NS34A construct were 
combined and used as templates to produce the final m utant NS34A[R-G] 
gene (Fig. 7.9.). To produce the NS34A[K-Q, R-G] insert the first round PCR 
reactions amplified from the NS34[K-Q] template were combined and used 
as templates.
The second round PCR products were digested with Bam HI before 
ligation into Bam HI cut pTF7.5 to produce pTF7.5 NS34A[R-G] and pTF7.5 
NS34A[K-Q, R-G]. After the nucleotide sequence of the two protease 
| constructs was confirmed, the region around the aspartic acid of the catalytic
i triad was excised from both constructs with Sal I and Sac I (as for the creation
of pTF7.5 NS3[K-Q]). These inserts were ligated into the NS3 constructs 
(digested with Bam HI) to produce pTF7.5 NS3[R-G] and pTF7.5 NS3[K-Q, R- 
i G].
! These new proteases were analysed for their processing ability as
were the wild type NS34A construct and both K-Q protease constructs in the 
standard trans-cleavage assay (Figs 7.11. and 7.12.). Both the wild type 
NS34A and NS34A[R-G] protease complexes cleaved tNS5T with the highest 
efficiency, with little difference in their processing efficiencies. Both the 
NS34A complexes containing the lysine to glutamine substitution were far 
less efficient in comparison to the other NS34A complexes. With the 
exception of the wild type HCV Gla NS3, which did not cleave the substrate,
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Fig. 7.9. Amino acid substitution by PCR. The central 
oligonucleotide primers ) encode the substituting amino acid 
codon for the NS34A gene. After the first round of PCR the 
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all the altered NS3 proteases processed at a similar efficiency 
(approximately 50% the efficiency of the most efficient NS34A complex).
The efficiency of processing of these proteases constructs is 
summarised in Table 7.1.
Protease Construct Relative % Cleavage 
Efficiency
Wild Type NS34A 100
NS34A[K-Q] 39-44
NS34A[R-G] 110
NS34A[K-Q, R-G] 28-44
Wild Type NS3 0
NS3[K-Q] 44-50
NS3[R-G] 33-39
NS3fK-Q, R-G] 28-44
Table 7.1. Relative % cleavage efficiency of HCV Gla 
proteases containing various point mutations. NS34A[R-G] was 
the most efficient protease at processing tNS5T. The m ost 
efficient NS3 contained the K-Q substitution, although by only a 
very small margin.
The R-G substitution within NS3 exerted a positive influence on 
processing that was more significant when the NS3 protease was expressed 
as NS34A. The K-Q substitution appeared to stimulate processing when NS3 
was expressed alone but when expressed as NS34A there was an inhibitory 
effect. When both substitutions were present in the same protease 
NS34A[K-Q, R-G] processed at a similar level to the NS34A[K-Q] construct. 
The effect of the R-G mutation does not seem to have an effect when present 
with the K-Q mutation. The NS3[K-Q, R-G] processing efficiency was 
essentially the same as the other two NS3 proteins. These observations 
were unexpected and further investigation was carried out to determine if 
any other factors were influencing these results.
It was speculated that contamination within the DNA preparations 
could be interfering with the assay and therefore account for these observed 
differences in processing. Four protease constructs (NS34A[R-G], NS3[R-G], 
NS34A[K-Q, R-G], NS3[K-Q, R-G]) were digested with Bam HI to produce the 
entire insert. The digested vectors were analysed through a 1% TBE gel to 
determine a) the purity of the DNA preparations and b) that the correct 
digest patterns were obtained. The digests revealed that although all four 
DNA preparations were free of contamination the NS34A[K-Q, R-G] 
preparation produced an insert that was marginally smaller than the 
NS34a[R-G] and larger than both NS3 constructs (Fig. 7.13.). The NS34A[K- 
Q, R-G] construct was produced by PCR from the NS34A[K-Q] construct.
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Fig. 7.13. Bam HI digestion of four protease cDNAs encoded 
w ith in  pTF7.5. The X BstE II m arkers (lane 1) illustrate the 
sizes of the d igested DNA fragments. The digests  carried 
ou t w ere  loaded: NS34A[R-G] (lane 2 ), NS3[R-G] (lane 3), 
NS34A[K-Q, R-G] (lane 4) and  NS3[K-Q, R-G] (lane 5). 
D igestion w ith  Bam HI excises the entireHCV insert. Both 
NS3 inserts are the sam e size (lanes 3 and  5). The NS34A 
in se r t  d e r iv e d  from  the  o r ig in a l  w ild  ty p e  c o n s tru c t  
(NS34A[R-G]) is larger than  the insert de r ived  from  the 
NS34A[K-Q] construct, (lanes 2 and 4).
In case the DNA digests were misleading all the proteases were 
expressed by coupled in vitro transcription/translation in rabbit reticulocyte 
lysates and the reactions analysed through a 12% SDS polyacrylamide gel 
(Fig. 7.14.). The TnT analysis shows that although all the NS34A complexes 
processed to give the NS3 protein the NS34A[K-Q] complex produced a 
smaller NS34A band although the NS3[K-Q] band appeared to be the same 
size as the wild type NS3. The NS34A[K-Q. R-G] complex was not observed 
and looked to be fully processed to NS3.
Although these constructs expressed an active NS3 serine pro tease the 
presence of a small deletion within the cDNA may effect the catalytic 
activity of the protease produced. Sequencing analysis was not carried out 
but as the NS3 proteins appeared to be the same size the deletion was 
presum ed to be within the NS4A region. The NS34A[K-Q] and NS34A[K-Q, 
R-G] construct were digested with Sal I and Sph I. The Sal I site was 50bp 
upstream  of the catalytic histidine codon and the Sph I site was 195bp 
downstream  of the catalytic serine codon. Digestion with these enzymes 
produced a 500bp insert that contained the region encoding the catalytic 
triad from these cDNAs. These inserts were ligated into Sal 1 /Sph I digested 
pTF7.5 NS34A constructs to give full length NS34A cDNAs that contained 
the desired amino acid substitutions. After cloning the inserts, the 
constructs were digested with Bam HI to check the size of the new insert 
(Fig. 7.15.). All the new clones of NS34A[K-Q] and NS34A[K-Q, R-G] 
produced inserts that were the same size as the wild type NS34A. The new 
constructs were tested for expression by coupled in vitro 
transcription/ translation in rabbit reticulocyte lysates and analysed by SDS- 
PAGE (Fig. 7.16.). The NS34A constructs produced NS34A bands the same 
size as the wild type NS34A and were subsequently tested for their trans- 
cleavage ability in comparison with the previous clones (Figs. 7.17. and 
7.18.). All the correctly sized NS34A complexes processed the tNS5T 
substrate with high efficiencies. The NS34A constructs containing the lysine 
to glutamine substitution produced protease complexes that were m ore 
efficient than the other two NS34A complexes (wt NS34A and NS34A[R-G]).
The efficiencies with which the NS34A complexes processed tNS5T 
are summarised in Table 7.2.
NS34A Constructs Relative % Cleavage Efficiency
Wild Type NS34A 100
NS34A[K-Q] 122 -125
NS34A[R-G] 100
NS34A[K-Q. R-G] 120 -125
Table 7.2. Efficiency of processing by the full length NS34A 
complexes. Both the wild type NS34A and the NS34A[R-G] 
process at similar levels. The inclusion of the K-Q substitution 
gives optimal processing both with and without the R-G 
substitution.
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Fig. 7.15. BamH I restriction enzym e digestion of recloned 
m u ta n t  NS34A constructs. Digestion w ith  Bam HI excises 
the entire  insert. Four NS34A[K-Q] constructs (lanes 1-4), 
four NS34A[K-Q, R-G] constructs  (lanes6-9) and  the w ild  
type NS34A construct (lane 10) w ere  digested w ith  BamH I 
before analysis  th rough  a 1% TBE agarose gel. All e ight 
m u ta n t  NS34A p lasm id  p rep a ra t io n s  contained  correctly 
sized inserts (in com parison to the wild type NS34A control 
digest).
NS34A
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Fig. 7.16. E x p ress io n  of rec lo n ed  m u ta n t  NS34A  
constructs by in vitro transcrip tion /transla tion . The wild 
type  NS34A (lane 1), the NS34A[K-Q] (lane 2) and  the 
NS34A[K-Q, R-G] w ere all expressed w ith in  a 25 pi T nT  
reaction and  then analysed by SDS-PAGE. This analysis 
corroborated the observation from the restriction enzym e 
digestion analysis of the p lasm id  DNAs (Fig. 7.14.). The 
recloned NS34A[K-Q] and  NS34A[K-Q, R-G] constructs 
p ro d u c e  NS34A com plexes  of the correct size w h e n  
expressed in vitro. These NS34A complexes self-processed 
to p ro d u ce  NS3 p ro te in  b an d s  of the correct size. The 
m olecular w eight m arkers  are located at the right of the 
gel.
^tNS5T
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Fig. 7.17. Trans-cleavage analysis with recloned m u tan t 
NS34A constructs. vTF7.3 infected CV-1 cells w ere  left 
un transfected  (lane 1) or transfected w ith  tNS5T alone 
(lane 2) or tNS5T + NS34A (lane 3), tNS5T + NS34A[K- 
Q] (lane 4), tNS5T + NS34A[K-Q, R-G]l (lane 5), tNS5T 
+ NS34A[K-Q, R-G]2 (lane 6 ). Fifteen h o u rs  p o s t ­
transfection the cells w ere  labelled w ith  35S-methionine, 
lysed and im m uneprecipita ted  w ith  the SV5-P-k antibody 
before analysis by SDS-PAGE. All three, correctly-sized 
m u ta n t  NS34A complexes w ere cotransfected w ith  the 
tN S5T s u b s t r a te  a n d  th e ir  c leav ag e  e ff ic ienc ies  
com pared  to the wild type NS34A construct (lanes 3 to 
6 ). The in tro d u c tio n  of the am ino  acid subs ti tu tion  
ly s in e  to g lu ta m in e  in c re a se d  the  e ff ic iency  of 
processing  w ith  respect to the w ild type (lane 4). The 
difference in cleavage efficiency w h en  the arginine to 
glycine m u ta t io n  w as in troduced  to the NS34A[K-Q] 
construct appeared  to be negligible (lanes 5 and 6 ). The 
molecular w eight m arkers are located at the right of the
3
C L
2  to j d3 rt- y
~ z  S'C D  3  
C O  i - 3
3  7 n JD 
A  T 3r-> I n
^ O S ’ 
“  33- to to TO O L<
* !  5 '
5 '  re* 8
^ ^  3
£  « 33
u  <Zi 05 
CfQ_ p T  2 .
c T
3  p j
■ £ L  3
^  5 3  
5 2 . n T
c/5  t o
^  o '<  3
C D
D  ^
c d  ^
3  T l  
3 - cro"
to
o n
to
p i  C/5
3  ^05 W
3  3 :  
O -  ^oo 0
55- $  crc
3 - ’ 3 0  3 '
3  8  &
§ < 2 
TO CD
3 - ^ r  w
05 3  ^CL • >
&> C O  >7?
52 3  ' 
CTO 3“ O
I s  3
2  S 33 to 33
C D
C o
4 l
>
n
O
3
” 2rtf
XTO
c/>
33
M
O
n
2
C D  
C n
H
+ TO y
£ T  C D
^ sT“ £ >
z  *
3 -  3 3
TO CD 
Cl 5
^ *
a
1 3  CO
TO •
2- nTO l0J
3
s r * o
H  &
-  s -
L - 1 O— 3
^ 33TO !-t3 ° t o  n
ON TO
^  G
OJcn
C D  C D  
> c n
3 Hs. +
£  2
o
3  w  
C ‘ 4 ^  
TO >
o  *  1-1 3 
K J  O
. Crc
TOn  
TO 3
C L  n  
<h CD
<  3  
3 '  d> 
C T  ro
2  O'
C D  2 .
Cn 3
^  %_  ro
ro
§  2 .  TO i-l
Cfl | N J
f U ,-_-
2 g
C D  i-i
C n c/5
H  G
(75 X3 « 3- TO
M
C D
TO
Cn &* 
H  2  + n .
33 053TO TO
%  G
C/5 '
CL
05
3
CL
3 “TO
3
TO
r j  p> 3  
c  3  3 -  
TO w05
TO
C/5 Q
on cr
C/5TO053  .
crq CL <
3  oo 3
3 3305 >-!
*1  O
? 3  nTO TO 05
l - l  C/5 C/5
10 58 3
C L  C/5
cm O
1-1 3 to 3 TO c  
3  o
^ 2
£  2
> * 3
7n 3
A  ^  
j O  a .
n  o
2
C D
Cn
H
+
2
C D
CO
4 l
>
*
• O
• * 3
■ < h
2
C D
CO4-
>
C o
? 3 ?
05
71
CtT
X 31
TO
s
a
t o ’05
05
3
TO
ON
3 -
TO
C D
<
cn  to
i TO
O 33
TO —
Cl w i- p
i -t  to-o — fD3 TO 7< 2 jj' TO 3.TO ’Toq
p .  2  5 '
O Q  3 -
3  05
3
a
3
3 -o
3
TO 
CL
^  31 
°  TO 
O -  rn
+ w"
2  ^
C D  TO 
W  34  ^ TO
A  / o '
o
o o
3  O l
TO
3  
^ O Q  05 E3
3  “TO g 
C
O N
2
CD
O J
4 *
>
c/5 0 0
<
H
31
' d
O J
05 ^
3  3TO TO
4 L  3^  n 
2 ^
c n  n>—] TO
2
cn
o n
0 3
2
c n
C J l>
H _______________________________i r d __________________ H
A
• o >
f ,
4 i<s\
A
A
' s ? ~ ,
3 N
A A3 '-
A  %
%  \  
1  A
'/ ) ,  'V c  
V> ^
2
GO 4 ^
On
Ox
O N
X O %
%
'Q*
‘Qi
P
2
Both the wild type NS34A construct and the NS34A[K-Q, R-G] 
construct were cotransfected into vTF7.3 infected CV-1 cells w ith the P6, PI 
and P I ' tNS5T substrate mutants described in section 3.3.2. to see if there was 
any difference in their ability to process the m utant cleavage sites. After 
labelling w ith 35S-methionine the cell lysates were imm uneprecipitated 
w ith the SV5-P-k antibody and analysed by SDS-PAGE (Figs. 7.19. and 7.20.). 
Despite the NS34A[K-Q, R-G] processing more of the substrate than the wild 
type NS34A there was no difference in the relative amounts of processing 
for the m utant cleavage sites. The cleavage efficiencies with which the 
proteases cleaved the m utant cleavage sites are illustrated below.
Substrate Relative % Cleavage Efficiency - 
Wild Type
Relative % Cleavage 
Efficiency - 
[K-Q, R-G]
Wild Type 100 100
P6 Glu - Gin 30 35
P6 Glu - Lys 15-25 20
PI Cys - Ser <10 <10
PI Cys - Arg 0 0
PI Cys - Gly 0 0
P I' Ser - Thr 30-40 33
P I' Ser - Ala 55-60 55
P I' Ser - Pro 0 0
Table 7.3. Comparison of processing between wild type NS34A 
and NS34A[K-Q. R-G]. Even though there was a difference in the 
am ount of substrate processed by two NS34As the relative 
processing of the m utant cleavage sites was the same.
7.3. Investigation into processing of the HCV Gla substrate by an NS3 
serine protease from a different genotype.
There are six major genotypes of HCV and the polyprotein produced 
by each genotype is processed by the NS3 serine protease. Each genotype 
contains amino acid differences compared to the polyprotein of a different 
genotype. The ability of an NS3 serine protease from one genotype to 
process a substrate from another has not been significantly investigated. It 
has been shown that a type la  protease can process a type lb  substrate and 
vice versa (Lin et al., 1994b). A plasmid encoding the protease dom ain of 
one genotype was cotransfected with a polyprotein substrate from the C- 
terminal region of NS3 to the end of NS5B. The NS3 protease added in trans 
was able to process all four cleavage sites of the polyprotein of a different
86
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subtype. This result has been corroborated by the work carried out in 7.2. as 
the HCV-A is a type lb  isolate and its NS3 protease was able to process the 
type la  HCV Gla NS5A/NS5B substrate.
A type 4 HCV isolate had been sequenced within the laboratory 
(Chamberlain et al., 1997) and so genotype 4 HCV clones were available in 
the laboratory to attempt to produce a type 4 HCV protease construct. 
Three independent plasmid clones (clones 9, 14, 15) corresponding to the 5' 
half of the type 4 open reading frame (encompassing the NS34A region) 
were supplied by Dr. R. Chamberlain. PCR primers were designed for the 
amplification of the type 4 HCV NS34A gene by PCR and ligation of the 
PCR product into pTF7.5. These primers were similar to those used for the 
production of the HCV Gla NS34A construct but were based on the type 4 
sequence. The 5' primer contains a Bam HI site followed by a start codon 
and nucleotide sequence corresponding to the 5' end of the NS3 gene. The 3' 
primer contains a Bam HI site, a termination codon and nucleotide sequence 
complementary to the 3' end of the NS4A gene.
PCRs using the proof-reading Pfu DNA polymerase were carried out 
using the three templates (clones 9, 14, 15) and these reactions produced 
inserts of the expected size (Fig. 7.21.). The PCR products were digested 
with Bam HI and ligated into Bam HI cut pTF7.5 the orientation of the insert 
was checked by digestion with Nco l/X ba  I. There is an Xba I site 668 
nucleotides upstream  of the multiple cloning site in pTF7.5 and an Nco I site 
430 nucleotides downstream of the initiation codon of the NS3 gene. 
Digestion of the type 4 NS34A gene with Nco I/Xba  I would give an insert of 
approximately llOObp if the insert was ligated in the correct orientation. A 
num ber of type 4 NS34A clones were obtained but analysis by coupled in 
vitro transcription/translation (TnT) showed that none of the constructs 
produced an NS34A complex that processed in cis to give the cleaved NS3 
protein (Fig. 7.22.). The nucleotide sequence of a few of the clones was 
determined using an automated sequencer to determine whether any 
mutations had been introduced into the catalytic triad. Such a mutation may 
have explained the lack of processing observed. The sequence obtained 
showed that the nucleotide sequence encoding the amino acids of the 
catalytic triad was correct.
The inability of the type 4 NS34A constructs to self-process may be 
due to a mutation in the NS3/NS4A cleavage site. However as it has been 
demonstrated that the NS3 protease is still active even when the NS4A 
protein is uncleaved from the C-terminus of the NS3 protein, these 
constructs were tested for fnms-cleavage activity in case the construct was 
still active despite the presence of the uncleaved NS4A. No processing was 
observed for any of these type 4 NS34A constructs (Fig. 7.23.). There was 
insufficient time to completely sequence all the clones to determine the 
reason for their inability to process.
An active type 4 NS34A construct was subsequently cloned by Dr R. 
Chamberlain and this construct, when expressed in vitro, could self-process. 
This construct has been shown to process the tNS5T substrate using the 
trans-cleavage assay I developed.
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Fig. 7.22. 
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Fig. 7.23. Analysis of trans-cleavage activity of the type 4 
NS34A clones . vTF7.3 in fec ted  CV-1 cells w e re  
transfected w ith  tNS5T + type 1 NS34A (lane 1) or tNS5T 
+ type 4 NS34A (lanes 2-5). The type 4 NS34A constructs 
w e re  d e r iv e d  from  th ree  sep a ra te  long  ran g e  PCR 
pro d u c ts  (9, 14, 15). Fifteen hours  post-transfection the 
cells w e re  labelled  w ith  35S-m eth ion ine , lysed  and  
im m u n ep re c ip i ta ted  w ith  the  SV5-P-k antibody before 
analysis by SDS-PAGE. N one of the type 4 NS34A clones 
processed the tNS5T substrate  w hen  co-transfected into 
m am m a lia n  cells. The m o lecu lar  w e ig h t m ark e rs  are 
located at the right of the gel.
Summary of results
An assay for frans-cleavage of HCV substrates by the NS3 serine 
protease was developed. This assay involved the co-transfection of the 
NS3 serine protease and relevant substrate cDNAs into m am m alian 
cells infected with vTF7.3. After labelling with 35S-methionine, cell 
lysis and immuneprecipitation the samples were analysed by SDS- 
PAGE to determine the success of the trans-cleavage.
Characterisation of the substrate requirements for processing 
was carried out. The effects of mutagenesis of the P6, PI and P I7 
residues within the NS5A/NS5B cleavage site were examined as was 
the ability of the NS3 protease to process potential cleavage sites. No 
(potential) cleavage sites, apart from those reported, were processed by 
NS3. A specific potential site (LITS) was examined in detail to 
determine if any specific residue was responsible for the absence of 
processing. No single residue was responsible for this effect.
An investigation of the protease requirements for processing at 
the NS5A/NS5B cleavage site was carried out. The HCV Gla NS3 
serine protease was only able to process the NS5A/NS5B cleavage site 
in the presence of the NS4A protein, in contrast to reported data. A 
trans-c leavage assay was carried out using an NS3 protease from a 
different HCV isolate and this NS3 alone was able to cleave the 
NS5A/NS5B cleavage site within tNS5T. An amino acid sequence 
comparison was carried out between the HCV Gla NS3 and the HCV-A 
NS3 and any differences examined. A number of potentially im portant 
amino acid changes were discovered and the effect of these on serine 
protease activity investigated. Replacement of two amino acids w ith 
the HCV-A NS3 amino acids enabled the HCV Gla NS3 protease to 
process the NS5A/NS5B cleavage site in the absence of NS4A.
The effect of the NS2 protein uncleaved from the N-terminus of 
NS3 on the serine protease activity was investigated. The presence of 
this uncleaved protein did not inhibit NS3 protease activity.
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Chapter 8 - Discussion
8.1. Development of a tmns-cleavage assay for the NS3 serine protease.
The initial object of this study was to develop a convenient assay for 
the analysis of processing by the NS3 serine protease. With such an assay 
for the trans-cleavage by the NS3 serine protease the substrate and protease 
requirements for processing could be examined. A trans-cleavage assay 
using in vitro transcription/ translation in rabbit reticulocyte lysates proved 
to be of no use. Although the protease and substrate proteins were 
expressed well in vitro no evidence for processing was observed. The co­
expression of substrate and protease within mammalian cells resulted in 
cleavage of both a full length and a truncated (at both termini) NS5 
substrate. The truncation of the NS5B region at the C-terminus produced a 
smaller NS5B protein that was stable when expressed in cells. This 
truncated NS5B protein was easily identifiable using a monoclonal antibody 
against an epitope tag introduced at its C-terminus.
In 5.1. a frarcs-cleavage assay was established and optimised w ith 
cotransfection of l |ig  substrate cDNA and 5pg of protease cDNA into T7 
polymerase expressing mammalian cells. The cDNAs were cotransfected 
using either cationic liposomes or polyethylene imine (PEI). Fifteen hours 
post transfection the cells were labelled with 35S-methionine, lysed and 
immuneprecipitated with the relevant antisera before analysis by SDS- 
PAGE.
Having established an assay for cleavage in trans by the NS3 serine 
protease, analysis of the substrate requirement for processing was 
examined.
It was not known how authentic the tNS5T substrate was in 
comparison to the full length NS5. The tNS5T substrate may have folded in 
a different manner due to the truncations at both termini giving a different 
secondary structure. The "Plotstructure" program was used to plot the 
measures of protein secondary structure of the NS5 substrates. The 
secondary structure was represented by a two-dimensional "squiggly" 
diagram  that demonstrated the Chou-Fasman prediction for the protein. 
The secondary structural features were initially calculated using the 
"Peptidestructure" program, from which the two-dimensional 
representation was plotted. The secondary structures of the full length NS5 
and truncated NS5 substrate were calculated and their representations 
compared (Fig. 8.1.). The peptide sequence corresponding to the tNS5T 
region is predicted to have the same secondary structure when expressed as 
part of the full length NS5 protein as it does when expressed alone.
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8.2. Mutagenesis of the cleavage site motif of the NS5A/NS5B cleavage site.
Since the beginning of my project there have been a num ber of 
mutagenesis studies carried out on the substrate specificity of NS3 m ediated 
cleavage. These analyses were carried out on several different cleavage sites 
in an attem pt to fully determine the importance of any conserved amino 
acids. Within the HCV polyprotein there are four sites processed by the 
NS3 serine protease (NS3/NS4A, NS4A/NS4B, NS4B/NS5A, NS5A/NS5B). 
All these sites are processed in trans by NS3 except the NS3/NS4A cleavage 
site which is processed in cis. By comparing the amino acid sequences of 
these cleavage sites the consensus amino acid motif for an NS3 m ediated 
cleavage site was determined. This motif consisted of an acidic residue at P6 
(aspartic acid or glutamic acid), a cysteine or threonine at PI and a serine 
residue at PP. The NS3-mediated cleavage occurred between PI and PI'. As 
only three amino acid positions exhibited any conservation it was these 
three positions that were extensively studied.
Leinbach et al. (1994) carried out a mutational analysis of the HCV BK 
(type lb) NS3/NS4A site in vitro and showed that when the amino acids at P6 
and PI' were mutated there was little or no effect on the efficiency with 
which this site was processed. Substitutions to polar or aliphatic side chain 
containing amino acids were permitted at PI, with the cleavage site still 
processed. There was no tolerance for basic or aromatic residues at PI and 
the degree of processing was drastically reduced. NS3/NS4A is processed in 
cis and the restrictions for processing may be different for processing in 
trans. The NS3 protein folds around the substrate in a conformation suitable 
for processing. As the cleavage site is part of the protein the amino acids 
defining may not be as important in protease recognition of the cleavage 
site.
Substitution at the HCV-H (type la) NS4A/NS4B site of the PI L-Cys 
to D-Cys was not tolerated indicating a stereospecific SI binding pocket for 
L-Cys (Zhang etal., 1997). At the HCV BK NS4A/NS4B site, substitutions at 
PI abolished processing although threonine was tolerated (Urbani et al., 
1997). The replacement of the sulphydryl group of the cysteine residue to an 
amino or a hydroxyl group abolished cleavage at this site. The PI residue 
was determined to make a relatively minor contribution to ground state 
binding (Urbani et al., 1997). The effect of mutation at the P6 residue at the 
NS4A/NS4B cleavage site was dependent on the amino acid substitution. 
Neutralisation of the negative charge decreased the efficiency of processing 
by a factor of five, whereas introduction of a positive charge resulted in a 
more pronounced decrease. This decrease was attributable to an 
impairm ent in ground state binding of protease to the substrate (Urbani et 
al., 1997). Mutations at the PI' residue had little effect although the 
introduction of a proline residue at this site dramatically reduced cleavage 
(Kolykhalov et a l, 1994). Alanine scanning mutagenesis of the cleavage site 
showed mutation of P3 had a significant effect on the efficiency w ith which
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this site was cleaved and that P4' favoured hydrophobic residues (Urbani et 
al., 1997).
Kolykhalov et al. (1994) demonstrated that, for the HCV H strain, the 
NS3/NS4A site was the least sensitive to mutation, followed by the 
NS4A/NS4B site, the NS4B/NS5A and most sensitive to mutation, the 
NS5A/NS5B site. In this study the effect of PI mutations at different sites 
showed that selected substitutions partially inhibited processing at the 
NS3/NS4A site. The same mutations at the NS4A/NS4B site showed 
significantly greater inhibition of processing. For the NS4B/NS5A site only 
one of these mutations permitted cleavage whereas for the NS5A/NS5B site 
all the substitutions blocked cleavage.
8.2.1. Mutagenesis of the P6 residue.
In all the cleavage site analyses there has been little study of the 
NS5A/NS5B cleavage site. The P6, PI and PI' amino acid substitutions 
illustrated in 5.2. demonstrated that mutation of the P6 residue within the 
NS5A/NS5B cleavage site had a significant negative effect on the efficiency 
of processing at this site. The amino acid substitutions at P6 are illustrated 
in Fig. 8.2. The neutralisation of the negative charge by substitution of the 
wild type glutamic acid with glutamine resulted in a fall in the efficiency by 
which this site was processed by approximately 70%. The glutamine side 
chain is the same relative size and organisation as the glutamic acid side 
chain with the negatively charged oxygen replaced by the NH2 group. The 
replacement of the negatively charged glutamic acid with the positively 
charged lysine residue had an even more deleterious effect on cleavage at 
this site, with a fall in efficiency by 80-85%. The lysine side chain is longer 
and thinner than the wild type glutamic acid as well as containing the 
positively charged NH3 group.
At the NS3/NS4A cleavage site, mutation of the P6 aspartic acid to 
either asparagine, lysine or serine had no effect on the efficiency of 
processing, suggesting that P6 was not important in cleavage site specificity 
(Leinbach et al., 1994). This site is processed in cis and so the P6 residue may 
be im portant in specificity of cleavage when processing takes place in trans. 
At the NS4A/NS4B cleavage site, Kolykhalov et al. (1994) demonstrated that 
m utation of the P6 residue to threonine, alanine, asparagine, glutamic acid 
or proline had no effect on the efficiency with which the cleavage site was 
processed. These observations also imply that an acidic residue at P6 is not 
important. In contrast to this it was shown that, at the same site w ithin a 
different HCV isolate, the neutralisation of the negative charge at P6 (by the 
substitution of the glutamic acid with asparagine) led to a decrease in the 
efficiency of processing by a factor of 5 (Urbani et al., 1997). The 
introduction of a positively charged lysine residue for the glutamic acid led 
to an even more pronounced decrease in cleavage efficiency (by a factor of 
12). These effects were observed in the absence of the NS4A cofactor (Urbani 
et al., 1997). In the presence of NS4A the effects of these mutations were less
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pronounced (a decrease in the efficiency of cleavage by a factor of 2 and 5 
respectively). These results illustrate similar effects as those observed in 5.2.
The importance of the P6 residue on the specificity of cleavage by the 
NS3 serine protease appears to depend on the nature by which the cleavage 
site is processed. The P6 residue is essentially unimportant for processing in 
cis at the NS3/NS4A site. Although an acidic P6 residue is not essential in 
the cleavage sites processed in trans its presence is required for optim al 
cleavage. The P6 residue may only be important for the cleavage sites 
processed in trans because of the nature in which these sites are processed. A 
possible way to determine if cleavage in cis lessens the importance of the P6 
residue could be to replace the NS3/NS4A cleavage site with a trans- 
cieavage site (NS4A/NS4B, NS4B/NS5A, NS5A/NS5B). This would produce 
an NS34A substrate containing a cleavage site normally processed in trans. 
If this altered NS34A substrate was processed then mutation of the P6 
residue would determine whether it was the residue within the cleavage site 
that alone had the effect or if the nature by which the cleavage site was 
processed was also important.
Determination of the crystal structure of the NS3 showed that the P6 
residue of the cleavage site interacted with Arg-161 and Lys-165 of the NS3 
protein. These two positively charged side chains would interact w ith the 
negatively charged P6 acidic side chain. This substrate/protease interaction 
explains the results obtained for cleavage in trans with loss of the negative 
charge at P6. The introduction of a positive charge especially would be 
expected to have a deleterious effect on processing as a positive charge at P6 
would repel the side chains extending from the protease that norm ally 
stabilise the substrate/pro tease binding. The negligible effect observed for 
mutagenesis of P6 within the NS3/NS4A cleavage site (Leinbach et al., 1994) 
may be because the protease and cleavage site are part of the same protein. 
Despite the antagonistic nature of the mutated P6, the protease still folds 
around the cleavage site to form the uncleaved NS34A precursor complex 
before processing takes place.
8.2.2. Mutagenesis of the PI residue.
Mutations of the PI residue in 5.2. all essentially abolished cleavage 
at the NS5A/NS5B site with only replacement of the wild type cysteine w ith 
serine perm itting a small level of processing (approximately 10% of w ild 
type efficiency). The amino acids introduced at PI are illustrated in Fig. 8.3.
For the NS3/NS4A cleavage site, substitution of the wild type 
threonine residue with cysteine, serine, glycine, alanine or leucine still 
resulted in cleavage of the substrate (Leinbach et al., 1994). When arginine 
or tyrosine were introduced in this experiment there was abolition of 
cleavage at this site. These results imply that amino acids with polar or 
aliphatic side chains of different lengths are tolerated at PI whereas basic or 
aromatic side chains are not. These results may only be relevant to cleavage 
in cis.
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Kolykhalov et al. (1994) demonstrated that, at the NS4A/NS4B 
cleavage site, mutation of the PI residue (cysteine) to threonine or leucine 
was tolerated whereas substitution with arginine rendered the site alm ost 
completely resistant to processing. Of the sites cleaved, the site containing 
an aspartic acid at PI was cleaved with the lowest efficiency while still 
perm itting some cleavage to occur. A gradual decrease in the inhibitory 
effect of PI residue substitution was observed with asparagine followed by 
glycine and finally serine. At the NS3/NS4A cleavage site only m utation of 
the PI threonine to arginine resulted in significant inhibition of processing 
w ith the other mutations introduced (glycine, asparagine and aspartic acid) 
having little effect. These observations are in agreement with the results 
obtained by Leinbach et al. (1994).
At the NS4B/NS5A cleavage site mutation of the PI cysteine residue 
to glycine, arginine or aspartic acid resulted in abolition of cleavage 
whereas replacement with asparagine dramatically reduced cleavage. At 
the NS5A/NS5B cleavage site none of the mutations introduced at PI 
(glycine, arginine, asparagine and aspartic acid) permitted cleavage of the 
substrate (Kolykhalov et al.r 1994). A number of PI mutations were 
introduced into an NS4A/NS4B cleavage site (threonine, alanine, proline, 
phenylalanine, serine) with only the presence of a threonine residue at PI 
resulting in detectable cleavage. Although the threonine residue at PI 
perm itted cleavage at this site the efficiency of processing was reduced by a 
factor of 140. A cysteine to serine substitution at PI of the NS5A/NS5B 
cleavage site formed a substrate that was very inefficiently processed 
(Zhang et al., 1997). The documented mutagenesis of PI agrees with the data 
reported in 5.2. as only substitution with a serine residue at PI produced a 
m utated NS5A/NS5B cleavage site that was processed by NS3.
All these results illustrate the importance of the PI residue for all the 
cleavage sites processed by the HCV NS3 with the NS3/NS4A cleavage site 
the most tolerant to mutation. This feature is probably due to the in cis 
nature by which this site is processed. For all the cleavage sites processed in 
trans, mutation of PI is not well tolerated. The PI residue was demonstrated 
to interact with a specific binding pocket (the SI specificity pocket) w ithin 
the NS3 protease. This specificity pocket, which is shallow and nonpolar, is 
formed primarily by the side chains of Phe-154, Ala-157 and Leu-135 (Love 
et al, 1996). The amino acid Phe-154 determines the shallow nature of the 
specificity pocket. The side chain of the PI residue in the substrate (SH 
although substitution with an OH group is tolerated) will interact w ith the 
electron-rich n clouds on the aromatic ring of Phe-154. This observation 
explains the specific nature of the residue found at PI and the tolerance for a 
serine residue only at this position.
8.2.3. Mutagenesis of the PI' residue.
The effect of mutation of the PI' residue depended largely on the 
amino acid introduced (5.2.). Replacement of the wild type PI' serine
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residue w ith threonine resulted in a fall in processing by 60-70%. 
Substitution with alanine gave a fall in processing of approximately 40% 
and introduction of a proline residue completely abolished any detectable 
processing. These amino acid substitutions are illustrated in Fig. 8.4.
At the NS3/NS4A cleavage site the basic amino acid arginine, the 
polar amino acids serine, cysteine, and threonine, and the aliphatic amino 
acids glycine, alanine, and leucine were all tolerated at PI' (Leinbach et al,
1994) producing cleavage sites that were processed by NS3. Kolykhalov et 
al. (1994) demonstrated that at the NS3/NS4A cleavage site only the presence 
of proline at P I1 produced a cleavage site that was processed at a 
significantly lower level compared to the wild type NS3/NS4A cleavage 
site. Substitution of the P I' residue with an arginine residue had little effect 
on the efficiency with which this cleavage site was processed.
At the NS4A/NS4B cleavage site PI' substitutions with isoleucine, 
threonine, arginine, alanine, asparagine and histidine all gave cleavage sites 
that were efficiently processed whereas the presence of proline dramatically 
reduced the level of processing (Kolykhalov et a l, 1994). At the NS4B/NS5A 
and the NS5A/NS5B cleavage sites the presence of proline at P I' abolished 
cleavage and a cleavage site containing arginine at exhibited a slightly 
lower level of processing (Kolykhalov et al, 1994). Urbani et al (1997) 
analysed an NS4A/NS4B cleavage site that contained a naturally occuring 
alanine at PI'. When this residue was substituted with a serine residue, as 
observed at this position in other sites, there was a fall in processing of 
approximately 2-5 fold. This result implies that the optimal favoured amino 
acid at PI' is an alanine. Replacement of the PI' serine residue at the 
NS5A/NS5B cleavage site with alanine had little effect on the efficiency of 
processing (Zhang et al, 1997). All these results imply that the effect of an 
amino acid substitution at the PI' residue is dependent on the amino acid 
introduced. That the introduction of an alanine residue at P I' has little effect 
on the efficiency by which the cleavage site is processed is understandable 
as some HCV NS4A/NS4B cleavage sites naturally contain an alanine at PI'.
The results of these mutational analyses show that the m ost 
important residue in cleavage site determination is the PI amino acid. The 
acidic residue at P6 appears to play an important role in the cleavage sites 
processed in trans within the HCV polyprotein. Mutation of the P6 residue, 
although not resulting in the abolition of cleavage, leads to a significant 
increase in the amount of uncleaved substrate. The only exception to this 
observation is seen for the NS3/NS4A cleavage site, which is processed in 
cis. The P I' serine residue is not essential for processing of the cleavage sites 
with alanine present at other sites and in other genotypes. Only the 
introduction of a proline residue at this position abolishes cleavage by the 
NS3 serine protease. The PI' residue was tolerant to the introduction of 
other amino acids which all permitted cleavage, albeit with different 
processing efficiencies.
The structural prediction program "Plotstructure" was used to carry 
out comparisons between the wild type tNS5T substrate and the m utated 
tNS5T substrates, to determine whether any amino acid substitution could 
be predicted to have a negative effect on processing of the substrate. In Fig.
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8.5. it can be seen that there is no difference in the predicted cleavage site 
structure for either the wild type substrate or the substrates containing 
m utations of P6. As none of these mutations abolished processing the 
predictions from the structural analyses seem to corroborate observed 
results. There were significant differences in the predicted secondary 
structure for the PI serine and glycine mutations in comparison w ith the 
wild type substrate and the substrate containing arginine at PI. The 
"Plotstructures" of the PI' substrates agreed with the observed cleavage 
patterns, with the uncleaved PI' Pro substrate having a significantly 
different predicted structure or the wild type and the two processed 
substrates exhibiting no discernible difference. It can not be determined for 
certain whether a substrate would be processed by NS3 using this 
"Plotstructure" program. When compared to the wild type substrate, the 
majority of substrates that have the same predicted structure as the wild 
type were processed. The majority of substrates whose predicted secondary 
structures differed from the wild type were not cleaved by NS3.
8.3. Investigation of cleavage site specificity.
There have been many investigations into the importance of the P6, 
PI and P I' residues of the HCV cleavage site motif, but little analysis of the 
additional residues present within the cleavage site sequence has been 
undertaken. It was demonstrated that when an alanine residue was 
introduced at P3 of the NS4A/NS4B cleavage site the level of processing fell 
by 7-fold (Urbani et al., 1997). This effect on processing was observed in the 
absence of NS4A. In the presence of NS4A this cleavage site was processed 
at a similar level to substrates containing other amino acid substitutions (i.e. 
P5-P2, P2' and P3') shown to be unimportant in substrate specificity. It was 
also demonstrated that there was a preference for a hydrophobic residue at 
P4' although the effect of amino acid substitution at this position was not 
investigated. Sequence comparison between different genotypes confirms 
that there is a hydrophobic residue at P4' for all HCV isolates.
Kolykhalov et al. (1994) m utated P7 (Phe to His or Arg), P5 (Glu to 
Lys), P3 (Glu to Asn or Lys), P2 (Glu to Asn or Lys) and P2' (Gin to Lys) of 
the HCV-H NS4A/NS4B cleavage site with no observable effect on cleavage. 
No other investigation into cleavage site specificity has been done.
8.3.1. Investigation of potential cleavage sites within the HCV Gla 
polyprotein.
If the amino acid sequence required to define an NS3-mediated 
cleavage site involved only the P6, PI and P I' residues, it would be unlikely 
that any other similar sequence existed within the HCV polyprotein except 
the documented cleavage sites. The amino acid sequence of the HCV Gla
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Fig. 8.5. Predicted secondary structures of the NS5A/NS5B 
cleavage sites containing point m utations at specific positions 
within the cleavage site motif. For all the substrates the rest of the 
predicted secondary structure was unchanged. The NS5A/NS5B 
cleavage site is processed at amino acid 315 of the tNS5T 
substrate. For both the P6 substitutions the predicted secondary 
structure is unchanged. Both the PI Ser and PI Gly substrates 
have different predicted secondary structures to that of wild type, 
whereas the PI Arg substrate appears to be identical. The only 
P I ' m utant substrate whose predicted secondary structure is 
different to the wild type is that containing' Pro at PI'.
polyprotein was searched for any D / E X X X X C / T S  motif and this search 
yielded three additional, potential cleavage sites. These potential sites all 
contained the "motif" shown to give a site suitable for processing by the 
NS3 protease. The first of these cleavage sites, present in NS5A, was not 
processed by the NS3 serine protease when either the full length or 
truncated NS5A proteins were cotransfected with NS34A (6.2.). The lack of 
processing observed at this potential site may be due to the folding of the 
NS5A protein, making the potential site inaccessible to the NS3 protease. 
Further analysis would be required to determine whether this site is either 
unsuitable for cleavage due to the amino acids surrounding P6, PI and P I' or 
that it is merely inaccessible to the NS3 protease due to the folding of the 
substrate used.
Investigations into this site could be carried out in a number of ways. 
As this site resembles the NS3/NS4A cleavage site, the seven amino acid 
sequence (DVAVLTS) could be substituted for the wild type NS3/NS4A 
cleavage site (DLEWTS) within the HCV Gla NS34A protein. This m ethod 
of mutagenesis would be similar to that used for the analysis of the LITS 
potential cleavage site (6.3.) within the tNS5T substrate. Sequence 
comparison between the two sites at the primary amino acid level reveals 
little dissimilarity. Except for the acidic residue aspartic acid, at P4 in the 
NS3/NS4A cleavage site and the alanine at P4 within the potential site there 
is little difference in the amino acids present. There is, however, little 
sequence variation between the NS3/NS4A cleavage sites of different 
isolates. The aspartic acid at P4 is completely conserved as are the amino 
acid residues at P6, P5, P3, PI and PI'. The P2 residue is primarily a valine 
although threonine and methionine have been reported at this position. 
The conservation of the acidic residue at P5 may be important for efficient 
cleavage in trans. As the NS3/NS4A cleavage site was extremely tolerant to 
mutations at P6, PI and PI' it is unlikely that mutation of the P4 residue 
would have any effect on processing.
An alternative analysis could be carried out on the cleavage site as it 
is found naturally. To determine whether this site could be processed in 
trans a substrate based around the NS5A protein could be used. It has been 
demonstrated that this site was not processed as part of the full length NS5A 
or the NS5A substrate truncated by 132 amino acids (6.2.) at its N-terminus. 
In the context of the truncated NS5A substrate the potential cleavage site 
was situated 68 amino acids from the N-terminus and 248 amino acids from  
the C-terminus. A series of further truncations from either terminus may 
produce an NS5A substrate that could be cleaved at this potential site. This 
method may not provide any further information if the substrate is not 
processed. A lack of cleavage at this site could still be due to the structural 
conformation of the NS5A protein. To determine the reason for any lack of 
processing, a site cleavable by NS3 (e.g. NS5A/NS5B) could be introduced in 
place of the theoretical cleavage site. Truncations of the substrate term ini 
could be carried out in tandem for the wild type and "cleavable" NS5A 
substrates. Any lack of processing for the NS5A substrate containing a 
cleavable site would be due to the structural conformation of the protein
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and not the amino acid sequence of the cleavage site. This potential site 
within the NS5A protein was also present in many other HCV isolates.
The two potential cleavage sites in NS5B are present in all the HCV 
isolates and are highly conserved. The ELITSCS potential cleavage site is 
completely conserved between different HCV isolates. The DLELITS 
potential site is highly conserved between isolates with only one isolate 
differing at P5 with the leucine residue replaced by a glutamine residue.
No analyses were carried out on the DLELITS cleavage site in this 
study. To investigate whether this potential site could be processed it could 
be analysed in a similar manner to the potential site in NS5A. The cleavage 
site could replace the NS3/NS4A cleavage site within the NS34A protein. 
The DLELITS sequence is even more similar to the NS3/NS4A site than the 
previous potential site. The only difference between the potential site and 
the wild type NS3/NS4A site (DLEWTS) is the leucine and isoleucine at P3 
and P2 instead of the pair of valines. All three of these amino acids are 
similar and it would be expected that this cleavage site would be processed 
if it was expressed in this manner.
Data were not available on whether this site was processed within the 
wild type NS5B. The NS5B protein could not be identified within cells as no 
antisera against this protein were available. The tNS5T substrate could not 
be used as the C-terminal truncation includes the potential site. Production 
of truncated NS5B substrates (with an epitope tag for identification) may 
provide an insight into whether this site could be processed in trans w ithin 
the NS5B protein.
These two potential cleavage sites were not analysed for their 
cleavability but potential tNS5T substrates containing these two cleavage 
sites were analysed using the "Plotstructure" program (Fig. 8.6.). The 
predicted structure of the tNS5T substrate containing the potential site from  
NS5A was different to the wild type tNS5T prediction. The tNS5T substrates 
containing the potential site from NS5B had a predicted structure identical 
to the wild type tNS5T. Whether these substrates are actually processed is 
not yet known but from these predictions one would be processed (NS5B 
potential site) and the other would not (NS5A potential site).
8.3.2. Investigation of a potential cleavage site within the NS5B protein.
The potential cleavage site (ELITSCS) within NS5B was not studied at 
its normal position within the NS5B protein as this was downstream of the 
C-terminus of the tNS5T substrate. The use of a full length NS5 substrate 
would be of no use as identification of the full length NS5B was not 
possible. Even a full length NS5B protein with an epitope tag attached may 
not be of any use as the NS5B is reported to be unstable in mammalian cells 
(Lin et al., 1994b). As this potential site resembles the cleavage sites 
processed in trans by the NS3 protease it was decided to replace the 
NS5A/NS5B cleavage site within the tNS5T substrate with the potential 
cleavage site (ELITSCS). This new tNS5T substrate, containing the amino
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Fig. 8.6. Comparison between the predicted secondary 
structures of the wild type tNS5T substrate and tNS5T substrates 
containing potential cleavage sites from within the HCV Gla. 
polyprotein. The potential cleavage site within NS5A 
(DVAVLTS) has a predicted secondary structure different to the 
wild type tNS5T whereas the potential site within NS5B 
(DLELITS) has a predicted secondary structure identical to the 
wild type substrate. From these secondary structure predictions 
it could be hypothesised that the potential NS5A cleavage site 
would not be processed within tNS5T whereas the potential 
NS5B cleavage site would be processed.
acid sequence LITS from P5-P2 at the NS5A/NS5B cleavage site, was 
cotransfected with NS34A. Coexpression of this substrate with the NS34A 
protease complex did not yield any observable cleavage products. 
Q uantitation using the phosphorimager demonstrated only a small degree 
of processing but this value was so small as to be negligible. This absence 
of processing is in contrast to the reported data that only P6, PI and P I' are 
required to define a cleavage site that can be processed by the NS3 protease.
This potential cleavage site contains the required P6, PI and PI' 
residues for correct interaction with NS3 protease and cleavage in trans. The 
lack of processing observed must be due to influence exerted by some or all 
of the amino acids from P5-P2. Sequence comparison of cleavage sites 
processed by the NS3 protease was carried out for all six genotypes to 
determine if any of these amino acids were present in cleavage sites 
processed by the NS3 protease. A leucine at P5 is found in cleavage sites of 
other HCV isolates although only in the highly conserved NS3/NS4A 
cleavage site. There does not seem to be any conservation of the type of 
amino acid present at this position. Non-polar side chains (Cys, Gly, Leu), 
uncharged polar side chains (Ser, Tyr) and negatively charged, acidic side 
chains (Asp, Glu) are all found at this position in different cleavage sites and 
in different HCV genotypes.
At P4 an isoleucine residue has been reported, as have other non­
polar residues (Met, Pro, Val), uncharged polar residues (Ser, Thr) and acidic 
residues (Glu). At P3 non-polar residues (Val, Iso, Ala), charged polar 
residues (Thr, Ser) and an acidic residues (Glu) are found.
The serine residue found at P2 of this potential cleavage site is not 
observed for any other site processed by the NS3 protease. An acidic 
residue (Glu) or a non-polar residue (Pro, Cys, Val) is observed but no HCV 
isolate contains a polar residues at this position, let alone a serine residue. 
As no serine residue was observed at this position it was hypothesised that 
this amino acid could be primarily responsible for the lack of processing 
observed for this potential cleavage site. Although it was not investigated 
further, the possibility that this serine residue may be phosphorylated and 
interferes with processing was considered.
An additional serine residue was also present at P2' of this potential 
cleavage site. A serine residue was not documented at this position when a 
serine was also present at PI', however a serine residue was present when 
there was an alanine residue at PI'. The effect of introducing a serine 
residue at P2' was also studied within the NS5A/NS5B cleavage site in 
tNS5T.
To investigate the importance of the serine residue at P2 two 
potential cleavage sites were constructed. The first cleavage site constructed 
was essentially the wild type NS5A/NS5B cleavage site with the P2 residue 
substituted to a serine residue from the wild type cysteine. The second 
cleavage site constructed was derived from the LITS potential site w ith the 
P2 residue restored to the wild type cysteine to give a P5-P2 sequence of 
LITC. Both substrates were analysed for their susceptibility to cleavage by 
the NS34A protease complex (6.3., Table 6.3.). The introduction of a serine 
residue at P2 of the wild type cleavage site had a significant effect on the
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efficiency by which the substrate was processed. Although the efficiency of 
cleavage did not fall to the levels observed for the LITS cleavage site the 
drop in the degree of cleavage was still significant (-50%). This result 
implies that although the serine residue is a contributing factor to the fall in 
the efficiency of cleavage it is not the sole factor.
This observation is confirmed by the second potential cleavage site 
constructed to investigate the importance of a serine residue at P2. The 
substrate containing LITC was processed at an observable level, a significant 
increase in the level of processing compared to the cleavage site containing 
LITS. The level of processing was still significantly lower than that of the 
wild type NS5A/NS5B cleavage site (-25%).
The introduction of a serine residue at P2' of the wild type cleavage 
site produced a tNS5T substrate that was still processed by the NS34A 
complex. The efficiency by which this substrate was cleaved was low er 
(60%) than that observed for the tNS5T substrate containing the wild type 
NS5A/NS5B cleavage site. All these mutated substrates demonstrate the 
effect of introducing an additional serine residue in close proximity to the 
site of cleavage, although a serine residue at P2 is not the only factor 
involved in the almost complete abolition of processing observed for the 
LITS potential cleavage site.
To characterise further the reason for the minimal processing 
observed for the LITS cleavage site three further potential cleavage sites 
were introduced into tNS5T substrate in place of the wild type NS5A/NS5B 
cleavage site. These three potential sites were derived from the LITS 
sequence with pairs of amino acids replaced by the wild type residues, thus 
giving DVTS, LVVS and LIVC at P5-P2. These substrates were cotransfected 
with the NS34A protease construct and the efficiency of processing by the 
protease determined (6.3., Table 6.4.)
When the amino acid sequence LITC was present at P5-P2 in the 
NS5A/NS5B cleavage site, processing was at an efficiency of 20-25% with 
respect to the wild type cleavage site. When this potential cleavage site was 
changed to contain LIVC at P5 to P2, the increase in the efficiency of 
processing was marginal, rising to 25-35% of the wild type efficiency. The 
increase in the efficiency of processing is attributable to the loss of the 
threonine residue at P3 as this is the only amino acid change between these 
two theoretical cleavage sites. It can be speculated that the presence of 
threonine at P3 has a small inhibitory effect on the cleavability of the site. 
Both serine and threonine have a polar hydroxyl group (OH) and the 
combined presence of these two similar amino acids may contribute to a fall 
in the efficiency of processing. These two factors are not alone in being 
responsible for the low level of processing observed when the LITS 
sequence is present from P5-P2 within the cleavage site. The efficiency w ith 
which the LIVC cleavage site is cleaved was still low in comparison to the 
wild type NS5A/NS5B cleavage site.
The threonine at P3 was also replaced when the two valine residues 
found at the wild type NS5A/NS5B cleavage site were introduced at P4 and 
P3 (giving the sequence L W S at P5-P2). The substitution of these two 
amino acids resulted in an increase in the efficiency of processing w ith
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respect to the LITS cleavage site by approximately 10%. As the isoleucine to 
valine substitution involves the replacement of one non-polar residue w ith 
another, the increase in the efficiency by which this substrate was processed 
is probably due to the loss of the threonine residue at P3. This increase 
agrees with the observation that the difference in the efficiency of 
processing between LITC and LIVC is also approximately 10%. Both these 
substitutions (LITC to LIVC and LITS to LW S) involve the replacement of 
the threonine residue at P3 to the wild type valine residue, resulting in a 
more efficiently cleaved site. The presence of the threonine residue at P3 
appears to have a definite but small negative effect on the efficiency by 
which the substrate is processed.
When the potential cleavage site containing LITS was replaced at P5 
and P4 to give the wild type aspartic acid and valine respectively (to give 
DVTS at P5-P2), the increase in the efficiency of processing from that 
observed for the cleavage site containing the LITS sequence was negligible. 
Despite the introduction of the wild type acidic residue (Asp) at P5 there was 
barely any increase in the cleavability of this substrate. The replacement of 
isoleucine with valine would be expected to have little effect as both are 
non-polar residues of a similar size. The retention of the inhibitory serine 
residue at P2 may be the dominant negative factor and any positive 
influence on processing exerted by the acidic residue at P5 may be 
insignificant while the serine is present at P2. The serine side chain and the 
aspartic acid side chain together have the capability of forming a hydrogen 
bond (Fig. 8.7.).
The spatial arrangement of amino acids within this cleavage site has 
not been determined. It is not known whether these two side chains are in 
close enough proximity to interact and hence form a hydrogen bond, but if 
they are close enough the positive influence normally exerted by the acidic 
residue at P5 may be inhibited.
One further potential cleavage site was constructed with only the P5 
leucine residue mutated from the wild type sequence. This cleavage site 
contained LVVC from P5 to P2 and was cotransfected with the NS34A 
construct before the efficiency with which this substrate was processed was 
calculated (6.3., Table 6.5.). This cleavage site was processed with a slightly 
higher efficiency than the L W S cleavage site although the increase was 
only approximately 5%. This cleavage site was processed at an efficiency of 
15-25% of the wild type efficiency. The increase in efficiency corresponds to 
the loss of the serine residue at P2. The effect of replacing the serine at P2 
was observed when the LITS cleavage site was mutated to LITC, with a 
similar rise in the efficiency of processing observed.
The "Plotstructures of all these LITS-derived cleavage sites were 
produced. All eight of these predicted secondary structures had the 
additional "squiggle" seen for the PI Ser and PI Gly substrates that were 
inefficiently processed by the NS3 serine protease (Fig. 8.8.)
These potential cleavage sites were all derived from the LITS 
sequence due to the effect on processing of the NS5A/NS5B cleavage site 
when this sequence was introduced from P5-P2. The presence of the serine 
residue at P2, and to a lesser extent the presence of threonine at P3, have
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Fig. 8.7. Hydrogen bonding between two amino acid side 
chains. The negatively charged, acidic aspartic acid (left) 
can form a hydrogen bond (illustrated by the broken line) 
to the uncharged, polar side chain of the serine residue.
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Fig. 8.8. Comparison of predicted secondary structures between the 
potential LITS cleavage site and its derivatives. The NS5A/NS5B 
cleavage site is processed at amino acid 315 of the tNS5T substrate. 
The predicted secondary structures for the cleavage sites containing 
the LITS and LITS-derived potential cleavage sites are significantly 
different to the wild type.
been shown to have a significant role in the fall in cleavage efficiency when 
they are introduced. Despite replacing these residues the two substrates 
(LIVC and LVVC) were processed with an efficiency 65-75% lower than the 
wild type substrate. Replacement of isoleucine at P4 with valine had little 
effect. This observation was not unexpected as the two residues are both 
non-polar. These analyses lead to the hypothesis that an acidic residue at P5 
(aspartic acid for the NS5A/NS5B cleavage site) has a significant role in the 
substrate specificity of a cleavage site processed by the NS3 serine protease. 
The only cleavage site (derived from the LITS potential site) constructed 
with an aspartic acid at P5 also contained a serine residue at P2 and was not 
processed efficiently. The serine residue may inhibit the positive influence 
of the acidic residue at P5 on substrate specificity.
As well as the conserved residues at P6, PI and PI', the NS5A/NS5B 
cleavage site is processed with a high efficiency apparently due to the 
presence of a positively charged, acidic residue at P5. Substitution of 
alanine at P5 of the NS5A/NS5B site resulted in a fall in the catalytic 
efficiency by a factor of 9 (Zhang et al, 1997). This observation agrees w ith 
the conclusion that the acidic residue at P5 is important in the specificity of 
cleavage by the NS3 serine protease.
All these substrates derived from the LITS potential cleavage site
were
Sequence analysis of NS5A/NS5B cleavage sites from different HCV 
isolates gives the following consensus sequence:
6 5 4 3 2 1 1'  2 '  3 '  4 '
E (D) D ( S , G) V V ( I ,  A) C C /  S M S Y
Although this sequence seems to illustrate a tolerance for amino acid
changes only very few isolates exhibit sequence variation. Two type 2 
isolates (HCV-J6 and HCV-J8) have an aspartic acid at P6 and a serine at P5 
with one of these having an isoleucine at P3 (HCV-J8). A type lb  isolate 
(HCV-T) has a glycine at P5 and an isoleucine at P3. Another type lb  isolate 
(HCV-JK1) has an alanine at P3. All the remaining 14 isolates from 
genotypes 1 to 4 had the conserved EDWCCSMSY sequence. The loss of the 
acidic residue at P5 has a significant effect on processing but the site is still 
processed. For the three isolates containing different amino acids at this 
position the NS5A/NS5B cleavage sites would still be processed, albeit w ith 
a lower level of efficiency than for cleavage sites containing the acidic P5 
residue.
8.4. Investigation of processing at different sites within the HCV
polyprotein.
An analysis of NS3 mediated cleavage at other sites in the HCV 
polyprotein was desirable to investigate the specificity of cleavage. Due to 
the lack of antisera against the other non-structural proteins within the
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laboratory the processing of these other cleavage sites was not carried out at 
their normal positions within the HCV polyprotein. The cleavage sites 
processed within the HCV polyprotein (NS3/NS4A, NS4A/NS4B and 
NS4B/NS5A) were introduced into the tNS5T substrate in place of the 
NS5A/NS5B cleavage site. These substrates were cotransfected w ith the 
NS34A construct and the efficiency by which they were processed calculated. 
The result of this analysis is summarised below, as are the amino acid 
sequences of the cleavage sites introduced. The NS3/NS4A cleavage site 
was not processed in trans when expressed in this manner and the other sites 
were processed with varying efficiencies.
Cleavage Site Sequence Relative % 
Cleavage 
Efficiency
NS3/NS4A DLEWTS 0
NS4A/NS4B DEMEECS 45-50
NS4B/NS5A DCTTPCS 20-25
NS5A/NS5B EDWCCS 100
Table 8.1. Summary of HCV Gla cleavage sites processed 
by the NS3 serine pro tease. The amino acid sequence of the 
cleavage sites is illustrated as is the efficiency by which these 
cleavage sites are processed when they replaced the NS5A/NS5B 
site within tNS5T.
The "Plotstructures" of these substrates (including an NS4B/NS5A 
substrate containing aspartic acid at P6) were produced and all four 
predicted structures were different from the predicted wild type structure 
with the exception of the NS4A/NS4B structure (Fig. 8.9.). An interesting 
feature was observed for the NS3/NS4A cleavage site (which was not 
processed within the assay) compared to the potential cleavage site in NS5B 
(DLELITS). Both these cleavage site motifs are very similar with the only 
difference being the W -L I change at P3 and P2. All three of these am ino 
acids are non-polar and it would not be expected that replacement from one 
pair of amino acids to another would have a significant effect on secondary 
structure. The predicted structure for the potential NS5B site in tNS5T 
appears to be a structure susceptible to cleavage by the NS3 serine protease, 
however the NS3/NS4A tNS5T substrate has a significantly different 
predicted secondary structure from the wild type tNS5T substrate.
The most efficiently processed cleavage site (besides the wild type 
NS5A/NS5B site) was the NS4A/NS4B site, which was processed at an 
efficiency of 50% compared to the wild type site. Comparison between the 
amino acid sequence of both sites shows an acidic residue at P6 and P5 for 
both these cleavage sites. It had been speculated above that the presence of 
an acidic residue at P5 influenced the efficiency with which a site is
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Fig. 8.9. Comparison between predicted secondary structures of 
tNS5T substrates containing the different HCV NS3-mediated 
cleavage sites. With the exception of the NS4A/NS4B tNS5T 
substrate the predicted secondary structures are significantly 
different to the wild type tNS5T substrate.
processed. The rest of the amino acid sequence within the cleavage site 
motif is significantly different between the two sites. The NS5A/NS5B 
cleavage site has Val, Val, Cys at P4 to P2 whereas the NS4A/NS4B site 
contains Met, Glu, Glu at these positions. The NS5A/NS5B sequence 
contains three non-polar residues. The NS4A/NS4B sequence consists of a 
non-polar amino acid at P4 followed by two acidic residues. The presence of 
an acidic chain at P5 may be as important for efficient cleavage as the acidic 
residue at P6. As they are highly conserved, the remaining amino acids may 
also be im portant for efficient cleavage at this site. The introduction of the 
bulkier methionine residue at P4 instead of valine and the acidic residues at 
the other positions may have an inhibitory effect on the specificity of 
cleavage.
The NS4B/NS5A cleavage site is processed inefficiently (25%) in 
comparison to the NS5A/NS5B cleavage site. The NS4B/NS5A sequence 
does not have an acidic residue at P5. The absence of this residue was shown 
previously to produce a substrate processed at 15-25% compared to the wild 
type. This low efficiency of processing corroborates the results obtained for 
the NS4B/NS5A cleavage site. As there is little difference in efficiency 
between the L W C  NS5A/NS5B cleavage site and the NS4B/NS5A cleavage 
site the remaining amino acid differences are likely not to have any 
significant influence on substrate specificity. The two valine residues at P4 
and P3 and cysteine at P2 are replaced by Thr, Thr, Pro. A valine to 
threonine substitution changes the nature of the amino acid from non-polar 
to uncharged polar although the sizes of the side chains are relatively 
similar with the valine side chain slightly larger. If these residues are not 
significantly important in cleavage site specificity then it is not surprising 
that these substitutions have little effect. The substitution of cysteine for 
proline, although not affecting the nature of the amino acid, may have an 
effect on the peptide backbone but as no significant effect on processing is 
observed the effect, if any, is likely to be negligible.
A cleavage site derived from the NS4B/NS5A site, containing a 
glutamic acid at P6 as opposed to an aspartic acid, was also introduced in 
place of the NS5A/NS5B cleavage site within the tNS5T substrate. This 
cleavage site was processed with a similar efficiency as the wild type 
NS4B/NS5A cleavage site, illustrating that the important feature at P6 is a 
negatively charged, acidic residue.
The NS3/NS4A cleavage site was not processed by the NS3 serine 
protease when it replaced the NS5A/NS5B cleavage site within tNS5T. As 
well as not having the acidic residue at P5, the NS3/NS4A cleavage site 
contains a threonine residue at PI instead of the cysteine residue found for 
all cleavage sites processed in trans. The combination of these factors is 
probably enough to produce a cleavage site unsuitable for processing by the 
NS34A protease complex. As the NS3/NS4A site is normally processed in cis 
these factors are not as important. The threonine side chain is bulkier than 
the serine side chain and will not fit into the SI specificity pocket of the NS3 
protease as ideally as serine, despite having the correct sulphydryl group to 
interact with Phe-154 of the protease. The only other significant difference 
in the amino acids present is the acidic side chain at P4 as opposed to the
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valine residue found in the NS5A/NS5B cleavage site. When processed in 
cis, the NS3/NS4A substrate is attached to the protease, which folds around 
the substrate and cleaves it despite the imperfect sequence of the cleavage 
site. It has been reported that the NS3/NS4A cleavage site can be processed 
in trans normally when the NS3 protease domain is cleaved form the N- 
terminus of the NS34A substrate (Lin et al., 1994b). These data are in contrast 
to the results here. The reasons for this discrepancy are unclear but the 
folding of the NS34A substrate may overcome the negative influences 
exerted by the amino acid sequence of the cleavage site and permit cleavage 
in trans.
An investigation of this processing could be carried out by 
developing an truncated NS34A substrate and replacing the NS3/NS4A 
cleavage site with a cleavage site normally processed in trans. Com parison 
of the wild type NS34A substrate and this altered NS34A (NS5A/NS5B) 
substrate would perhaps illustrate the difference in efficiency obtained at 
this site. If the NS3/NS4A site is processed in trans within this substrate it 
may still be cleaved at a significantly lower level than a cleavage site 
normally processed in trans. Alternatively the reason that the NS3/NS4A 
cleavage site is processed in trans within the NS34A substrate may be 
entirely due to the amino acid sequence at the cleavage site w ithin the 
context of the folded protein. A cleavage site processed normally in trans 
may not be efficiently processed within the NS34A substrate.
The introduction of the HCV cleavage sites into the tNS5T substrate 
provides some information into the specificity of cleavage by the NS3 
protease. This analysis also seems to confirm the importance of the acidic 
residue at P5 for efficient cleavage in trans. For efficient processing at the 
NS5A/NS5B cleavage site it was hypothesised that an acidic residue at P5 
was important. This deduction was the result of the analyses carried out 
with respect to the LITS potential cleavage site.
When the NS5A/NS5B cleavage site was replaced by the cleavage 
sites normally processed within the HCV polyprotein (NS3/NS4A, 
NS4A/NS4B, NS4B/NS5A) a significant variation in the efficiency w ith 
which these sites were processed was observed. Analysis of the amino acid 
sequences of these cleavage sites illustrated that the presence of an acidic 
residue at P5 was important for efficient processing in trans by the NS3 
serine protease. The most efficient site cleaved by the NS3 protease 
contained an acidic residue at P5 whereas those sites that did not contain an 
acidic P5 residue were inefficiently processed (if at all) by NS3. These 
cleavage sites were all processed at a significantly lower level in 
comparison to the NS5A/NS5B cleavage site (in this analysis). If this 
analysis illustrates processing by the NS3 protease at its optimum, then the 
amino acid sequence, as well as the folding of the polyprotein, is im portant 
in determining the order in which the HCV non-structural proteins are 
released.
Analyses of processing at other cleavage sites within the HCV 
polyprotein have led to the deduction that these cleavage sites are less 
sensitive to mutation (Kolykhalov et al., 1994). If these cleavage sites are 
processed with a lower efficiency within the HCV polyprotein due to the
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lack of an acidic residue at P5 then any further mutation of this amino acid 
may not yield any information. Alternatively the introduction of an 
aspartic acid or a glutamic acid at this position may have a positive 
influence on the processing of these other sites at their normal positions. 
Substitution of the P5 residue within an NS4A/NS4B or an NS4B/NS5A 
substrate may reveal a significant increase in the efficiency of processing. 
Due to the nature of the cleavage at the NS3/NS4A cleavage site, m utation 
of the P5 residue within an NS34A substrate may not contribute any 
valuable information.
As well as an acidic residue at P5, the remaining amino acids w ithin 
the NS5A/NS5B cleavage site have small, non-polar side chains (Val, Val, 
Cys). The NS4A/NS4B cleavage site was the site most efficiently processed 
next to the NS5A/NS5B cleavage site. This site contained an acidic residue 
at P5 but contained an additional two aspartic acid residues at P3 and P2. 
The only other cleavage site processed was the NS4B/NS5A cleavage site. 
This site did not have an acidic P5 and contained a proline residue at P2 that 
can have a significant effect on the secondary structure of the peptide 
backbone. The NS3/NS4A site, which was not processed in trans, had a 
leucine at P5, an aspartic acid at P4 and a threonine at PI.
The rapid release of the viral polymerase may be im portant in the 
viral replication cycle and so the NS5A/NS5B cleavage site is quickly and 
efficiently processed. The lesser importance of the remaining non-structural 
proteins or the importance in delaying the release of these proteins may be 
a factor in the lower substrate specificity of these cleavage sites.
8.5. Investigation of the protease requirements for processing by the NS3 
serine protease.
Processing at NS3/NS4A does not require any other viral proteins 
and both NS3 and NS4A are required for the cleavage event to take place 
(Failla et a l, 1994). The cleavage event between NS3 and NS4A occurs in cis, 
rapidly and is the first NS3 mediated cleavage (Bartenschlager et al., 1994) to 
take place during polyprotein processing. Protease inactivation through a 
serine to alanine mutation of the catalytic serine was observed to abolish 
cleavage at this site. Introduction of an enzymatically active NS3 protein 
was not observed to mediate cleavage of this site in trans. An inactivated 
NS3 may still form a complex around the NS3/NS4A site, protecting it from  
processing in trans. Removal of the protease domain permits processing of 
the NS3/NS4A site in trans (Lin et al., 1994b).
NS4A is essential for processing at NS3/NS4A and at NS4B/NS5A 
(Lin et al, 1994b; Failla et al., 1995; Bouffard et al., 1995) but seems to have 
little effect at the NS4A/NS4B junction (Failla et al., 1994). The lack of 
requirement for the presence of NS4A for processing at NS4A/NS4B may be 
because an endogenous NS4A is present within the substrate. The 
NS4A/NS4B site cannot be processed in vitro in the absence of microsomal 
membranes (Lin and Rice, 1995).
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NS5A/NS5B processing is the most efficient trans-cleavage event 
(D'Souza et al., 1994). Processing at the NS5A/NS5B cleavage site does not 
require NS4A (Bouffard et al., 1995) although the presence of NS4A 
significantly enhances the efficiency of processing (Failla et al., 1994). 
W ithin the context of the poly protein the NS5A/NS5B site is processed 
efficiently with NS5B being produced either cotranslationally or from an 
unstable processing intermediate (Bartenschlager et al., 1994). The rate of 
cleavage of the different frans-cleavage sites varies between different sites 
(D'Souza et al., 1995). The NS4A protein can actively stimulate processing by 
NS3 even when uncleaved (Failla et al., 1994; Bartenschlager et al., 1995a). 
For in vitro analysis uncleaved NS4A cannot act as a cofactor (Bouffard et al.,
1995) for NS3 mediated processing.
The protease requirements for processing in trans of the HCV Gla 
NS5A/NS5B cleavage site were examined in Chapter 7. The importance of 
the NS3 N-terminus for frans-cleavage activity was investigated in 7.1. A 
cDNA encoding the HCV Gla polyprotein NS234A region was cotransfected 
with the tNS5T substrate and the ability of this protease complex to process 
determined. This NS234A polyprotein contained a point mutation w ithin 
the NS2 region that abolished the activity of the NS2/3 protease. The 
NS3/NS4A cleavage site was processed in cis producing an NS3 protease that 
had an additional 290 amino acids attached at its N-terminus. The effect of 
this large protein fragment on the ability of NS3 to process in trans was 
unknown. This additional protein fragment encoded not only the NS2 
protein but also the p7 protein. The presence of this extra sequence was 
shown not abolish the NS3 frans-cleavage activity (7.1.).
The level of processing observed with cotransfection of the NS234Mut 
construct was significantly lower than for cotransfection with the NS34A 
construct. Both these protease cDNAs were under the control of the T7 
promoter alone (NS34A in pTF7.5 and NS234Mut in pTZ18) and are likely to 
be expressed at similar levels. As the NS234A is a significantly longer 
cDNA, less of the NS3 protease will be produced relative to the NS34A 
construct. A quantitative comparison between these two protease constructs 
could be carried out so that the amount of NS3 protease introduced was the 
same for both constructs. This analysis would determine the effect, if any, of 
having the additional sequence at the N-terminus of NS3.
W hat can be determined from this analysis is that the folding of the 
NS3 serine protease is not affected by the additional N-terminal sequence in 
such a way that the NS3 protease is inactive. The quantitative analysis 
would give a more complete insight into this question.
A more detailed characterisation of the protease requirement was 
carried out to determine the minimal protease region required to process 
the NS5A/NS5B cleavage site. The tNS5T substrate was cotransfected with a 
variety of different combinations of protease constructs (7.2.). This analysis 
showed that only cotransfection with NS34A resulted in processing of the 
tNS5T substrate. Cotransfection of the substrate with either NS3 or NS3P 
did not produce cleavage products. When these cotransfections were 
repeated with the NS4A cofactor also introduced, no cleavage products were 
observed. These results are in contrast to the reported data that demonstrate
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that processing of the NS5A/NS5B cleavage site does not require NS4A 
(Bouffard et a l, 1995).
Cotransfection of the tNS5T substrate with an NS3 construct derived 
from HCV-A resulted in cleavage of the tNS5T substrate. This experiment 
yielded two pieces of information. The NS5A/NS5B cleavage site could be 
processed by NS3 alone and that an NS3 construct from a different subtype 
(lb) could process the HCV Gla polyprotein.
As the HCV-A NS3 was able to process the tNS5T substrate alone and 
the HCV Gla NS3 required NS4A there must be some factor that 
differentiates these two proteases. The amino acid sequence of these two 
protease constructs was compared to see if any differences were present that 
could contribute to the difference in processing ability.
Sequence analysis demonstrated that there were a number of am ino 
acid differences between the protease constructs. Most of these differences 
were either substitution to a similar amino acid an d /o r observed for other 
HCV isolates. A positively charged basic amino acid, lysine, was present 
immediately next to the aspartic acid of the catalytic triad. The negative 
charge of this amino acid is important as it stabilises the correct 
conformation of the histidine residue of the catalytic triad. The presence of 
the positive charge adjacent to this residue may have a detrimental effect on 
the catalytic triad. In the presence of the stabilising cofactor NS4A this 
negative effect may be overcome, producing an active NS3 protease. W hen 
this lysine residue was substituted with the glutamine residue norm ally 
found at this position the HCV Gla NS3 protease was able to process the 
tNS5T substrate alone. When this amino acid was substituted w ithin the 
NS34A construct the efficiency of cleavage was slightly higher than for the 
wild type NS34A. This increase in efficiency may be due to the existence of 
a more stable catalytic triad within the HCV Gla NS3. Sequence comparison 
of NS3 proteins from different HCV isolates illustrated that although the 
residue adjacent to the catalytic aspartic acid was not completely conserved 
a basic residue was never found at this position. The majority of isolates 
contained a glutamine at this position although a leucine residue and a 
glycine residue were found in two isolates each. It would seem that it is 
important that there is no complementary charged residue in close 
proximity to the aspartic acid of the catalytic triad.
In Figs. 8.10. and 8.11. the active site of the NS3 protease dom ain is 
illustrated in the determined crystal structure of NS3. As well as being in 
close proximity to the catalytic histidine residue, the aspartic acid is also 
near to an arginine residue with which it could also interact. The presence 
of an additional positively charged residue adjacent to the aspartic acid m ay 
not only affect the interaction with the catalytic histidine residue but also 
this other amino acid, altering the structure of the protease. The presence of 
NS4A may stabilise the structure of the NS3 protein, overcome the 
inhibitory influence of the lysine residue and induce the proteolytic activity 
of the protease.
One further amino acid difference between the two NS3 constructs 
was investigated. Eleven amino acids downstream of the catalytic triad 
there was an arginine residue within the HCV Gla NS3 sequence whereas
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Fig. 8.10. Active site of NS3P (taken from Love et al, 1996). 
Side-by-side view of the active site and surroundings of HCV 
NS3P. A Ca trace is given for clarity. Side chains are labeled 
by the single-letter amino acid code. Shown here is the active 
site triad (H57, D81, S139) and residues defining the SI 
specificity pocket (L135, F154, A157). Overall, this SI pocket is 
relatively small and non-polar.
Fig. 8.11. Electron density maps around the active site of 
tNS3:NS4A (taken from Kim et al., 1996). Electron density map at 
2.7 angstroms (left) and 2.5 angstroms (right). The active site 
residues His-1083, Asp-1107, and Ser-1165 are labeled, as well as 
Phe-1180, which defines part of the PI substrate-binding pocket. A 
well-ordered water molecule occupies the oxyanion hole.
there was a glycine residue within the HCV-A sequence. Analysis of other 
isolates showed that in all but one of the sequences there was a basic am ino 
acid (arginine for the type 1 HCV isolates and lysine for types 2 and 3) w ith 
the exception of one isolate that contained an alanine residue. The 
relatively widespread conservation of a positive charge at this position was 
investigated to determine if this feature was of any importance.
The HCV Gla arginine residue was substituted with the glycine 
residue both within the wild type HCV NS3 sequence and the HCV NS3 
sequence containing the glutamine residue beside the catalytic aspartic acid 
to produce four new protease constructs (NS3[R-G], NS3[K-Q, R-G], 
NS34A[R-G], NS34A[K-Q, R-G]. When tested for their ability to process, the 
tNS5T substrate all four protease constructs successfully produced cleavage 
products.
Although the Arg-Gly substitution enabled the NS3 alone to process 
it was not as efficient as the NS3[K-Q] protease. When this substitution was 
present alongside the Lys-Gln substitution the NS3 protease processed w ith 
an efficiency between that of the NS3[K-Q] and the NS3[R-G] proteases. The 
NS34A[R-G] protease processed at essentially the same efficiency as the wild 
type NS34A. The NS34A[K-Q, R-G] protease processed at the same efficiency 
as the NS34A[K-Q] protease.
The presence of the glycine 11 amino acids downstream of the 
catalytic aspartic acid enables the NS3 alone to process the tNS5T substrate 
despite the presence of the adjacent, inhibitory lysine residue. The loss of 
the arginine downstream (or replacement with glycine) may have a small 
effect on the folding an d /o r the structure of the NS3 and orient the lysine 
residue further from the aspartic acid, abolishing its inhibitory effect on 
processing. When the two substitutions are present together the influences 
exerted may be slightly in opposition, hence the fall in processing efficiency 
from the NS3[K-Q] protease.
The NS34A[R-G] protease processes at a similar level to the wild type 
NS34A and this may be a feature of the stabilising nature of the NS4A 
cofactor. Any influence on structure exerted by the presence of the glycine 
may be negated by the presence of the NS4A cofactor. The NS34A[K-Q, R-G] 
protease processes at the same efficiency as the NS34A[K-Q] protease and 
this may be due to combined effect of the more stable catalytic triad (due to 
the Lys-Gln substitution) and the presence of NS4A. The possible 
compensatory effect of the Arg-Gly substitution is not substantial and when 
the stabilising NS4A cofactor is present the effect is negated.
8.6. Essential nature of viral proteases.
Not every virus encodes a protease but those that do ensure that the 
proteolytic process occurs at a specific place and at a specific tim e 
throughout the viral life cycle. These proteolytic events take place at a 
particular location within the cell and the protease is targetted to a specific 
site(s) w ithin the target protein. The activity of the viral protease is
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independent of the host cell. The action of the protease is such that it plays 
an essential role in the maturation of the virus particle, processing the viral 
polyprotein into proteins required for replication and particle assembly.
Virus-encoded proteases are found in a variety of different viruses 
and their presence is not dependent on the nature of the genome, 
complexity of the capsid or presence of a lipid envelope. These proteases 
have been observed in non-enveloped ssRNA viruses (picornaviruses), 
enveloped ssRNA viruses (flaviviruses and retroviruses), non-enveloped 
dsDNA viruses (adenoviruses) and enveloped dsDNA viruses 
(herpesviruses). The proteases encoded within all these different virus 
families are essential for the replication of the virus and exhibit a diversity 
in protease function.
The nature of the flavivirus serine proteases has been discussed 
previously (1.8.4). The activity of other viral proteases can also be 
demonstrated to be essential for virus replication despite having a 
significantly different method of action.
Herpes virus particles contain a capsid shell that is initially 
constructed by the assembly of scaffolding proteins within the capsid core 
before the viral DNA is packaged. These scaffolding proteins are rem oved 
from the herpesvirus particle after DNA introduction to produce the m ature 
virion. For the hum an cytomegalovirus (CMV) the scaffolding proteins are 
encoded by two overlapping genes that contain the same 3' terminus. The 
processing of these two proteins is carried out by a protease encoded w ithin 
the N-terminal domain of the larger gene. The C-terminal domain contains 
the assembly protein. This CMV pro tease (and all the other equivelant 
herpesvirus proteases) has been shown to be a serine protease and is highly 
conserved between different herpesviruses despite having no sequence 
homology to known serine proteases. This cleavage event is essential for 
herpesvirus replication. Herpesviruses containing an inactive protease are 
severely restricted in their replication. The second, downstream gene 
encodes the assembly protein required for assembly of the scaffold in 
hepresvirus capsid formation.
The larger protein is cleaved at two sites in all herpesviruses. The M- 
site (maturation site) is located upstream of the C-terminus of the assembly 
protein, whereas the R-site (release site) is located upstream of the N- 
terminus of the assembly protein. The remaining N-terminal fragm ent 
contains the catalytically competent enzyme. Both these cleavage events 
take place at a conserved motif - (V,L) - X - A /  S. There is an additional site 
cleaved within the HCMV protease region called the internal site (I-site). 
Cleavage at this site produces two fragments that associate together to form  
an active, "two-chain" protease (Holwedra et al., 1997).
For all herpesviruses, however, the major substrate cleaved by the 
protease is the smaller, assembly protein translated from the downstream  
start. After the B-capsid is formed, the protease cleaves the assembly 
protein at the M-site which enables removal of the scaffold before 
packaging of the viral DNA.
The CMV protease crystal structure was determined and found to 
contain a novel active site (Qiu et al, 1996) and a previously unseen fold.
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This structural determination showed that the CMV serine protease 
consisted of a single (3-barrel structure as opposed to the two p-barrel 
structure observed for chymotrypsin and other classical serine pro teases. 
Seven strands composed the p-barrel core that was surrounded by seven a- 
helices on three sides. The p-barrel core contains two parallel strands with 
strand B3 forming a P-bend that closes one corner of the barrel. The other 
corner is closed by two hydrogen bonds between strands B5 and B7. The 
first four stands (B1-B4) of the HCMV protease form a Greek key motif quite 
different to that of trypsin. The HCMV protease is believed to be 
evolutionary unrelated to other serine protease p-barrels and is folded in a 
unique way compared to other serine proteases.
The dimer interface between the two subunits is composed of one 
helix from one monomer and four helices of the other. This interface is 
predom inantly hydrophobic and is conserved between herpesviruses. The 
dimer interface is not close to the active site and it is unclear why 
dimerisation is required to form an active protease.
The catalytic triad was composed of H is/H is/S er instead of 
A sp/H is/S er normally observed for serine proteases. The CMV protease 
and the other herpesvirus serine proteases have a low turnover num ber that 
may be due to the presence of the His residue as opposed to the usual Asp 
residue. Although this His residue orients the catalytic His residue it does 
not increase the nucleophilicity of the serine residue (a feature of the Asp 
residue when present within the catalytic triad). This His residue, although 
important for catalytic activity, is not essential. The relatively low turnover 
rate may be advantageous for correct particle assembly of the hepresvirus 
virion as scaffold maturation is a relatively slow process. The encapsidation 
of the viral DNA and the removal of the scaffold proteins takes place only if 
the serine protease mediated processing takes place. A faster assembly of 
the virus scaffold may result in incorrectly organised virions leading to less 
infectious particles.
The CMV serine protease assembles as an allosteric hom odim er 
which processes at the nucleus. The protease is only active as a dimer. The 
pro tease cleaves between an alanine residue and a serine residue.
The HSV-1 protease is able to cleave a small peptide substrate 
containing 5-8 amino acids either side of the cleaved peptide bond. The 
HCMV protease requires only 5 amino acids either side of the target peptide 
bond to efficiently process. Mutation of the residues at P4-P1 result in a 
large decrease in cleavage efficiency. Substitution with the serine at PI' 
with alanine did not drastically reduce cleavage. As the I-site contains an 
alanine at P I ' this observation is not unexpected. The hepresvirus proteases 
are reviewed in Holwedra (1997).
The adenovirus protease is essential for virus replication and creation 
of infectious virus. The adenovirus protease (AVP) has a cysteine protease 
catalytic triad (G lu/H is/Cys), in a similar arrangement to cysteine 
proteases like papain, which is located within a completely novel protein 
fold. This fold also incorporates a peptide cofactor (Ding et al., 1996). The 
AVP acts at the nucleus but recognises the GX/G G/X motif. Three a-
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helices and a single five-stranded p-sheet form a unique "p-sheet sandwich". 
Three a-helices from the blunt end of the structure and a seventh a-helix 
forms the pointed end. An eleven amino acid peptide seems to act as a sixth 
P-strand next to the core P-sheet and interacts with a number of residues, 
including a disulphide bond. This factor does not encounter any catalytic 
residues but may play a conformational role. The AVP processes the core 
proteins of an assembled adenovirus virion within the nucleus of an 
infected cell. The AVP binds to the viral DNA non-specifically using four 
large, positively charged clusters located on the surface of the molecule. 
This binding, as well as the use of a peptide cofactor, can be viewed as a 
regulatory step to ensure that the protease activity is not activated until the 
protease has entered the virion.
As for flaviviruses, the picornavirus replication cycle involves the 
processing of a single polyprotein to produce the mature virus proteins. 
The core protein is processed cotranslationally by the 2A protease before 
protease-independent cleavage during final core maturation. The non- 
structural region of the picornavirus polyprotein is processed by the 3C 
protease. Both the 2A and the 3C proteases have an essential cysteine 
residue. The 3C protease was shown to fold into a chymotrypsin-like 
double (3-barrel (Bazan and Fletterick, 1988).
The picornaviruses are single stranded, positive sense RNA viruses. 
The RNA genome contains a single open reading frame that encodes a 
polyprotein that is rapidly processed cotranslationally. Throughout the 
picornaviruses there are three protease types (LPro, 2APro, 3CPro). The 
Aphthovirus Lpro is found at the N-terminus of the polyprotein and cleaves 
cotranslationally at its own C-terminus (Burroughs et al., 1984). LPro can exist 
as two forms, translated from two in frame AUG codons separated by 84 
nucleotides. Both forms cleave at the L /P l junction. There is a similarity to 
thiol proteases w ith the highly conserved residues Cys-51, His-148, Asp-164 
forming the catalytic triad. Glu-76 and Asp-164 may play a role in substrate 
binding. LPro also can cleave the host cell protein eIF-4G in trans in a sim ilar 
manner to entero- and rhino - viruses 2APro.
The enterovirus and rhinovirus 2APro cleaved between the capsid 
precursor PI and the replicative domains of the polyprotein. The 17kDa 
2APro cleaves at its own N-terminus between a tyrosine and a glycine 
residue although there seem to be a preference rather than requirement for 
the amino acids present. This protease also cleaves inefficiently at another 
site within the 3D protein depending on the virus strain. The nature of 2APro 
is not known but it has sequence homology to a sub-class of cellular serine 
pro teases despite the nucleophile being a cysteine residue. 2APro is 
suggested to have a His, Asp, Cys catalytic triad with a zinc atom in a 
structural role. 2APro also inhibits host-cell protein synthesis by cleaving 
eIF-4G, a protein associated in the cap binding protein complex. Inhibition 
of cap-dependent translation results in host cell shut off. 2APro also 
transactivates IRES-mediated translation. The aphthovirus and cardiovirus 
2APro cleaves at the C-terminus of 2A, has no known protease motifs and has 
no similarity to the 2A pto to enterovirus 2APro.
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3CPro is found in all picornaviruses and exhibits high sequence 
sim ilarity across the genera. This protease is required to cleave at a distal 
site between 2C and 3A as well as for a series of secondary cleavages that 
produce the capsid and replicative protein precursors.
The hum an rhinovirus (HRV) 3C protease structure illustrated that 
the catalytic triad G lu /H is/C ys was positioned in a similar manner of the 
A sp /H is/S er triad of serine proteases (Matthews et ah, 1994). The HRV 3C 
protease folded in a very similar manner to chymotrypsin but w ith a 
num ber of slight differences. The precise orientation of the catalytic triad, 
regions required for transition state stabilisation and some connecting loops 
were different for the 3C protease. The 3C proteases, although m ore 
efficient than the CMV protease, is not highly efficient. This factor may be 
due to the weaker Cys/H is catalytic dyad as opposed to the H is/Ser dyad 
seen for serine proteases. The third residue in the catalytic triad is not 
strictly conserved (Glu or Asp) and from structural analyses seems to point 
away from the active site. The 3C protease processes between a glutam ine 
residue and a glycine residue.
The 3C protease binds directly to viral RNA and is important for the 
initiation of RNA replication. The region involved in RNA binding is 
located distal from the active site. The 3C protease is fused to the viral RNA 
polymerase (3D) for a large portion of the replication cycle with no effect on 
the protease activity. The 3C polymerase is inactive in this uncleaved state. 
As the release of the 3D polymerase from the polyprotein is essential for 
viral replication the functional activity of the 3C protease is required. The 
picornavirus pro teases are reviewed in Ryan and Flint (1997).
Sindbis virus is an enveloped virus containing a positive sense, 
single-stranded RNA genome. The Sindbis virus core protein (SCP) has two 
functions (Tong et ah, 1993). As well as binding the RNA genome the SCP 
contains a proteolytic activity. The Sindbis virus genomic RNA produces 
two polyproteins that are processed post-translationally by both cellular 
and viral proteases. The pl30 polyprotein encodes the structural proteins 
including the SCP. At the N-terminus, SCP is released from the polyprotein 
through a single autocatalytic cleavage in cis to release itself from the 
polyprotein. This cleavage occurs between a tryptophan residue and a 
serine residue. After this first step in m aturation the remainder of the 
polyprotein is processed by other proteases.
The active SCP structure is a chymotrypsin-like serine protease. The 
SCP folds into a chymotrypsin-like double (3-barrel that flank the substrate 
binding site. The polypeptide backbone of SCP is similar to chymotrypsin, 
consisting of two similar Greek key p-barrel domains. The p-barrel is 
closed when strand D forms hydrogen bonds with strands A and E. The C- 
terminal P-barrel contains a central, hydrophobic core as does the N- 
terminal P-barrel, although this core is smaller. The SCP can form a dim er 
with a relatively small interface and the interaction between the two 
monomers is mostly hydrophobic. This dimeric form of the protein m ay 
also be found in the Sindbis virus core. The N-terminal region associates 
with the viral RNA and is essential for encapsidation.
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The catalytic triad was shown to be A sp/H is/Ser. The arrangem ent 
of the triad residues is conserved between SCP and other proteases although 
the orientation of the scissile bond relative to the catalytic residues is 
different compared to chymotrypsin. The specificity pocket of SCP is a 
deep, essentially hydrophobic groove on the surface. Once the SCP has been 
cleaved from the polyprotein the C-terminal tryptophan residue of SCP 
inserts itself into this groove to inactivate the SCP enzymatic activity. This 
new structure then assembles into the icosahedrally symmetric core protein.
All retroviruses encode a single protease. The HIV protease (PR) 
processes the gag and gag-pol polyproteins to produce the mature structural 
proteins and viral protein itself. Sequence alignment with other proteases 
suggests that the HIV protease could fold to form a single domain of an 
aspartic protease similar to pepsin. The main difference to pepsin is in the 
interface region where two HIV-1 PR monomers have significantly shorter 
N- and C-terminal strands that interact to form a dimer whose structure and 
properties similar to pepsin. The active site triad (Asp-25, Thr-26 and Gly- 
27) is located deep within a loop stabilised by a network of hydrogen bonds, 
a feature of aspartic proteases (Wlodawer et al., 1989). The requirement of 
dimerisation for protease activity introduces a regulatory element into the 
virus life cycle. Only when the virions are assembling on the plasma 
membranes are the polyproteins close enough to permit protease 
dimerisation and activation. Once dimerised, the proteolytically active 
hom odim er processes between a phenylalanine (or tyrosine residue) and a 
proline residue.
These proteases, although varied in structure and functional 
requirement, are all essential for the virus m aturation and replication.
8.7. The importance of antiviral therapy.
Viral proteases play an important and usually essential role in viral 
replication. For the majority of RNA viruses e.g. HIV and HCV, the virus 
population is constantly changing such that a preventative or therapeutic 
vaccine is unlikely to be of any use. Targetting of essential proteins such as 
the viral protease or polymerase with antivirals is the only realistic 
treatment. To inhibit protease function the use of substrate mimics or other 
antiviral compounds could be effective. A detailed understanding of 
substrate specificity and protease function and requirements is invaluable 
for the development of antivirals.
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